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ABSTRACT
Prion diseases are fatal, transmissible neurodegenerative disorders characterised by 
accumulation throughout the brain of PrPSc, an abnormally folded isoform of the 
normal cellular prion protein, PrP . PrPSc is associated with infectivity but is not 
directly neurotoxic and targeting it is of limited efficacy in prion therapeutics.
However, PrP-null mice are resistant to prion infection and neurotoxicity. Transgene-
cmediated depletion of neuronal PrP in mice with established prion infection reverses 
early spongiosis, neuronal loss and cognitive deficits, and prevents clinical disease 
progression. Thus, reducing PrP expression in the brain through extrinsic means is 
likely to be an effective therapy for prion diseases.
RNA interference can be exploited to mediate gene silencing and can be stably achieved 
in non-dividing cells such as neurons by incorporation of the small interfering RNAs 
into replication-deficient lentiviruses.
The work described in this thesis strongly validates the use of lentiviral-mediated RNA 
interference as a therapeutic approach in prion disease. Reducing PrPc expression with 
siRNA duplexes enabled clearance of PrPSc and infectivity from prion-infected cells in 
vitro. Lentiviruses constructed to express the interfering sequences demonstrated 
effective reduction of PrPc expression in vitro. Stable expression of the interfering RNA 
molecules in vivo through lentiviral transduction of the hippocampus reduced local 
pathology and significantly prolonged survival in a mouse model of prion disease. This 
represents an important and novel advance in the treatment of established prion disease 
with relevance for all prion strains.
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INTRODUCTION
1.1 T he p rion  d iseases and the p rion  p ro te in  gene
1.1.1 The prion diseases
Transmissible spongiform encephalopathies (TSEs), more commonly known as prion 
diseases, are fatal neurodegenerative diseases of humans and animals (Collinge, 1998). 
They include scrapie of sheep, bovine spongiform encephalopathy (BSE) of cattle (Hope 
et al., 1989), chronic wasting disease of mule deer and elk (Williams and Young, 1993), 
and the human diseases Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler- 
Scheinker syndrome (GSS), fatal familial insomnia (FFI), kuru and variant CJD 
(vCJD). Pathologically, they are characterised by spongiform change, neuronal cell loss, 
astrocyte proliferation, and frequently, deposition of amyloid plaques containing 
insoluble aggregates of prion protein. They can be transmitted experimentally both 
within and between mammalian species by inoculation or ingestion of prion- 
contaminated material and are unique in having sporadic, inherited and acquired 
origins.
Scrapie; a unique class of transmissible diseases
Scrapie, a TSE of sheep, was first documented in a parliamentary enquiry in 1755 and 
has been studied extensively as a model of prion diseases. The disease is characterised 
by a loss of co-ordination, an uncontrollable urge to itch, excitability and progressive
16
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paralysis resulting in death. The neuropathological hallmarks of scrapie include global 
neuronal loss and cytoplasmic vacuolation: the spongiform degeneration that 
characterizes the TSEs (Foster et al., 2001).
The first experimental transmission of scrapie was achieved in 1936 through inoculation 
of healthy sheep with spinal cord from an affected sheep (Cuille and Chelle, 1936). 
Accidental transmission occurred when lymphoid tissue used to vaccinate sheep against 
louping ill virus caused scrapie in the inoculated sheep (Gordon, 1946). This also 
provided the first demonstration of the unusual resistance of the infectious agent to 
chemical treatment as the lymphoid tissue used to make the vaccine had been formalin 
fixed. The observation that formalin failed to inactivate the infectious agent 
contributed to the proposal of revolutionary new theories that the infectious agent 
lacked nucleic acid (Alper et al., 1967) and transmission occurred via a protein-only 
mechanism (Griffith, 1967).
During the 1950s, a fatal neurological disease called kuru reached epidemic proportions 
amongst the eastern highland Fore people of Papua New Guinea. This was the first 
human TSE to be defined as such and striking similarities with scrapie pathology were 
quickly recognised (Gajdusek and Zigas, 1957). These observations prompted the 
suggestion that kuru, like scrapie, may be an infectious disease (Hadlow, 1959). 
Inoculation of chimpanzees with brain homogenate from a kuru patient resulted in 
transmission of the disease, confirming its infectious nature (Gajdusek et al., 1966). The 
mode of transmission was proposed to be via consumption of contaminated material 
during ritual cannibalism practiced by the Fore people (Alpers, 1969). Banning the 
practice in the late 1950s resulted in a near total disappearance of the disease,
17
INTRODUCTION
substantiating its cannibalistic origin. No new cases have been recorded in people born 
since 1959 and the 11 cases documented between 1996 -  2004 in people born prior to 
1959 reflect the extremes of the incubation period of kuru in some individuals (Collinge 
et al., 2006).
Another outbreak of prion disease occurred in the mid 1980s amongst the UK cattle 
population in the form of BSE, stimulating increased research into this unusual family 
of diseases. The origin of BSE, or ‘mad cow disease’ as it became commonly known, is 
unexplained but the impact of the initial infection was amplified by reprocessing of 
infected carcasses into cattle feed, resulting in a full-scale epidemic. This contaminated 
fodder was also fed to other animals and led to identification of new TSEs in exotic 
ungulates (Kirkwood et al., 1990), domestic cats (Wyatt et al., 1991) and zoo animals 
(Kirkwood and Cunningham, 1994). The neuropathological and molecular 
characteristics of these TSEs were nearly identical to those of BSE, reflecting a common 
origin (Collinge et al., 1996;Hill et al., 1997). The transmission of BSE to other species 
raised concerns about the possibility of an epidemic in humans and in 1996 a new 
human prion disease, variant CJD, was identified (Will et al., 1996). This aggressive 
new disease was shown to be due to exposure to BSE (Collinge et al., 1996;Hill et al., 
1997;Bruce et al., 1997) and prompted further research into the pathogenesis and 
aetiology of prion diseases.
The human prion diseases
The human TSEs share many characteristics with their animal counterparts including 
pathological features and similar disease progression. With an annual incidence of one
MLW'liile - l vl i l l  TlM s is
18
INTRODUCTION
to two cases per million worldwide, they are rare, but are well known due largely to the 
kuru and BSE epidemics. Intense research into the human prion diseases has revealed a 
range of closely related, yet distinct, disorders. They can be inherited, acquired or 
sporadic in origin and are traditionally categorised as the clinicopathological syndromes 
of Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome (GSS), 
fatal familial insomnia (FFI) and kuru.
Sporadic, or classical, CJD accounts for 85% of the human prion diseases and is 
recognized by occurrence of a rapidly progressive dementia with myoclonus and 
development of movement disorders such as tremor, spasticity and rigidity. The mean 
age of onset is 65 years and the clinical course is rapid with an average duration of 7.6 
months. Abnormal electro-encephalogram (EEG) recordings are common with 
characteristic periodic sharp-wave complexes. Definitive diagnosis requires 
histopathological confirmation of extensive spongiform degeneration and neuronal loss, 
accompanied by gliosis and deposits of prion protein within the brain. Although 
sporadic in origin, CJD is also transmissible, as demonstrated by experimental passage 
to chimpanzees (Gibbs et al., 1968;Gajdusek and Gibbs, 1971), and occasional iatrogenic 
transmissions to humans (Brown et al., 1985;Billette de Villemeur et al., 1991;Martinez- 
Lage et al., 1994;Cavanagh and Hogan, 1999).
Around 14% of human prion diseases are inherited and result from coding mutations in 
the human prion protein gene PRNP. These include the diseases traditionally classified 
as familial Creutzfeld-Jakob disease (fCJD), GSS and FFI. They are autosomal 
dominant in inheritance and result either from expansion of an octapeptide repeat in 
the normal sequence of the prion protein, non-conservative point mutations or stop
19
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mutations within the PRNP  open reading frame (ORF). Over 30 different pathological 
mutations have been described which produce a wide spectrum of clinical phenotypes 
but generally have an earlier onset and longer disease duration than sporadic prion 
disease (reviewed in: Mead, 2006). The core features of the inherited prion diseases 
include rapidly progressive dementia with myoclonus and pseudoperiodic EEG 
discharges in fCJD, slow progression of ataxia accompanied by late onset dementia in 
GSS, and refractory insomnia, dysautonomia and motor signs in FFI, although there 
can be broad phenotypic and pathological variation between individuals with the same 
mutation (Collinge et al., 1992;Tranchant et al., 1992;Mallucci et al., 1999).
The acquired human prion diseases include kuru, iatrogenic CJD (iCJD) and variant 
CJD (vCJD). The name kuru means shaking or trembling and is used by the Fore 
people to describe the progressive cerebellar ataxia that characterizes this disease. Mood 
and personality changes are often present and dementia commonly develops during the 
final stages of the disease (Gajdusek and Zigas, 1957). Death occurs, often through 
starvation, after a disease course of around one year. Iatrogenic CJD is very rare and 
results from exposure of patients to prion-infected materials during medical treatment. 
Transmission has been described in recipients of contaminated growth hormone and 
gonadotrophin as well as dura mater and corneal grafts (Gibbs et al., 1985). More 
recently, transfusion of blood from a donor with pre-symptomatic vC JD resulted in 
transmission of disease to recipients, sparking further public health concerns (Llewelyn 
et al., 2004;Peden et al., 2004;Wroe et al., 2006). Peripheral inoculation usually results 
in prolonged incubation times with marked ataxia and late-onset dementia, whereas
- S’ i s l l
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intracerebral inoculation causes a rapid disease course with prominent early dementia 
(Collinge, 1998).
The most recently described acquired human TSE, vCJD, emerged in the mid 1990s in 
the wake of the UK BSE epidemic (Will et al., 1996). The clinicopathological features 
were unlike those of sporadic CJD, with a mean age of onset of 29 years and patients as 
young as 16 being diagnosed. The initial symptoms are mainly neuropsychiatric and 
behavioural, followed by ataxia and movement disorders. Unlike sCJD, dementia and 
myoclonus occur during the later stages of disease and EEG abnormalities are 
frequently absent. The disease course is also longer than that of sC JD, with a mean 
duration of 14 months (Collinge, 2001). None of the patients had PRNP  mutations or 
iatrogenic exposure and the possibility of a new human prion disease resulting from 
exposure to BSE-contaminated food was considered. Transmission studies performed in 
mice demonstrated a similar neuropathological profile between BSE and vC JD and 
molecular studies of PrPSc from affected bovine and human brains revealed similar 
biochemical characteristics (Raymond et al., 1997;Lasmezas et al., 1996;Hill et al., 
1997;Prusiner, 1997;Manuelidis et al., 1997;Scott et al., 1999). I t is now widely accepted 
that vC JD arose as a result of human infection with BSE prions.
The unusual nature of the scrapie agent and the protein-only hypothesis
The unusual nature of the scrapie agent first recognised by its resistance to formalin 
(Gordon, 1946), was further demonstrated when its infectivity was also shown to resist 
inactivation by high temperature and ultraviolet light (Alper et al., 1966). Examination 
of infected and infectious tissues revealed no evidence of bacteria or virions and it was
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proposed that the infectious agent was devoid of nucleic acid (Alper et al., 1967), and 
composed mainly of protein. That a protein alone might self-replicate and be infectious 
was first proposed in 1967 by Griffith (Griffith, 1967) and ran counter to the central 
dogma of molecular biology. The theory did not gain credence until 1982, when Prusiner 
achieved substantial purification of the scrapie agent and showed its physiochemical 
properties were characteristic of proteins, not nucleic acids (Prusiner, 1982). In a 
seminal paper, he coined the term ‘prion’ to describe the proteinaceous infectious 
particle of the scrapie agent. Extending Griffith’s theory from over a decade before, 
Prusiner set forth the ‘protein-only hypothesis’ in which he stated that a protein was 
capable of self-replication within vulnerable host cells and was the causative agent of 
scrapie. Shortly after, a scrapie-associated protein which correlated with infectivity was 
isolated from infected hamster brain (McKinley et al., 1983). This protein was found to 
be aggregated, highly insoluble in non-ionic detergents and partially protease resistant 
with a molecular mass of 27 — 30kDa. In accordance with the protein-only hypothesis, it 
was proposed to be the major constituent of the scrapie agent and was designated the 
prion protein, or PrP.
Purification of PrP to homogeneity allowed determination of its N-terminal amino acid 
sequence (Prusiner et al., 1984) and led to the recovery of PrP cDNA clones from 
scrapie-infected Syrian hamster (Oesch et al., 1985) and murine (Chesebro et al., 1985) 
brain libraries. PrP was shown to be encoded by a host gene, called Prnp, which was 
equally expressed in both infected and uninfected animals (Chesebro et al., 1985). The 
normal product of Prnp was a protease sensitive protein of 33 -  35kDa and was 
designated PrPc, for cellular prion protein. The previously isolated 27 — 30kDa disease-
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specific protein was found to be a protease resistant core of a 33 — 35kDa protein, 
designated PrPSc for scrapie-associated prion protein. These two isoforms of PrP had 
identical primary structures but differed in secondary or tertiary structure, prompting 
Prusiner to update the protein-only hypothesis by proposing that the central 
mechanism of infectivity involved a change of the normal cellular isoform, PrPc, into 
the scrapie-associated isoform, PrPSc (Prusiner, 1989). This change is thought to be a 
post-translational conformational alteration which would initiate a catalytic cascade in 
which new molecules of PrPSc are able to recruit further PrPc molecules for conversion. 
This hypothesis neatly provides an explanation for all three categories of prion disease 
through the same mechanism. In sporadic disease, rare spontaneous conversion of PrPc 
into PrPSc would instigate the disease process, whereas familial disease may arise as the 
result of destabilizing mutations in PrPc facilitating conversion. Acquired prion diseases 
would arise through introduction of foreign PrPSc molecules capable of converting host 
PrPc.
Further support for this notion comes from the field of yeast genetics where 
propagation of the [PSI+] and [URE] phenotypes occurs through a prion-like 
mechanism involving conformational templating of proteins in the absence of nucleic 
acids (reviewed in: Kushnirov and Ter-Avanesyan, 1998;Liebman and Derkatch, 1999). 
More recently, a normal, physiological function for this mechanism has been proposed 
for a member of the cytoplasmic polyadenylation element binding protein (CPEB) 
family, where a conformational change is associated with translation of mRNAs 
involved in memory storage (Si et al., 2003;Berger-Sweeney et al., 2006).
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Two main models have been proposed for the PrP conversion process including a 
heterodimer model in which PrPSc binds PrPc and acts as a template, forcing refolding 
of PrPc (Prusiner, 1991), and a nucleated or seed polymerization model in which the 
two isoforms normally exist in an equilibrium skewed towards PrPc but mutations or 
the presence of aggregated seed PrPSc shifts the equilibrium towards PrPSc replication 
(Jarrett and Lansbury, 1993;Caughey et al., 1995).
Conversion of PrPc to PrPSc has been achieved in cell-free systems in vitro but 
infectivity of the de novo generated PrPSc could not be established (Kocisko et al., 
1994;Kocisko et al., 1995;Hill et al., 1999). Recently, a more sophisticated in vitro 
conversion technique called Protein Misfolding Cyclical Amplification has allowed much 
more efficient replication and detection of PrPSc (Bieschke et al., 2004;Sarafoff et al., 
2005) which is infectious upon intracerebral inoculation of hamsters, although with a 
significantly prolonged incubation time (Castilla et al., 2005).
The identity of the infectious agent is still debatable and even in highly purified 
infectious fractions, only one in 105 PrPSc particles is infectious (Bolton and Bendheim, 
1991). The most infectious prion protein particles have been shown to be non-fibrillar 
particles containing 14 — 28 PrP molecules with infectivity significantly reduced in 
oligomers larger and smaller than this (Silveira et al., 2005). Partial protease resistance 
is not consistently associated with infectivity and noninfectious protease resistant PrP 
can be produced (Riesner et al., 1996). In FFI patients, PrPSc is often not detectable in 
the brain, yet the disease is transmissible (Tateishi et al., 1995;Collinge et al., 1995). 
There is, however, compelling genetic and biochemical evidence that some form of PrP
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is the essential, and possibly only, component of the infectious agent (Prusiner, 
1989;Weissmann, 1996;Legname et al., 2004).
1.1.2 The prion protein gene, Prnp , and its product, PrP
Prnp  gene organization and PrP biosynthesis
In the mid-1980s, the genes encoding scrapie-associated PrP in mice and hamsters were 
found to be host specific (Oesch et al., 1985;Chesebro et al., 1985;Basler et al., 
1986;Locht et al., 1986). Shortly after, the prion genes of humans, rats, goat, sheep, 
mink, cattle and chicken were cloned. Human PRNP  mapped to the short arm of 
chromosome 20 and the mouse Prnp mapped to the homologous murine chromosome 
21(Sparkes et al., 1986). Over 85% homology in the amino acid sequence was found 
between mammalian species and hybridization studies with hamster PrP indicated 
homologous sequences in Drosophila and yeast (Westaway and Prusiner, 1986). The 
PrP gene is a single copy gene consisting of two (or three differentially spliced) exons in 
humans (Puckett et al., 1991) and hamsters (Basler et al., 1986) and three exons in mice 
(Westaway et al., 1994). The ORF is entirely contained within the second exon in all 
species examined (Kretzschmar et al., 1986;Puckett et al., 1991), and encodes 253 — 257 
amino acids; 254 in the mouse. The primary sequence of PrP contains a hydrophobic 
signal sequence of 22 — 24 C-terminal amino acids which targets the newly synthesized 
polypeptide to the endoplasmic reticulum (ER). Here, PrP may be glycosylated on two 
N-linked glycosylation sites and a single disulphide bond is formed between two C- 
terminal cysteines (Stahl and Prusiner, 1991;Rudd et al., 2001). Glycosylation of PrP is
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variable, resulting in un-, mono-, or diglycosylated species (Haraguchi et al., 1989) and 
the conservation of both N-linked glycosylation sites in all mammalian PrP genes 
suggests functional significance of this modification. Subsequent cleavage of the signal 
sequence precedes addition of a glycosyl-phosphatidyl-inositol (GPI) anchor (Stahl et 
al., 1987). PrP is then trafficked through the Golgi apparatus where further processing 
of the N-linked oligosaccharides occurs before the protein is transported to the cell 
surface. The mature polypeptide is attached to the cell surface by its GPI anchor (Stahl 
et al., 1993) which localizes the protein predominantly to detergent-resistant 
microdomains (Vey et al., 1996). From here, the protein may be released through 
cleavage of the GPI anchor or subjected to endocytosis whereby it can cycle between 
endocytic vesicles and the cell surface (Shyng et al., 1993).
Prnp  expression
Prnp is expressed in the brain, spinal cord, peripheral nervous system, ganglia and 
nerve trunks of the autonomic nervous system of the developing mouse embryo from
13.5 days (Manson et al., 1992). In the adult mouse, high levels of PrP mRNA have 
been detected in the brain, with intermediate levels in heart and lung, and lower levels 
in the spleen (Oesch et al., 1985;Caughey et al., 1988). Post-natally, PrP gene expression 
is developmentally regulated in the brain (Mobley et al., 1988;McKinley et al., 1988), 
and in the adult, PrPc is clustered at the neuronal surface in coated pits, consistent with 
endocytic trafficking (Madore et al., 1999). Although PrP mRNA is detectable in all 
neurons, only a subset express PrPc protein. Neurons in the cerebral cortex generally
hiiv - Thvits
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direct PrPc to their soma and dendrites, whilst those in the brainstem and spinal cord 
direct it to their axons (Madore et al., 1999).
High PrPc expression is also found in the parasympathetic and enteric nervous systems, 
the neuroendocrine system, antigen-presenting cells and subpopulations of lymphocytes 
(Ford et al., 2002).
PrP structure
Expression of recombinant PrP in E. coli allowed determination of the three dimensional 
structure of hamster, mouse and human PrP using nuclear magnetic resonance (Riek et 
al., 1996;James et al., 1997;Riek et al., 1998;Hosszu et al., 1999;Liu et al., 1999;Zahn et 
al., 2000). The recombinant protein was shown to consist of a structured C-terminal 
domain containing three alpha helices and two short beta anti-parallel sheets, plus an 
unstructured N-terminal domain. The structure of PrPSc has not been resolved due to 
its insolubility and tendency to form aggregates. Low resolution studies have indicated 
that PrPSc contains ~43% beta sheet and 34% alpha helix, in contrast to the 43% 
alpha-helical content of PrPc which contains only 3% beta sheet (Pan et al., 1993). This 
observation led to the suggestion that the infective process results in a switch from the 
predominantly alpha-helical PrPc to the predominantly beta sheet PrPSc (Caughey et 
al., 1991;Gasset et al., 1993;Pan et al., 1993). The observed increase in beta sheet 
content in PrPSc has been proposed to result from refolding of the flexible tail of PrPc 
(Riek et al., 1997).
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The N-terminal region of PrPc contains a series of highly conserved octapeptide repeats 
which are implicated in copper binding (Brown et al., 1997a) and may play a role in the 
normal function of the prion protein (Pauly and Harris, 1998;Brown, 1999).
1.1.3 Investigations into PrP function
Prnp  knockout models
Despite extensive research, the function of PrPc is still unknown. The observation that 
PRNP  is a highly conserved gene in mammals which is tightly regulated 
developmentally (Manson et al., 1992) and post-natally (Lazarini et al., 1991) led to the 
assumption that PrPc had an essential biological function. Knockout mouse models of 
Prnp were produced by homologous recombination in embryonic stem cells in an 
attempt to elucidate the function of PrPc. The first knockout model created was 
designated Prnp010 (also referred to as the ‘Zurich I’ mouse), and was made by replacing 
codons 4 -  187 of the Prnp ORF with a neo gene cassette (Bueler et al., 1992). Shortly 
after, a second line designated Prnp1' was created by disruption of the ORF by insertion 
of a neo cassette at a unique restriction site (Manson et al., 1994a). In both of these 
lines, the knockout was restricted to the ORF and the 5’ splice site was unaffected, 
unlike in subsequent models (Sakaguchi et al., 1996;Moore et al., 1999). The mice were 
created on different genetic backgrounds and did not express detectable PrPc. 
Unexpectedly, both lines were developmentally and phenotypically essentially normal. 
The possibility that functional compensation was occurring developmentally in these 
knockout models was eliminated by the creation of a conditional, adult-onset Prnp
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knockout mouse (Mallucci et al., 2002). This model was created by crossing mice 
carrying a ‘floxed’ Prnp gene on a Prnp010 background with Prnp010 mice expressing Cre 
recombinase under the control of the neurofilament heavy chain (NFH) promoter. The 
NFH promoter here becomes active at around 9-10 weeks of age, leading to Cre- 
mediated excision of Prnp in neuronal cells. The mice remained healthy following 
ablation of neuronal PrPc, confirming the limited effects of loss of PrP function found 
in previous models.
Three lines of PrP knockout mice did develop a neurodegenerative phenotype 
(Sakaguchi et al., 1996;Moore et al., 1999;Rossi et al., 2001), but this was shown to 
result from ectopic expression of the downstream Prnd gene due to deletion of a splice 
acceptor site 5’ to the Prnp ORF in exon three. Prnd encodes the Dpi protein, and exon 
skipping leads to splicing of the Dpl-encoding exon to the first two exons of Prnp, 
resulting in expression of Dpi driven by the Prnp promoter (Rossi et al., 2001;Flechsig 
et al., 2003).
Putative functions of PrP
Despite the lack of gross abnormalities in PrP null mice, intensive research has revealed 
some subtle phenotypic differences. Both synaptic function (Collinge et al.,
1994;Manson et al., 1995) and intrinsic features of hippocampal cells (Colling et al., 
1995;Mallucci et al., 2002) have been shown to be altered upon PrP knockout. PrP null 
mice also have altered circadian rhythms (Tobler et al., 1996), an intriguing finding in 
light of the sleep disturbances characteristic of the human inherited prion disease, FFI. 
Changes in the membrane localization of neuronal nitric oxide synthase (nNOS) also
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occur following Prnp knockout, suggesting a role for PrPc in targeting nNOS to the 
cholesterol-rich microdomains it usually occupies (Keshet et al., 1999).
PrP binds copper with femtomolar efficiency (Brown et al., 1997a;Brown, 2001;Jackson 
et al., 2001) and is endocytosed, leading to suggestions that it may act as a copper 
transporter in the brain (Pauly and Harris, 1998;Brown, 1999).
Reduced Cu2+/Zn2+-dependant SOD activity has been reported in vivo in Prnp0/0 mice 
and neurons derived from these mice exhibit increased vulnerability to oxidative stress 
in vitro (Brown et al., 1997b). A neuro-protective role for PrPc is further supported by 
the observations that serum-deprivation induced apoptosis is significantly higher in 
cultured cells in Prnpm  cell lines (Kuwahara et al., 1999), and PrPc protects human 
primary neurons (Bounhar et al., 2001) and yeast (Li and Harris, 2005) against Bax- 
mediated cell death. Expression of N-terminally truncated PrP in transgenic mice 
results in extensive degeneration and death of cerebellar granule neurons by 8 weeks of 
age (Shmerling et al., 1998). That this can be rescued by expression of wild-type PrPc 
implies a neuroprotective signaling function of the N-terminal region of PrP.
The cell surface location of PrPc and its observed recycling between the plasma 
membrane and endocyctic compartments led to speculations of a role in cell adhesion or 
cell signaling. Interaction between PrPc and neuronal cell adhesion molecules (Schmitt- 
Ulms et al., 2001), and the observation that PrPc over-expression increases cell 
aggregation in a neuronal cell line (Mange et al., 2002), tend to support a role in cell 
adhesion.
PrPc has been implicated in cell signaling by the demonstrations that binding to stress- 
inducible protein 1 (STI1) mediates neuro-protection through a cAMP/PKA signaling
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pathway (Zanata et al., 2002), and antibody-mediated cross-linking of PrPc triggers 
signal transduction through the non-receptor tyrosine kinase Fyn (Mouillet-Richard et 
al., 2000). PrPc has also been shown to interact directly with proteins involved in 
signaling pathways, including Grb2, Synapsin lb and P intl (Spielhaupter and Schatzl,
2001) and to mediate neuritogenesis, cell differentiation and memory consolidation 
through an interaction with laminin (Graner et al., 2000a;Graner et al., 2000b;Coitinho 
et al., 2006).
Role of PrP in prion disease
A number of key observations highlight the important role the prion protein has in 
defining the onset and phenotype of prion diseases. The length of prion disease 
incubation time correlates with two coding mutations in the murine Prnp gene at 
codons 108 and 189 (Westaway et al., 1987), suggesting a link between PrP structure 
and susceptibility to prion disease. This link is further supported by the observation 
that amino acid polymorphisms also influence the onset and phenotype of prion disease 
in sheep and humans (Prusiner, 1998;Collinge, 2001). In sheep, polymorphisms at three 
PrP codons, 136 (A/V), 154 (R/H) and 171 (R/H/Q), determine incubation time and 
susceptibility to scrapie (Tranulis, 2002). In humans, codon 129 is polymorphic for 
methionine (M) or valine (V) and this modulates the protease sensitivity of PrPSc 
(Parchi et al., 2000), and the kinetics of amyloid formation (Lewis et al., 2006). 
Homozygosity at codon 129 for either M or V is associated with increased susceptibility 
to sporadic CJD (Palmer et al., 1991) and iatrogenic CJD (Collinge et al., 1991), whereas 
heterozygosity has a protective effect against sporadic, acquired and some of the
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inherited prion diseases (Collinge, 2001). All clinical cases of variant CJD studied to date 
have been homozygous for methionine at codon 129 of PRNP  (Collinge, 2005) and the 
valine allele is protective against kuru (Lee et al., 2001).
The octapeptide repeat region of PrP appears to modulate prion replication and 
pathogenicity (Flechsig et al., 2000), and extension of repeat number is associated with 
earlier disease onset in a human kindred (Collinge, 2001).
But the most striking confirmation of the role of PrP in prion disease is the absolute 
requirement of the protein for disease susceptibility. PrP knockout mice are resistant to 
prion infection and unable to replicate infectivity (Bueler et al., 1993;Manson et al., 
1994b) and incubation time is determined by Prnp gene dosage (Manson et al., 
1994b;Safar et al., 2005). Prion inoculation of Prnp010 mice with PrP-expressing 
neuroectodermal grafts results in damage and degeneration only in the PrP-expressing 
graft whilst surrounding Prnp0/0 tissue remains unaffected (Brandner et al., 1996). 
Furthermore, depletion of neuronal PrPc in mice with established prion infection 
reverses early spongiform change and prevents disease progression (Mallucci et al., 
2003). This is despite continued accumulation of PrPSc in non-neuronal cells, reinforcing 
that expression of PrPc is required in neurons for neurodegeneration and clinical 
disease.
The species barrier
Further emphasizing the central role of PrPc in prion pathology is the finding that 
transmission of prions from one species to another is much less efficient than 
transmission within the same species — an effect called the ‘species barrier’. This results
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in extended incubation times upon passage from the first species into the second. Once 
transmission has been achieved between species, the barrier has been overcome and 
subsequent passages of infectivity to homologous hosts occur with normal efficiency 
and constant incubation times. Wild-type mice are resistant to hamster prions but this 
barrier can be overcome by the expression of hamster PrP in transgenic mice, 
demonstrating that the critical determinant of the species barrier is the primary 
sequence of PrP (Prusiner et al., 1990). PrP glycoform patterns and 3-dimensional 
structure are also thought to modulate prion species compatibility (reviewed in: Moore 
et al., 2005).
Subclinical disease
In some circumstances, prion infection may result in a subclinical disease state in which 
the animal harbours the infection without progressing to clinical symptoms. The species 
barrier which limits passage of hamster prions to mice results in a subclinical disease 
state in the inoculated mice (Race and Chesebro, 1998;Hill et al., 2000). The prions 
continue to replicate in the mice and are infectious upon subsequent passage to both 
hamsters and mice, but fail to cause clinical symptoms in the incubating mice. Infection 
of mice with low doses of prions can also result in subclinical disease despite high levels 
of PrPSc and infectivity in the brain (Taylor et al., 2000;Thackray et al., 2002;Thackray 
et al., 2003). Additionally, immunodeficient mice can accumulate PrPSc and infectivity 
whilst remaining asymptomatic (Frigg et al., 1999).
33
INTRODUCTION
Prion strains
One of the most remarkable features of prion disease is the existence of distinct prion 
strains with well-defined heritable properties. These strains were originally 
characterized by incubation time and resultant neuropathology (Bruce et al., 1992), but 
they can additionally be differentiated on the basis of PrPSc distribution in the brain 
and physicochemical properties of PrPSc, including susceptibility to PK digestion, 
electrophoretic mobility following digestion and glycoform ratios (reviewed in: Bruce et 
al., 1996). As different prion strains can be serially propagated in inbred mice with the 
same Prnp genotype, they can not be encoded by the primary sequence of PrP. It is 
now thought that strain specificity is determined by PrP conformation and 
glycosylation. Different PrP conformers could interact with differing efficiencies and 
glycosylation may influence the neuropathological targeting of a strain (Collinge et al., 
1996;DeArmond et al., 1997). It is known that different cell types may glycosylate 
proteins differently, therefore particular PrPSc glycoforms might replicate most 
favourably in cells expressing a similar PrP glycoform. This regional targeting could 
also explain the differences in incubation times between various strains with targeting 
of more critical brain regions resulting in shorter incubation periods.
Prion spread and neuroinvasion
Under natural conditions, prion diseases are usually acquired by oral infection in 
animals which results in much less efficient transmission and longer incubation times 
than intracerebral inoculation. Following infection, prions must spread from the 
periphery to the CNS before causing neurodegeneration. The first phase of infection
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involves transport of the prions from the entry site to the lymphoreticular system in a 
process that involves myeloid dendritic cells (Huang et al., 2002). Prion replication 
then occurs within the lymphoreticular system (Kitamoto et al., 1991), with B cells 
playing a vital role in subsequent neuroinvasion (Klein et al., 1998). As PrP expression 
is not required in B cells, it is thought to be their role in the maturation of follicular 
dendritic cells (FDCs) that facilitates prion neuroinvasion. FDCs accumulate high levels 
of PrPSc during prion infection (Kitamoto et al., 1991), are crucial for efficient disease 
progression after oral scrapie inoculation (Mabbott et al., 2003) and infection of mice 
with ME7 prions (Brown et al., 1999), and they mediate faster neuroinvasion if 
positioned closer to splenic nerves (Prinz et al., 2003). Hence, the topography of 
lymphoid organs contributes to prion spread, but as there is no physical synapse 
between FDCs and sympathetic nerves (Heinen et al., 1995), it remains to be 
determined whether this is a passive process, or relies on active transport via mobile 
cells.
Following amplification in the spleen, prions are transferred to the CNS, presumably 
via the main innervation of the lymphoid system, the sympathetic nervous system. This 
route of spread is supported by the finding that chemical sympathectomy delays the 
onset of scrapie, whereas sympathetic hyperinnervation promotes splenic replication 
and neuroinvasion (Glatzel et al., 2001). Once the prions reach the CNS, the typical 
neuropathological changes associated with prion diseases commence.
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Mechanisms of neurotoxicity
Various mechanisms have been proposed to explain neuronal cell death in prion 
diseases, but it is thought to occur largely by apoptosis (Hetz et al., 2003;Hetz and 
Soto, 2003;Cronier et al., 2004). Apoptosis has been described in the brains of patients 
with CJD, FFI and in scrapie-infected hamsters, mice and sheep (Hetz and Soto, 2003). 
PrPSe-induced apoptosis has been associated with the induction of ER-stress inducible 
chaperones and caspase activation both in vitro and in vivo (Hetz et al.,
2003;Kristiansen et al., 2005). Caspases 3 and 8 were also shown to trigger apoptosis in 
prion-infected cells following mild proteasomal inhibition which resulted in formation of 
cytosolic PrPSc-containing aggresomes (Kristiansen et al., 2005). The authors propose it 
is the presence of these cytosolic aggresomes which is particularly pro-apoptotic. 
Aggresomes accompanied by proteasomal dysfunction have also been observed in 
uninfected cells over-expressing cytosolic PrPc (Ma and Lindquist, 2001), but the more 
recent study suggests any resultant neurotoxicity was due to excessively large doses of 
proteasome inhibitors (Kristiansen et al., 2005).
Apoptosis may not be the only type of cell death responsible for neuronal loss in TSEs. 
No morphological evidence of apoptosis was found in prion-infected human biopsies 
using either ultrastructural (Sikorska et al., 2004) or light (Ferrer, 1999) microscopy and 
the features of cell death were more consistent with autophagy. More recently, a 
neuronal marker of autophagy, initially discovered as a gene up-regulated in TSEs, was 
found to be induced in the neurons of scrapie-infected mice, reinforcing the role of this 
pathway in neurodegeneration (Dron et al., 2005;Dron et al., 2006).
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Although it is still largely unknown how the conversion of PrPc to PrPSc causes 
neuronal cell death, the continued extraneuronal PrPSc accumulation observed in the 
otherwise healthy conditional knockout mice suggests it is only toxic if it occurs within 
neurons. Moreover, the finding that removing PrPc expression, even in adult mice, has 
no gross phenotypic consequences (Mallucci et al., 2002), argues against loss of PrPc 
being a central cause of the neurotoxicity of prion disease.
Traditionally, it was assumed that PrPSc itself is the toxic species, but this assumption 
was based largely on the temporal and anatomical correlation between PrPSc deposition 
and neuropathology and there are occasions when this correlation is weak or absent 
(Chiesa et al., 2001). There are some prion diseases in which PrPSc levels in the brain are 
very low, and conversely, subclinical disease states which show extensive PrPSc 
deposition without clinical symptoms (Hill et al., 2000;Hill and Collinge, 2003). Purified 
PrpSe (Hetz et al., 2003) and shorter fragments corresponding to a putative 
transmembrane domain (Forloni et al., 1993;0’Donovan et al., 2001) have both shown 
toxicity in vitro, arguing for a toxic gain of function of PrPSc.
However, PrPc with an altered transmembrane topology, CtmPrP, also causes 
neurotoxicity in a concentration-dependent manner and accumulates in an inherited 
prion disease, A117V, where PrPSc accumulation is rare (Hegde et al., 1998;Hegde et al., 
1999;Stewart et al., 2005). The concept of a toxic gain of function for PrPc is 
additionally supported by the finding that accumulation of even small amounts of 
cytosolic PrPc has been shown to be strongly neurotoxic in vitro and in vivo (Ma et al., 
2002), suggesting a toxicity due to altered trafficking of PrPc. But the data is 
conflicting, with evidence both for (Rane et al., 2004;Wang et al., 2004) and against
M.While - PM*
37
INTRODUCTION
(Drisaldi et al., 2003;Roucou et al., 2003;Fioriti et al., 2005) cytosolic PrPc being a 
neurotoxic species.
Whatever the toxic species is, it is clear that the major pathological changes in prion 
disease do not result from loss of PrPc, and PrPSc does not cause neurotoxicity directly 
but exhibits its toxicity only where PrPc is also expressed. I t has been suggested that a 
neurotoxic intermediate, termed PrPL, for lethal, may be formed during the conversion 
reaction (Hill et al., 2000;Hill and Collinge, 2003), mediating toxicity in a manner 
similar to Ap oligomers in Alzheimer’s disease (Hardy and Selkoe, 2002) and potential 
toxic intermediates in other protein misfolding disorders (Kayed et al., 2003). If this is 
the case, targeting either PrPc, the substrate for conversion, or the conversion process 
itself, should both be valid therapeutic approaches.
1.1.4 Therapeutic approaches to prion disease
The uncertainties about the identity of the neurotoxic species and the possible 
mechanisms of neurodegeneration in prion diseases have complicated therapeutic 
approaches, meaning that prion diseases are invariably fatal and no therapy is currently 
available. Additionally, a lack of sensitive preclinical diagnostic tests means that 
diagnosis of prion disease presently relies on development of clinical symptoms which 
reflect advanced neurodegeneration. Pathogenesis studies in rodents have indicated that 
CNS damage and even subtle cognitive and behavioural changes occur long before 
appearance of conventional clinical symptoms (Cunningham et al., 2003;Mallucci et al.,
2007). As neurodegeneration is already established by the time a diagnosis is made, the j
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therapeutic window is inevitably small, although reversal of early pathological ]
(Mallucci et al., 2003) and cognitive changes (Mallucci et al., 2007) is possible if 
intraneuronal PrPc conversion is halted.
As PrPSc is associated with both pathology t\nd infectivity, many potential therapies 
have targeted this molecule. Several compounds have been identified which reduce 
PrPSc accumulation in prion-infected cell models including, Congo red, polyanionic 
compounds, amphotericin B, porphyrins and  quinacrine, but in vivo results have been 
disappointing (reviewed in: Trevitt and Collinge, 2006). Many of these substances only 
have an effect if administered together with, or soon after, the prion inoculum and may 
simply reduce the effective titre of the inoculum instead of preventing pathogenesis.
Pentosan polysulphate is one of the only agents to lengthen the incubation time in mice 
inoculated with prions intracerebrally (Doh-ura et al., 2004), but results have been 
discouraging in human prion disease patients (Todd et al., 2005;Whittle et al., 2006).
Although PrPSc is defined as partially protease resistant, this is only a relative measure 
and natural clearance mechanisms do exist for this molecule. Compounds such as 
branched polyamines (Supattapone et al., 1999) and a tyrosine kinase inhibitor (Ertmer 
et al., 2004) are able to enhance the endogenous clearance of PrPSc in vitro. They do not, 
however, prevent de novo formation of PrPSc, meaning they will be of limited 
therapeutic value if the toxic species occurs upstream of PrPSc in the conversion 
reaction.
As the conversion process is now known to be central to the pathogenesis of prion 
diseases, many more recent potential therapeutic agents have aimed to inhibit this 
reaction either directly, or by targeting the substrate for conversion, PrPc. In theory,
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ligands which selectively bind PrPc may prevent the conversion process by stabilising 
PrPc or preventing its interaction with PrPSc. One recently identified class of molecules 
thought to act in this manner is degenerate phosphorothioate oligonucleotides which 
inhibit PrPSc formation in vitro and when delivered prophylactically in vivo (Kocisko et 
al., 2006). Unfortunately, these molecules do not cross the blood-brain barrier and rapid 
intracerebral infusion was not tolerated in vivo. Whilst a gradual infusion might 
circumvent this limitation, it still remains to be seen if these molecules can be effective 
when administered later in the course of infection.
Another class of therapeutic agents which seem to act by binding PrPc and reducing its 
availability for conversion is anti-PrP antibodies. Antibodies against several PrP 
epitopes can inhibit PrPSc replication in vitro and transgenic mice expressing anti-PrP p, 
chains are protected against peripheral, but not central, prion infection (reviewed in: 
Trevitt and Collinge, 2006). Passive immunisation of peripherally infected mice with 
anti-PrP antibodies markedly reduced peripheral PrPSc accumulation but could not 
treat intracerebrally infected mice due to failure to cross the blood-brain barrier (White 
et al., 2003). Unfortunately, when administered intracerebrally, anti-PrP antibodies can 
cause severe neuronal apoptosis showing further investigation of the consequences of 
PrP binding and refinement of this approach is required (Solforosi et al., 2004).
Active immunisation methods have been limited by the immune tolerance of PrP, but 
some approaches to overcoming this have reported modest effects (Sigurdsson et al., 
2002;Schwarz et al., 2003).
Once severe neuronal loss has occurred, any form of rescue is challenging. Replacement 
of lost neurons may be possible using embryonic stem cells (McKay, 1997), or neuronal
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precursor cells (Gage, 2000;Alvarez-Buy 11a et al., 2000) but they would need to be Prnp 
null unless the prion infection could be eliminated.
To date, the only approach that is effective for the prevention of clinical disease in 
animals with established prion neuropathology is the removal of neuronal PrPc through 
conditional knockout in transgenic animals (Mallucci et al., 2003). The demonstration 
that removing neuronal PrPc is harmless in adult mice (Mallucci et al., 2002), and 
prevents prion disease progression (Mallucci et al., 2003) has confirmed the rational of 
therapies based on the removal or elimination of PrPc. Prion replication continues in 
non-neuronal cells in these conditional knockout mice, demonstrating that global 
removal of PrPc is not required for therapeutic benefit. Depleting neuronal PrPc in 
prion-infected mice with early pathology appears to switch the infection to a subclinical 
state in which prions replicate and remain infectious but further neuropathology does 
not ensue.
In order to translate this approach into a viable therapy however, an extrinsic means of 
reducing PrPc expression must be employed. Recent advances in the field of RNA 
interference have provided techniques for achieving this extrinsic removal of PrPc.
1 .2  RNA In terference
1.2.1 Post-transcriptional gene silencing
RNA interference is the general term for the process in which double-stranded RNA 
corresponding to a particular gene prevents or reduces the expression of that gene. It
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was originally discovered fortuitously by researchers trying to deepen the colour of !
petunias through introduction of a pigment-producing gene driven by a powerful 
promoter (Napoli et al., 1990). Instead of the more intense colour expected, many of the 
flowers were variegated or even white^ The researchers called this phenomenon 
“cosuppression” because the expression of both the exogenous and the endogenous 
genes were suppressed (reviewed in: Jorgensen, 1990). Initially, the effect was thought 
to be specific to petunias, but cosuppr^ssion has since been found to occur in many 
species of plants, nematodes, Drosophila and mammals (Bingham, 1997;Matzke et al.,
2001;Vance and Vaucheret, 2001;Waterhouse et al., 2001;Kavi et al., 2005).
The mechanism underlying this was uticlear, but evidence from a number of different 
studies suggested the silencing was at th e  post-transcriptional level (post-transcriptional 
gene silencing, PTGS), because although the gene was expressed, the resulting mRNA 
did not accumulate due to rapid degradation in the cytoplasm of the cell (Ingelbrecht et 
al., 1994;Baulcombe, 1996;Meyer, 1996).
The first evidence that double-stranded RNA (dsRNA) could be used as a tool for gene 
silencing came from work in the nematode Caenorhabditis elegans. Fire and colleagues 
showed in 1998 that injection of dsRNA was a much more potent inhibitor of gene 
expression than single-stranded antisense RNA, the technology of choice at the time 
(Fire et al., 1998). I t was then confirmed that the injected dsRNA silenced gene 
expression by targeting the endogenous mRNA for degradation through a post- 
transcriptional mechanism (Montgomery et al., 1998). Researchers rapidly tried to 
exploit this dsRNA-induced silencing in other model organisms such as Drosophila 
melanogaster (Kennerdell and Carthew, 1998), mouse embryos (Wianny and ernicka-
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Goetz, 2000) and mouse oocytes (Svoboda et al., 2000). Before long, cell-free (Tuschl et 
al., 1999) and cell culture models (Caplen et al., 2000) were established and it was shown 
that the introduced dsRNA is processed into 21 — 23 nucleotide fragments that guide 
cleavage of endogenous transcripts in an ATP-dependent and translation-independent 
manner (Zamore et al., 2000). These fragments are known as short interfering RNAs 
(siRNAs).
1.2.2 Avoiding the interferon response
Many early attempts at exploiting the endogenous RNAi pathway through the 
introduction of dsRNA homologous to the gene of interest were problematic in 
vertebrates due to induction of the interferon response (Caplen et al., 2000;0ates et al., 
2000;Zhao et al., 2001). Mammals have evolved defense mechanisms against dsRNA 
which is a characteristic signature of viruses. The presence of dsRNA > 30bp leads to 
induction of interferon and transcription of hundreds of interferon stimulated genes 
that mediate the cellular stress response (reviewed in: Stark et al., 1998). These include 
a family of oligoadenylate synthase enzymes (OAS), the toll-like receptor and the well 
characterised dsRNA-dependent protein kinase, PKR (de Veer et al., 2005). Activation 
of these proteins by dsRNA binding blocks translation of both viral and cellular protein 
and leads to apoptosis of infected cells (Stark et al., 1998;Williams, 1999;de Veer et al., 
2005). The viral dsRNA is rapidly processed into siRNAs by a cellular enzyme 
(Hamilton and Baulcombe, 1999;Bernstein et al., 2001). The siRNAs then act as guide 
sequences to direct the sequence-specific degradation of the single-stranded mRNAs of
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the invading viral genes (Elbashir et al., 2001b), suggesting viral defence as one 
plausible reason for the evolution and broad conservation of an endogenous RNAi 
pathway.
In 2001, Elbashir and colleagues cleverly circumvented induction of the mammalian 
interferon response by introducing the dsRNA as synthetic 21 or 22 nucleotide siRNAs, 
thereby preventing cellular detection of the dsRNA and successfully silencing target 
genes (Elbashir et al., 2001a). This seminal study opened the door for gene silencing by 
RNAi in mammalian cells.
1.2.3 The mechanism of RNAi
siRNAs
Understanding of the mechanism of RNAi is still growing and many of the key proteins 
in the pathway have now been identified. Viewed simplistically, the process of RNAi 
can be divided into an initiation step and an effector step. In the initiation step, long 
dsRNA is cleaved into siRNAs in the cytoplasm by an RNase III dsRNA ribonuclease 
called Dicer (Zamore et al., 2000). Together with cytoplasmic proteins, the siRNA now 
forms the RNA-induced silencing complex (RISC). This is a multi-component nuclease 
which plays the key role in the effector step in which target mRNA is degraded. The 
siRNA duplex is unwound and the strand which has the less thermodynamically stable 
5’ region is loaded into RISC (Khvorova et al., 2003).This strand becomes the ‘guide’ for 
locating fully complementary target mRNA within the cell (Martinez et al., 2002). The 
strand that is not incorporated into RISC is known as the ‘passenger’ strand and is
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cleaved by RISC itself (Matranga et al., 2005;Rand et al., 2005). RISC now becomes 
activated and can target mRNAs for degradation by endonucleolytic cleavage of the 
mRNA within the region complementary to the siRNA. The endonuclease responsible 
for cleavage of both the passenger strand and the target mRNA is termed Slicer and was 
shown to be a highly conserved protein called Argonaute 2 (Ago-2) (Liu et al.,
2004;Song et al., 2004). Although many different proteins may associate with RISC 
(reviewed in: Sontheimer, 2005). Ago-2 and an siRNA are sufficient for minimal target 
cleavage activity (Rivas et al., 2005). Cleavage of the target mRNA inhibits translation 
and protein synthesis, effectively silencing gene expression. A schematic illustrating the 
basic mechanism of RNAi is shown in Figure 1.1.
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Figure 1.1 Illustration of key events in the RNAi pathway
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Figure adapted from ‘RNA Interference in Functional Genomics and Medicine’ (Kim, 2003). 
During the initiation step of RNAi, Dicer cleaves long dsRNA to generate a siRNA duplex (1). 
In  the effector step, RISC is formed (2), activated by siRNA duplex binding and unwinding (3) 
and target mRNA is located and degraded (4).
microRNAs
In addition to siRNAs, another class of small RNA molecules called microRNAs 
(miRNAs) also silence gene expression. Whilst siRNAs are usually produced in a cell 
upon introduction of long dsRNA from viruses, transposons or transfection, miRNAs 
are the products of endogenous, non-coding genes whose precursor RNA transcripts 
contain repeat regions that enable formation of small dsRNA stem-loops. These stem-
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loop structures form short hairpin RNA molecules (shRNAs) which can be processed 
intracellularly to effect silencing of endogenous genes (Pasquinelli et al., 2000;Reinhart 
et al., 2000). An important feature of miRNA hairpins is the presence of mismatched 
bases in the pairing regions, or stems, which create ‘bubbles’ in the structure (Lagos- 
Quintana et al., 2001;Lau et al., 2001;Lee and Ambros, 2001). Like siRNAs, miRNAs 
are recognised by Dicer which cleaves off the loop region creating mature 21 — 23 
nucleotide miRNAs analogous to siRNAs (Bernstein et al., 2001). miRNAs also 
associate with RISC, but due to their imperfect complementarity to the target mRNA, 
most miRNAs silence gene expression through translational repression rather than 
mRNA degradation (Grishok et al., 2001;Hutvagner et al., 2001;Ketting et al., 2001). 
Although the mechanism is poorly understood, it is believed miRNA binding to target 
mRNA causes accumulation of the mRNA in cytoplasmic processing bodies (P-bodies) 
in which the mRNAs are stored or degraded by decapping enzymes and exonucleases 
(reviewed in: Tsuchiya et al., 2006). Many more miRNAs are being identified and they 
have been shown to be important in modulating cellular activities such as 
morphogenesis, proliferation, differentiation and apoptosis (recently reviewed in: 
Carthew, 2006).
shRNAs
RNAi induced through transfection of siRNA duplexes into cells is extremely useful for 
studying gene function, but it is also limited by the efficiency of transfection, dilution of 
the siRNA below effective levels through cell division and unsuitability for many in vivo 
applications. To generate stable knockdown which could be adapted for in vivo
• PlhKJ 1 Im sis
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therapeutics, researchers took advantage of the growing understanding of miRNA 
processing and expressed interfering RNA molecules as hairpins from DNA vectors. 
Several groups concurrently developed vector systems using the U6 or HI promoters to 
drive expression of a shRNA (Brummelkamp et al., 2002;Sui et al., 2002;Paddison et al.,
2002). The shRNA consisted of a duplex stem of 19 — 29 nucleotides corresponding to 
the sense and antisense strands of a ‘traditional’ siRNA, separated by a short loop 
sequence. Unlike miRNA precursors however, these shRNAs were generated with 
perfect complementarity in the stem region to mediate target mRNA destruction. Once 
expressed within the cell by an endogenous RNA Polymerase, the shRNA is recognised 
by Dicer which cleaves the loop region off, yielding a functional siRNA (Meister and 
Tuschl, 2004). The use of vectors to express shRNAs enables long-term silencing 
through selection of stably transfected cells or through exploitation of recombinant 
virus techniques to incorporate the shRNA expression cassette into the host cell 
genome.
1.2.4 Virally-mediated RNAi
The most efficient way to introduce shRNA-expressing vectors into cells is through 
production of recombinant viruses which efficiently gain access to host cells and exploit 
endogenous machinery to express the shRNA. Retroviruses, adenoviruses, adeno- 
associated viruses, herpes-simplex virus and lentiviruses have all been harnessed for this 
purpose (reviewed in: Thomas et al., 2003). Retroviral vectors are commonly used due 
to their relatively low immunogenic potential and their ability to integrate into the host
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genome facilitating stable shRNA expression. Retroviruses do not, however, transduce 
post-mitotic cells such as neurons as they are unable to gain access to the nucleus unless 
the nuclear membrane breaks down during cell division. This limits their utility in 
neurological systems. Lentiviruses are a member of the retrovirus family which can 
translocate across the nuclear membrane and transduce non-dividing cells making them 
an attractive tool for use in the CNS. They have proven to be effective for gene delivery 
in the brain, resulting in long-term expression in the absence of inflammation (Blomer 
et al., 1997).
To improve safety and reduce toxicity of lentiviruses, ~95% of the parental genes are 
deleted from lentiviral vectors, leaving only those necessary for functions such as 
packaging the vector into viral particles or integrating the expression cassette into the 
host cell genome. The expression cassette encoding the shRNA can then be cloned into 
the viral backbone in place of the deleted sequences. Deleted genes which are involved 
in replication or encode structural and envelope proteins are provided on one or more 
additional vectors to provide helper functions in trans. Co-transfection of the lentivector 
and helper plasmids into permissive cell lines allows production of recombinant viruses 
which can transduce target cells, but are unable to replicate themselves.
1.2.5 Precedents for therapeutic RNAi in neurological disease
The use of RNAi as a treatment is of particular interest in neurological diseases which 
are problematic for traditional small molecule approaches due to the difficulty in 
crossing the blood-brain-barrier and lack of effective drug binding.
- I*Jill
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Non-viral delivery of RNAi directly to the nervous system has been achieved 
successfully with infusion of naked siRNA duplexes alone (Thakker et al., 2004;Dorn et 
al., 2004), in conjunction with transfection reagents (Hassani et al., 2005;Luo et al., 
2005;Tan et al., 2005;Wang et al., 2005;Kumar et al., 2006) and conjugated to a vector 
peptide, Penetratin-1 (Davidson et al., 2004). Whilst promising results have been 
attained, current technologies mean clinical translation for treatment of many 
neurodegenerative diseases would require continuous or repeated long-term infusion of 
the interfering RNAi directly to the CNS. Stable transduction of cells with virally 
expressed RNAi does not have this restriction, making it an attractive candidate for 
treatment for ‘non-druggable’ targets.
The first proof-of-principle experiment demonstrating the potential of virally-mediated 
RNA interference as a therapeutic strategy for neurological disorders was performed by 
Xia and colleagues who silenced EGFP in the brains of transgenic mice using a shRNA 
expressed from an adenovirus (Xia et al., 2002). Direct injection of the adenovirus into 
the brain striatal region reduced EGFP expression in the ipsalateral hemisphere within 
5 days. The same group then applied this approach to a mouse model of spinocerebellar 
ataxia (SCA), a progressive neurodegenerative disease caused by a polyglutamine 
expansion in the ataxin-1 protein. By injecting an adeno-associated virus (AAV) 
expressing shRNA directed against human ataxin-1 into the cerebellar lobules, they 
reduced inclusions of the mutant protein in the cerebellum and preserved the cerebellar 
molecular layer, alleviating clinical symptoms (Xia et al., 2004). Interestingly, the virus 
was beneficial despite transducing only 5 — 10% of the cerebellar Purkinje cells and 
reducing ataxin-1 protein by 50 -  60%, suggesting that complete ablation of the mutant
- I*hM
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protein was not required for therapeutic benefit. RNAi is also an effective treatment for 
another polyglutamine expansion disorder, Huntington’s Disease. AAYs expressing 
shRNAs against the coding sequence (Harper et al., 2005) and the 5’-UTR (Rodriguez- 
Lebron et al., 2005) of mutant huntingtin partially reduced mRNA and protein levels in 
transduced cells following striatal injection. Huntingtin-reactive inclusions were 
reduced and motor symptoms were improved up to 4 months post-injection (Harper et 
al., 2005), again without complete elimination of the mutant protein.
The therapeutic benefit of lentivirally-mediated RNAi in neurological disease has been 
demonstrated in a transgenic mouse model of amyotrophic lateral sclerosis (ALS). 
Lentiviruses expressing shRNAs targeting mutant superoxide dismutase (SOD1) were 
injected into the lumbar spinal cord of transgenic mice (Raoul et al., 2005). Reduction 
of the mutant protein diminished motoneuron and motor fibre losses, ameliorated 
neuromuscular deficits and prolonged survival. Likewise, injection of SOD 1-targeting 
lentiviruses into multiple muscle groups of one week old transgenic mice achieved 
substantial improvement in motor dysfunction and extended lifespan, confirming 
reduction in SOD1 levels is enough to alleviate disease symptoms (Ralph et al., 2005). 
Mouse models of Alzheimer’s disease have been effectively treated using a lentivirus 
directed against the enzyme responsible for cleavage of the amyloid precursor protein, 
BACE-1 (Singer et al., 2005). Injection of the lentivirus directly into the hippocampus 
of a transgenic mouse model reduced BACE-1 by ~60%, resulting in reduction of 
disease-associated AP-immunoreactive plaques and improvement in learning and 
memory tasks.
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1.2.6 RNAi directed against the prion protein
As no clear and major phenotypes have been described in Prnp knockout mice and 
removal of neuronal PrPc protects against neurodegeneration despite continued 
accumulation of non-neuronal PrPSc (Mallucci et al., 2003), the prion protein is an 
appealing target for RNAi-mediated therapeutics. In 2003, Daude and colleagues 
silenced Prnp in scrapie-infected neuroblastoma cells using transient transfection of a 
siRNA duplex (Daude et al., 2003). They showed that reducing PrPc in this manner 
abrogated accumulation of PrPres, thereby demonstrating the validity of this approach. 
Although the effect was only transient, they showed it was independent of both host 
cell type and mouse-adapted scrapie strain. Shortly after, Tilly and colleagues used a 
vector based system to express a shRNA which silenced ovine PrP, suggesting that 
retroviral-mediated shRNA expression might be a promising new therapy for prion 
disease (Tilly et al., 2003). More recently, two groups have used lentiviral-mediated 
RNAi to reduce expression of PrPc (Pfeifer et al., 2006;Golding et al., 2006). Both of 
these studies, however, resulted in the production of transgenic animals and neither of 
them demonstrated a therapeutic use for their lentiviruses in animals with established 
prion disease.
The recent successes of viral-mediated RNAi in mouse models of other neurological 
diseases combined with the fact that reducing expression levels of PrPc increases the 
incubation time in prion-infected mice (Bueler et al., 1994;Fischer et al., 1996;Tremblay 
et al., 1998) suggests that RNAi could be of great therapeutic benefit in prion disease.
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1.3  A im  o f th e  th esis
The aim of this thesis is to evaluate the use of RNA interference to reduce Prnp 
expression as a therapeutic approach in prion-infected mice. I t is hoped that reducing 
PrPc in mice with established prion disease using this extrinsic method will slow disease 
pathology and generate a subclinical state analogous to that achieved by transgene- 
mediated depletion of neuronal Prnp. Success requires identification of effective target 
sequences within Prnp for silencing of gene expression by RNA interference. 
Examination of the consequences of RNAi-mediated reduction of Prnp on PrPSc and 
infectivity in a cell model of prion disease should provide an indication of the validity of 
the approach. Construction of lentiviral vectors for RNAi will be required to facilitate 
stable long-term reduction of Prnp expression in the target cell type, post-mitotic 
neurons. Stereotaxic delivery of these lentiviruses into the brains of mice with 
established prion neuropathology will be used to assess the effects of reducing Prnp 
expression in this manner and evaluate the potential of this approach as a therapy for 
prion disease.
il*M» r i u s l
53
M ETHODS AND M ATERIALS
2 .1  P ro ced u res for an a lysis of DNA
2.1.1 Preparation of plasmid DNA 
Miniprep of plasmid DNA
Qiagen miniprep kits were used to perform preparation of up to 20pg of high purity 
plasmid DNA. The kit utilises alkaline lysis of bacterial cells followed by adsorption to a 
silica-gel membrane which selectively binds plasmid DNA under appropriate low-salt 
and pH conditions. The manufacturer’s protocol was followed (Qiagen QIAprep 
Miniprep Handbook, 2004). 1 - 5ml of saturated LB or TB cultures containing selective 
antibiotic was centrifuged for 15 minutes at 4°C at 6000g. The supernatant was 
discarded and the bacterial pellet was resuspended completely in 250pl buffer PI. The 
cells were lysed under alkaline conditions by addition of 250pl buffer P2 at room 
temperature for 5 minutes. Genomic DNA was precipitated through the addition of 
350pl chilled buffer P3 with immediate inversion of the tube 4 - 6  times to avoid 
localised precipitation. The lysate was centrifuged at 13,000rpm for 10 minutes, and the 
supernatant applied to a QIAprep spin column. The column was centrifuged at 
13,000rpm for 1 minute to bind the plasmid DNA and the flow-through discarded. 
Trace nuclease activity was removed by washing the column with 500pl Buffer PB and 
centrifuging as before for 1 minute. Any remaining impurities were removed by washing
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the DNA with 750pl Buffer PE containing ethanol and centrifuging for 1 minute. The 
flow-through was discarded and the column was centrifuged again at 13,000rpm for 1 
minute to remove residual ethanol. The column was placed into a clean 1.5ml tube and 
30 - 50pl of Buffer EB was added to the centre of the membrane. The column was 
incubated at room temperature for 1 minute before centrifuging at 13,000rpm for a final 
minute to elute the purified plasmid DNA.
Maxiprep of plasmid DNA
Qiagen maxiprep kits were used to prepare up to 750pg of high purity plasmid DNA.
The purification protocol is based on a modified alkaline lysis method followed by 
binding of plasmid DNA to an anion-exchange resin under suitable low salt and pH 
conditions. The manufacturer’s protocol was followed (Qiagen HiSpeed Plasmid 
Purification Handbook, 2001). 250ml of saturated LB or TB cultures was centrifuged 
for 15 minutes at 4°C at 6000g. Following removal of the supernatant, the pelleted cells 
were resuspended in 10ml buffer P I containing lOOpg/ml of RNase A. Lysis was 
achieved through the addition of 10ml buffer P2 containing NaOH-SDS, followed by 
thorough mixing and incubation at room temperature for 5 minutes. The SDS disrupts 
cell membranes releasing DNA and proteins which are then denatured by the NaOH. 
The lysis reaction was halted by the addition of 10ml chilled neutralisation buffer P3 
containing potassium acetate. The high salt concentration of this buffer causes the 
precipitation of KDS which traps genomic DNA, proteins and cell debris in salt- 
detergent complexes. The lysates were inverted 4 -6  times and immediately poured into 
the barrel of a QIAfilter cartridge. Incubation at room temperature for 10 minutes
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allowed the precipitated material to form a layer on top of the solution, preventing 
clogging of the filter. During this time, 10ml equilibration buffer QBT was added to a 
HiSpeed Maxi Tip and allowed to drain through the column by gravity flow. The cap 
was removed from the QIAfilter outlet and the plunger inserted to filter the lysate into 
the equilibrated Maxi Tip. The cleared lysate entered the anion-exchange resin by 
gravity flow and plasmid DNA was bound to the resin while degraded RNA, cellular 
proteins and metabolites passed through. The bound DNA was washed by addition of 
60ml wash buffer QC to remove remaining contaminants. 15ml of high salt elution 
buffer EB was then added to elute the DNA off the resin. The eluted DNA was 
precipitated by the addition of 0.7 volumes of isopropanol and incubated for 5 minutes 
at room temperature. The eluate/isopropanol mixture was transferred into a 30ml 
syringe attached to a QIAprecipitator Maxi Module. Insertion of the plunger into the 
syringe forced the mixture through the QIAprecipitator which traps the precipitated 
DNA. 2ml of 70% ethanol was added to the syringe and forced through the 
QIAprecipitator to wash the DNA. Air was then pressed quickly and forcefully through 
the syringe to dry the membrane and remove residual ethanol. Finally, a new 5ml 
syringe was attached to the QIAprecipitator and the purified plasmid DNA was eluted 
by the addition of 1ml TE. To ensure the maximal recovery of DNA, the eluate was 
transferred back into the 5ml syringe and pushed through the membrane a second time.
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2.1.1 Spectroscopic measurement of nucleic acids
Nucleic acid concentrations were determined by spectroscopic analysis on a NanoDrop 
ND-1000 Spectrophotometer (NanoDrop Technologies). The Nucleic Acid Measurement 
module was selected and RNA or DNA was specified. The pedestal was cleaned with 
dHbO before measurement of a lpl blank, lpl samples of unknown RNA or DNA 
concentration were then measured and the 260/280 absorbance ratio was also examined 
for assessment of nucleic acid purity. Samples with a ratio of ~ 1.8 for DNA or ~2.0 for 
RNA were considered sufficiently pure.
2.1.2 Restriction enzyme digestion of DNA 
Restriction enzyme digestion of plasmid DNA
DNA digestion by specific restriction enzymes (endonucleases) was performed using 1-5 
units of enzyme per pg of plasmid DNA at 37°C for a minimum of 1 hour. Restriction 
enzymes (New England Biolabs) were used with appropriate lOx NEB buffers giving 
optimal salt and pH conditions for the reaction. The volume of enzyme used was less 
than l/10th of the total reaction volume to prevent inhibition of the enzyme by high 
glycerol concentration.
Digestion of DNA by two restriction enzymes
Where 2 restriction enzymes shared the same buffer, digestion was performed with both 
enzymes simultaneously. When 2 restriction enzymes required different buffers, a
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sequential digest was carried out. Following digestion with the 1st enzyme, the DNA 
was electrophoresed on an agarose gel and the linearised DNA was then purified using a 
QIAquick Gel Extraction kit (QIAgen) and digested with the 2nd enzyme.
2.1.3 Dephosphorylation of DNA restriction fragments
Antartic phosphatase (New England BioLabs) was used to remove 5’ phosphate groups 
from the termini of DNA fragments following restriction enzyme digestion, to prevent 
self-ligation. In a microfuge tube containing restriction enzyme digestion products, 5pi 
of lOx phosphatase buffer (50mM Bis-Tris-Propane-HCl, ImM MgCk, O.lmM ZnCk, pH 
6.0), ljLtl Antartic Phosphatase and ddH20 to a final volume of 50pl were added. The 
mixture was incubated at 37°C for 15 minutes, and the enzyme was then heat- 
inactivated at 65°C for 5 minutes. A control reaction was performed in the absence of 
enzyme. The dephosphorylated vector DNA was extracted from agarose after 
electrophoresis.
2.1.4 Ligation of DNA
T4 DNA ligase (New England BioLabs) was used for all ligation reactions of DNA 
fragments. Ligation reactions were set up using a wide range of molar ratios of insert 
DNA: vector DNA from 0.5:1 to 100:1. Molar ratios were converted to mass ratios using 
the formula:
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vector (ng) x size of insert (kh) x molar ratio of insert = insert (ng) 
size of vector (kb) vector
Routine controls were performed to check the efficiency of ligation by religating the cut 
vector alone, and to check complete digestion of the vector by omitting T4 DNA ligase. 
After pre-treatment of vector DNA by dephosphorylation to prevent intramolecular 
ligation, vector DNA (usually 100-200ng), insert DNA (as calculated) and ddH20 to a 
total volume of 8 pi were added to a microfuge tube. The vector and insert DNA mixture 
was heated to 45°C for 5 minutes to melt any cohesive ends that had annealed. After 
brief centrifugation, the mixture was placed on ice and lpl (l-3U/pl) T4 DNA ligase and 
lpl lOx ligase buffer (lOmM MgCh, ImM ATP, 50mM Tris-HCl pH 7.5, lOmM DTT, 
and 25jilg /ml BSA) were added. Ligation was performed at room temperature for 30 
minutes or overnight at 16°C.
2.1.5 Transformation of DNA into E. co li
Heat-shock transformation of DNA into E. coli
lOOpl competent cells were thawed on wet ice and mixed with 1 - lOpl ligation mix in a 
chilled 1.5ml microfuge tube. The mixture was incubated on ice for 30 minutes. The 
cells were heat-shocked by incubation in a 42°C waterbath for 90 seconds, then 
transferred back to ice for a further 2 minutes. 900pl LB medium was added and the 
suspension was incubated at 37°C, with shaking at 225rpm for 1 hour to allow the cells 
to recover. The cells were pelleted by centrifugation at 4,000rpm for 5 minutes and
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resuspended in lOOpi LB medium before spreading onto LB Agar plates with the 
appropriate selective antibiotic.
Selection of transformants
The cells plated on LB Agar medium were incubated overnight at 37°C. Colonies 
evident the following day were picked with a pipette tip and incubated overnight in 5ml 
of LB containing the appropriate selective antibiotic at 37°C, 225rpm. Cultures were 
used fresh or stored at 4°C for several days before use in small or large-scale DNA 
preparation.
Glycerol stocks of transformed E. coli
For long-term storage, autoclaved 50% glycerol was added to fresh cultures in the log 
Ph ase of growth resulting in a 15% v/v solution. The glycerol culture was aliquoted into 
1.5ml tubes, snap frozen in dry ice and stored at —70°C.
2.1.6 Agarose gel electrophoresis of DNA
DNA fragments were separated according to size by electrophoresis through agarose 
gels.
Agarose gel preparation
A 1 - 4% agarose mini-gel was made by heating 1.5 - 6g of electrophoresis-grade agarose 
(Invitrogen) in 150ml of lx  TAE buffer in a microwave oven until it dissolved. The gel
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was cooled to approximately 50°C by stirring and ethidium bromide solution (lOmg/ml) 
was added to a final concentration 0.02% v/v. The molten gel was then poured into a gel 
tray fitted with the appropriate comb(s) (Hybaid). Gel volumes were varied (mini, midi 
and maxi) according to number of samples to be loaded and distance required for 
fragment separation. (Ethidium bromide is a potent carcinogen and was handled 
carefully according to local safety rules).
Agarose gel electrophoresis
DNA samples were mixed with l/10th volume of loading buffer (containing 
Bromophenol Blue as a tracking dye), vortexed and briefly centrifuged. The samples 
were loaded into individual wells of the gel using a pipette. A molecular weight marker 
was also loaded on each gel to allow determination of DNA fragment sizes by 
comparison. Horizontal electrophoresis was performed in appropriate tanks (Hybaid) 
containing lx  TAE buffer at 2.5-5V/cm until the fragments were adequately separated.
Visualisation of DNA in agarose gels
DNA was visualised by examining the gel on a BioRad Gel Doc 1000 imaging system 
under UV light. Gels were photographed and analysed using Quantity One software 
(version 4.5.1, BioRad).
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Extraction of DNA from agarose
DNA was electrophoresed on an agarose gel as described above. The gel was placed on a 
302nm UV transilluminator (UV products Ltd) and the desired band of DNA excised 
using a clean scalpel blade. Care was taken to minimise the amount of agarose excised. 
All DNA extractions from agarose were performed using the QIAquick Gel Extraction 
Kit (QIAGEN) according to manufacturer’s instructions. This kit solubilises the agarose 
and passes it through a mini column containing a silica membrane. The DNA binds to 
the membrane in a salt and pH-dependent manner and any contaminants pass through. 
The DNA can then be washed with ethanol-containing buffer to remove the salt and 
eluted off using a higher pH buffer.
The gel slice was weighed in a 1.5ml tube and 3 volumes of Solubilisation and Binding 
Buffer QG were added. If the slice weighed over 400mg, it was split into 2 equal parts 
and extracted separately to avoid overloading a single column. The agarose was 
solubilised by heating it in Buffer QG at 50°C for lOmin, vortexing every 2 -3  minutes.
1 gel volume of isopropanol was added to the sample and it was mixed by vortexing 
briefly. The sample was then loaded onto a QIAquick column in a 2ml collection tube 
and centrifuged for 1 minute at 13,000rpm to bind the DNA to the membrane. To 
remove any traces of agarose, 0.5ml of Buffer QG was applied to the column and it was 
centrifuged again for 1 minute at 13,000rpm. The DNA was washed and any salts 
quantitatively removed by adding 0.75ml of the ethanol-containing Buffer PE before 
centrifuging at 13,000rpm for 1 minute. The flow-through was discarded and the 
column centrifuged again at I3,000rpm for 1 minute to remove residual ethanol which 
may interfere with downstream applications. To elute the DNA, the column was placed
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in a fresh 1.5ml tube and 50jll1 of Buffer EB was added. The column was incubated at 
room temperature for 1 minute to allow the increased pH to elute the DNA off the silica 
membrane. The purified DNA was collected by centrifuging at 13,000rpm for 1 minute.
2.1.7 Polyacrylamide gel electrophoresis of DNA
To more accurately resolve small size differences in DNA fragments, samples were run 
on a polyacrylamide gel. lOOng of DNA was combined with an equal volume of 2x DNA 
loading buffer and loaded onto a 6% TBE polyacrylamide gel (Invitrogen). lOpl of 2-log 
Tri-Dye DNA ladder (New England BioLabs) was loaded into the 1st lane as a size 
marker. The gel was run at 100V until the Xylene Tylanol dye in the DNA ladder 
reached the bottom.
To stain the DNA, the gel was incubated in TBE containing 0.1% Ethidium bromide 
solution (lOmg/ml) for 30 minutes at room temperature. Excess buffer was removed by 
rinsing the gel twice in ddH20 before visualising the DNA using a BioRad Gel Doc 1000 
imaging system as for agarose electrophoresis.
2.1.8 Sequencing of DNA constructs 
Standard sequencing
Purified DNA was resuspended in TE buffer pH 8.0 at 50ng/|tl and sequenced using an 
ABI 377 automated sequencer with sequencing primers at 2pmol/|tl. Sequencing of all 
constructs was performed by G. Adamson.
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7-deaza-dGTP sequencing
Some DNA structures are refractory to standard sequencing procedures due to the 
presence of extraordinarily stable base pairing structures which are not fully denatured 
during electrophoresis. This interrupts migration of DNA bands resulting in 
compression and loss of sequence information. Substitution of the nucleotide analog 7- 
deaza-dGTP for dGTP forms weaker secondary structures and allows sequencing of 
difficult DNA constructs. Lentivector constructs which failed to yield sequences using 
standard protocols were sequenced by J. Raby at UCL Scientific Support Services using 
a 7-deaza GTP nucleotide set (Beckman Coulter) on a Beckman Coulter CEQ 8000 
genetic analysis system.
2.1.9 Design and preparation of shRNA insert oligonucleotides
To convert siRNA sequences into the required format for expression as shRNA 
molecules from the pLL3.7 lentivector, the instructions for stem loop design published 
on the McManus Lab website were followed
(http://mcmanuslab.ucsf.edu/protocols/1137stemloop design.pdf).
The design of oligonucleotide shRNA-MWl is shown below. All shRNA oligonucleotides 
were designed likewise.
siRNA sequence = G(N18)
GTACCGCTACCCTAACCAA
M.White - PhD Thesis
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1. Add T to the beginning of G(N18) to recreate -1 in U6 promoter 
TGTACCGCTACCCTAACCAA
2. Add loop sequence to end -  TTCAAGAGA 
TGTACCGCTACCCTAACCAATTCAAGAGA
3. Add reverse complement of G(N18) to end 
TGTACCGCTACCCTAACCAATTCAAGAGATTGGTTAGGGTAGCGGTAC
4. Add terminator sequence - 6 Ts 
TGTACCGCTACCCTAACCAATTCAAGAGATTGGTTAGGGTAGCGGTACTTTTTT
5. Create antisense strand
TGTACCGCTACCCTAACCAATTCAAGAGATTGGTTAGGGTAGCGGTACTTTTTT
ACATGGCGATGGGATTGGTTAAGTTCTCTAACCAATCCCATCGCCATGAAAAAA
6. Add sticky end to create Xho I site
+1
Loop Terminator
5’ -  TGTACCGCTACCCTAACCAATTCAAGAGATTGGTTAGGGTAGCGGTACTTTTTTC -  3’ 
ACATGGCGATGGGATTGGTTAAGTTCTCTAACCAATCCCATCGCCATGAAAAAAGAGCT
All oligonucleotides were ordered from MWG Biotech with a 5’ Phosphate and PAGE 
purification. They were resuspended in ddEGO ready for annealing.
2.1.10 Annealing shRNA oligonucleotides
60pmol of sense and antisense oligonucleotides were added to 48pl Annealing Buffer 
(Xeragon) and denatured by heating to 95°C for 10 minutes. The temperature was
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reduced to 70°C for 10 minutes and then allowed to cool gradually to room temperature 
overnight in a waterbath to promote annealing of complementary oligonucleotides.
2 .2  P ro ced u res fo r  a n a ly sis o f R N A
2.2.1 Controlling ribonuclease activity
RNA is rapidly degraded by RNases, which are very stable active enzymes even in 
minute amounts. Microbiological aseptic technique was used when preparing or working 
with RNA, sterile RNase-free plasticware was used and solutions were prepared using 
RNase-free glassware which had been treated with RNaseZAP (Ambion). Dedicated 
chemicals and pipette tips were reserved for RNA work. Benches, gloves, electrophoresis 
equipment and pipettes were treated with RNaseZAP and rinsed with DEPC-treated 
water (Ambion) prior to use. Gloves were changed frequently throughout procedures.
2.2.2 Design and preparation of siRNA duplexes
The ORF of the target gene for RNAi was manually searched for sequences conforming 
to the following standard rules for siRNA design:
1. GC content of 30 — 50% (Elbashir et al., 2002;Reynolds et al., 2004a)
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2. No continuous stretches of 4 or more thymine or adenine nucleotides -  a known 
termination signal for RNA Polymerase III, preventing successful expression of 
the siRNA sequence as a functional shRNA in future experiments
3. No stretches of more than 3 guanine or cytosine nucleotides due to the potential 
of these bases to hyperstack
4. Sequence does not contain known Single Nucleotide Polymorphisms
5. No internal repeats or palindromes due to their ability to form internal fold-back 
structures
6. Less than 15/19 nucleotide matches to any other mouse gene (including known 
Prnp homologs, Prnd and Sprn) as determined by Blast searching against 
murine EST libraries and mRNA sequences (www.ncbi.nlm.nih.gov/BLAST)
Desired sequences were ordered as custom RNA duplexes from Invitrogen with a 3’ 
dinucleotide thymine overhang and a 6-carboxyfluorescein tag on the 3’ end of the sense 
strand.
2.2.3 Agarose gel electrophoresis of RNA 
RNA agarose gel preparation
All equipment to be used in the preparation and running of the gel was thoroughly 
cleaned with RNaseZAP (Ambion) and rinsed twice with DEPC-treated H2O (Ambion) 
to remove any contaminating RNases. 1.5g of agarose (Invitrogen) was melted in lx  Gel 
Prep/Gel Running Buffer (Ambion) in the microwave. The solution was allowed to cool
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to 50 - 60°C in a waterbath and the gel poured to ~0.6cm depth in a gel tray fitted with 
appropriate combs (Hybaid). The gel was allowed to solidify at room temperature 
before removal of the combs to form the wells.
Sample RNA preparation and electrophoresis
lpg total RNA was mixed with an equal volume of Glyoxal Load Dye (Ambion) 
containing ethidium bromide. The samples were incubated at 50°C for 30 minutes to 
denature RNA secondary structure and allow binding of ethidium bromide. The 
samples were then placed on ice or immediately loaded onto the gel.
Horizontal electrophoresis was performed in IX Gel Prep/Gel Running Buffer (Ambion) 
at 100V for 90 minutes or until the bromophenol blue dye front had migrated to the 
bottom of the gel. Bands were visualised as for DNA electrophoresis.
2.2.4 Extraction of total RNA
Brain tissue harvested for RNA analysis was cut into pieces less than 0.5cm thick and 
immediately submerged in 10 volumes of RNA later RNA Stabilization Reagent 
(QIAgen) to prevent degradation of cellular RNA during storage. Stabilised samples 
were incubated overnight at 4°C before transfer to -20°C for longer term storage. 
RNeasy® Plus Mini kits (QIAgen) were used to extract up to 100pg of total RNA 
according to manufacturer’s instructions (RNeasy® Plus Mini Handbook, Oct 2005). 
The kit utilises a highly denaturing guanidine isothiocyanate (GITC)-containing buffer, 
RLT, to inactivate RNases during tissue lysis and homogenisation. Genomic DNA is
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removed by passing the lysates through a gDNA eliminator mini column. Samples are 
then applied to an RNeasy mini column containing a silica-gel membrane that 
selectively binds RNA molecules longer than 200 nucleotides. This enriches for mRNAs 
which are then washed before elution off the column.
Sample homogenisation
Brain samples
Brain samples stored in RNA later® were placed in 2ml screw-cap tubes containing 
~0.5g of ceramic beads. 600pl Buffer RLT was added with lOpl/ml P-Mercaptoethanol 
to further inhibit RNase activity. The samples were disrupted at 6.5M/s for 45s in a 
ribolyser (Hybaid).
Cell lines
Prior to extraction of RNA from cell lines, up to 1 x 107 cells were washed with PBS and 
harvested as usual. 350pl Buffer RLT containing P-Mercaptoethanol was added to the 
pelleted cells and they were resuspended by vortexing. The cells were then passed 5 
times through a 20-gauge needle to ensure thorough homogenisation.
Purification of RNA
Homogenised lysates were transferred to a gDNA Eliminator spin column placed in a 
2ml collection tube. The columns were spun at 10,000rpm for 30s and the flow-through 
was retained. An equal volume of 70% ethanol was added and the sample was mixed by
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pipetting. 700p,l of the lysate was then transferred to an RNeasy spin column and 
centrifuged at 10,000rpm for 15s. Samples exceeding 700pl were centrifuged in 
successive aliquots in the same column. The flow-through was discarded and 700pl of 
Buffer RW1 was added to wash the bound RNA. The column was spun as before and 
the flow-through discarded. 500pl of Buffer RPE containing 80% ethanol was added to 
the column as a second wash step and spun as before. Another 500pl of Buffer RPE was 
added and the column centrifuged for 2min to dry the silica-gel membrane and remove 
residual ethanol which may interfere with downstream applications. The column was 
carefully removed from the collection tube without contacting the flow-through and 
placed in a clean 1.5ml tube. 30 — 50pl of RNase-free water was added directly to the 
membrane and the column was spun at 10,000rpm for lmin to elute the RNA. A second 
elution was performed using an additional 30 — 50pl of RNase-free water or the previous 
eluate if the expected yield was >30pg. Purified RNA was stored short-term at -20°C or 
long-term at -70°C.
2.2.5 One-step RT-PCR
RT-PCR was performed using the Quantitect® Mulitplex RT-PCR kit according to 
manufacturer’s instructions (Qiagen). The reagents in this kit perform reverse 
transcription (RT) and polymerase chain reaction (PCR) amplification of a specific 
target from either total RNA or mRNA. A Passive Reference (ROX) dye is also 
included to provide an internal reference for normalisation of the reporter dye during 
data analysis to correct for well-to-well fluorescent fluctuations. The RT-PCR reaction
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exploits the 5’ nuclease activity of a DNA Polymerase to cleave a TaqMan probe during 
the PCR phase. The probe is homologous to the target sequence and contains a reporter 
dye at the 5’ end and a quencher dye at the 3’ end which suppresses reporter 
fluorescence when the probe is intact. During the PCR, cleavage of the probe separates 
the reporter and quencher dyes, allowing reporter fluorescence. Cleavage only occurs if 
the probe hybridises to its target sequence between the forward and reverse PCR 
primers. Accumulation of PCR products is detected directly by monitoring the increase 
in reporter fluorescence during each cycle.
When possible, commercially available, pre-validated sets of primers and probes were 
used. Otherwise, primer and probe sets were designed using Primer Express software 
v2.0 (Applied Biosystems).
Duplex reactions for the gene of interest combined with a housekeeping control gene 
were performed on 25ng of total RNA. Reverse transcription of RNA into cDNA by the 
Ominscript and Sensiscript Reverse Transcriptases was carried out at 50°C for 20 
minutes followed by activation of the DNA polymerase at 95°C for 15 minutes. 40 
cycles of target sequence amplification by HotStarTaq DNA Polymerase were 
performed at 94°C for 45 seconds then 60°C for 45 seconds. Reactions were analysed 
using the ABI Prism model 7000 sequence detection system (Applied Biosystems). 
During every run, samples lacking RNA or Reverse Transcriptase were included to 
control for contamination of reagents and amplification of residual DNA contaminants. 
mRNA expression of the genes of interest was normalised to the expression of the 
housekeeping gene amplified within the same well.
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2 .3  M am m alian  c e ll cu ltu re
All work with mammalian cell lines was carried out in a designated tissue culture 
facility using strict aseptic technique. All media and solutions were bought pre-sterilised 
or were autoclaved, and sterile plasticware was used. All procedures, including 
preparation of media, were performed in a tissue culture hood with a laminar flow unit. 
Water-baths and incubators were cleaned and sterilised regularly. All solutions and 
media were pre-warmed to 37°C prior to use.
2.3.1 Propagation of adherent cell lines 
Mouse cell lines
The N2a, N2aMoPrP and GT1 cell lines were maintained in OptiMEM growth medium 
(Gibco BRL) containing HEPES buffer, 2400mg/l sodium bicarbonate, hypoxanthine, 
thymidine, sodium pyruvate, L-glutamine, trace elements, growth factors, and phenol 
red reduced to 1.1 mg/1, supplemented with 10% v/v foetal calf serum (FCS)(Gibco 
BRL), and 50U/ml each of penicillin and streptomycin (Sigma). They were maintained 
in vented plastic flasks (NUNC, Fisher Scientific) in a humidified CO2 incubator, in an 
atmosphere of 5-7% CO2 at 37°C. The nutrient medium was changed every 3 days, and 
cells were seeded 1:3-1:8 every 5-7 days or when they had reached 85% confluence. To 
seed the N2a and N2aMoPrP cells, all medium was aspirated from the flask or dish, fresh 
growth medium was added and the cells were gently triturated from the dish. They were 
pipetted up and down until a homogenous suspension was attained and then diluted as 
necessary in fresh medium and transferred to a fresh flask. To seed the GT1 cells, old
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medium was aspirated off, the cells were rinsed with sterile PBS and trypsin-EDTA lx  
solution (0.05% trypsin, 0.5mM EDTA) (Gibco BRL) was added sufficient to cover the 
cell monolayer. The flask was placed at 37°C for 2-5 minutes until the cells were seen to 
be detaching, and an excess volume of growth medium was added, inhibiting further 
activity of the trypsin. The cell suspension was aspirated, and placed in a polypropylene 
tube (Falcon) and centrifuged at 1000 xg for 5 minutes. The supernatant was discarded 
and the cell pellet was resuspended in fresh growth medium, taking care to avoid 
clumping of the cells and transferred to a fresh flask.
When an accurate number of cells had to be seeded they were lifted as usual and 
counted using a haemocytometer (Hausser Scientific Company) and polarised light 
microscope, prior to seeding into fresh flasks with an appropriate volume of medium.
Human cell lines
The HEK293FT cell line (Invitrogen) is a fast growing derivative of the Human 
Embryonic Kidney 293 cell line which stably expresses the SV40 large T antigen for 
optimal virus production. These cells were propagated in growth medium consisting of 
Dulbecco’s Modified Eagle Medium High Glucose containing 4500mg/l D-glucose and 
4mM L-glutamine (Gibco BRL), supplemented with 10% v/v foetal calf serum 
(FCS)(Gibco BRL), 50U/ml each of penicillin and streptomycin (Sigma) and 50mg/ml 
Geneticin® (Gibco BRL) to maintain expression of the large T antigen . They were 
maintained in vented plastic flasks (NUNC, Fisher Scientific) in a humidified CO2 
incubator, in an atmosphere of 5-7% CO2 at 37°C. The nutrient medium was changed 
every 3 days, and cells were seeded 1:5-1:10 every 5-7 days or when they had reached
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85% confluence. To seed the cells, all medium was aspirated from the flask or dish, and 
the cells were lifted with trypsin-EDTA as for the GT1 cell line. The HEK293FT cell 
line was maintained for no more than 20 passages to prevent loss of optimal viral 
production.
2.3.2 Cryopreservation of cell lines
Low passage cells which were 85% confluent were harvested as above. After 
centrifugation, the cell pellet was placed on ice and resuspended in DMEM with 20% 
FCS and 10% DMSO, at a final concentration of 1 x 106 cells/ml. 1.0ml aliquots were 
frozen at a rate of -1°C per minute using a Cryo 1°C freezing container (NALGENE), 
according to the manufacturer’s instructions. These were stored overnight at —70°C 
before transfer to liquid nitrogen for long term storage at —140°C. When reanimating 
frozen cells for experimental use, they were thawed at 37°C, then diluted in nine 
volumes of fresh media. The suspension was then centrifuged at 1000 xg for 5 minutes, 
the supernatant discarded and the cells resuspended in fresh media and seeded in flasks 
or dishes.
2.3.3 Transfection of mammalian cell lines 
Transient transfection of plasmid DNA
All DNA transfections of mammalian cell lines were performed using the FuGENE6 
liposomal transfection reagent according to manufacturer’s instructions (Roche).
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FuGENE6 was used at a transfection reagent:DNA ratio of 3pl:lpg with reactions 
scaled to use lpl of FuGENE6 for every 12mm2 of culture dish. DNA was prepared 
using miniprep or maxiprep kits (Qiagen)
Briefly, the required volume of FuGENE6 was diluted into warm serum-free Optimem 
media (Invitrogen) to a final volume of lOOpl fori well of a 6-well plate or lOOOpl for a 
T75cm flask. Care was taken when adding the FuGENE6 to pipette directly into the 
media without touching the sides of the tube. The mixture was incubated at room 
temperature for 5 minutes. During this time, 1 — 16pg of DNA to be transfected was 
added to separate 1.5ml tubes. If more than 1 plasmid was to be transfected into the 
same cells, the DNA was combined at appropriate ratios up to a total of 16pg. The 
FuGENE6/media mix was added to the DNA dropwise, mixed and incubated at room 
temperature for 15 minutes. Old media was poured off the cells and replaced with fresh 
media before the transfection mixture was added dropwise. The culture vessel was 
swirled to mix the media and the cells were cultured at 37°C, 5% CO2 until ready for 
analysis.
Transient transfection of siRNA duplexes
Cells were plated in 6 well plates (NUNC, Fisher Scientific) 24 hours before transfection 
at a density to provide 40 — 60% confluency at the time of transfection.
The following day, 10 — 400nM of siRNA duplex was added to 225pl OptiMEM 
(Invitrogen). 5pl of Oligofectamine Transfection Reagent (Invitrogen) was added to 
20pl of OptiMEM. Both mixtures were incubated at room temperature for 10 minutes. 
The2 mixtures were combined and incubated for a further 10 minutes at room
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temperature. During this time, the cells were washed twice in 2ml OptiMEM . 1ml of 
OptiMEM was then added to each well of cells. The siRNA/Oligofectamine complex was 
added to the wells and swirled to mix. Cells were incubated at 37°C for 4 hours to allow 
uptake of the transfection complexes. Finally, 625pl of OptiMEM containing 30% FCS 
was added to each well to adjust the final serum concentration to 10%. Cells were then 
incubated at 37°C until ready for analysis.
2 .4  P roced u res for  th e  d etectio n  o f p ro te in s
2.4.1 Western blotting of proteins 
Preparation of cell lysates
4 x 105 — 8 x 106 cells to be lysed were washed three times with sterile PBS before lifting 
with lx  Trysin-EDTA (Invitrogen) or by trituration in PBS according to the cell line. 
Cells were then collected by centrifugation at l,000rpm for 5 minutes and the 
supernatant removed. The cell pellet was resuspended in 100 — 300pl ice-cold lysis buffer 
(TTBS) containing complete protease inhibitors (Roche) and agitated at 4°C in a 
thermomixer (Eppendorf) for 2 hours. The lysates were centrifuged at maximum speed 
in a benchtop microfuge (Eppendorf) to pellet cellular debris and the supernatant 
removed to a clean 1.5ml tube.
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Proteinase K digestion of cell lysates
This was performed to detect protease resistant PrP in lysates of prion infected PK1 
cells. Proteinase K (YWR) at was added to homogenates at a final concentration of 
10pg/ml, and the sample was incubated at 37°C for 45 minutes. The reaction was 
terminated by the addition of AEBSF (Merck) to a final concentration of 2mM. The 
samples were then prepared for electrophoresis or frozen overnight at -20°C.
Preparation of brain homogenates
A 10% (w/v) homogenate of either freshly dissected or snap-frozen mouse brain was 
made using ice-cold sterile PBS containing 2x Complete protease inhibitor tablets 
(Roche) by disruption at maximum speed for 45 seconds in a Ribolyser (Hybaid). The 
sample was kept on ice throughout homogenisation and stored at -70°C. When brains 
from mice inoculated with prions were homogenised, this was done in a designated Class 
1 hood according to local safety rules.
Proteinase K digestion of brain homogenates
This was performed to detect protease resistant PrP in homogenates of prion-inoculated 
mouse brains. Proteinase K (YWR) at was added to homogenates at a final 
concentration of 50|tg/ml, and the sample was incubated at 37°C for 1 hour. The 
reaction was terminated by the addition of AEBSF (Merck) to a final concentration of 
2mM. The sample was then prepared for electrophoresis or frozen overnight at -20°C.
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Quantification of protein using BCA assay
All assays were performed using a BCA Protein Assay Reagent kit (Pierce) according to 
manufacturer’s instructions. To conserve lysates, the microplate procedure was used. 
Briefly, 25pl of each BSA standard (125 -  2000pg/ml) was added to wells in a 96 well 
microplate (Fisher Scientific). 25pl of at least 2 of the following dilutions of sample 
lysates were also added to the microplate; 1:10, 1:5, 1:2 or undiluted. Fresh Working 
Reagent was prepared by mixing 50 parts of BCA Reagent A with 1 part of BCA 
Reagent B. 200pl of Working Reagent was added to each well and the plate was 
incubated at 37°C for 30 minutes to allow formation of the purple-coloured reaction 
product. All assays were performed in duplicate and read at 570nm on a microplate 
reader (Model 550, Bio-Rad Laboratories).
A standard curve was prepared and unknown protein concentrations calculated using a 
statistical analysis program (GraphPad Instat Version 3.02, GraphPad Software).
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Samples to be analysed were combined with an equal volume of 2x Sample buffer 
(125mM Tris-HCL, 20% glycerol, 4% SDS, 0.05% bromophenol blue, pH 6.8) and 
boiled at 100°C for 5 minutes in 1.5ml tubes with a small hole in the lid. Each sample 
was then loaded onto a 16% polyacrylamide gel (Novex) with 5pl SeeBlue pre-stained 
molecular weight markers (Novex) in an outside lane. Gels were electrophoresed 
vertically in Tris-Glycine/SDS running buffer (National Diagnostics) in a XCell 
SureLock™ Mini-Cell (Invitrogen) using a constant current of 15 — 20 mA until the dye 
front ran off the end of the gel.
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Electroblotting of gels
Following SDS-PAGE, electroblotting was performed by transfer onto Immobilon 
polyvinylidene fluoride (PVDF) membrane (Millipore). Membranes were cut to the 
same size as the gel and pre-soaked in 100% Methanol for 1 minute to ensure even 
hydration before transfer into blotting buffer (National Diagnostics). Proteins were 
transferred from the gel to the membrane in Novex X-Cell II ™ Blot modules 
(Invitrogen) at either 35V for 90 minutes, or 15V overnight.
Immunoblotting of gels
After electroblotting, membranes were transferred to square tissue culture dishes and 
washed in phosphate buffered saline, containing 0.05 % v/v tween 20, (PBST). 
Incubation with blocking solution, 5 % w/v non fat milk powder (Marvel), made up in 
PBST, was fori hour with gentle agitation. Membranes were rinsed briefly in PBS 
before incubation with primary antibody diluted in PBST for 1 hour or overnight at 
room temperature with gentle agitation. The membranes were then washed for at least 
1 hour in PBST with a minimum of 5 changes of wash buffer. Incubations with 
secondary antibodies diluted in PBST were performed fori hour at room temperature as 
before. To remove unbound antibody, the membranes were washed in PBST for at least 
1 hour with a minimum of 5 changes of wash buffer.
Detection of bound antibody was performed with SuperSignal West Pico 
Chemiluminescent substrate (Pierce) according to manufacturer’s instructions. Excess 
reagents were poured off and the membranes were placed between acetate sheets and 
transferred to a photographic cassette. Biomax MR films (Anachem) were developed
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using Kodak developer and fixative by hand or by using an Xograph imaging machine 
(Xograph Imaging Systems). Developed films were scanned using an Epson scanner for 
electronic format and densitometry of digital images was performed using a Kodak 
Image Station 440 CF (Kodak).
2.4.2 Imimmohistochemistry on sections of mouse brain 
Preparation of fixed brain sections
Brains from freshly culled mice were fixed in 10% formaldehyde in PBS overnight and 
processed and paraffin embedded by J. Linehan. 4pm sections were cut and stuck to 
Super-frost slides and allowed to dry overnight at room temperature, and then for 2 
hours at 60°C.
Antibody detection and binding in fixed brain sections
Antigen retrieval in fixed brain sections was accomplished by immersion in a low ionic 
strength buffer (2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium citrate, pH 7.8) and 
boiling in the microwave for 20 minutes. The slides were dewaxed in xylene (Sigma- 
Aldrich) and rehydrated through graded alcohols, 100% - 70%, to distilled water. 
Immunodetection was accomplished on a Yentana automated immunostaining system 
(Ventana Medical Systems) according to manufacturer’s instructions. Slides were 
mounted in DPX (CellPath) using a Robot coverslipping machine RCM3660 (Hacker- 
Meisei).
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Preparation of frozen brain sections
Frozen sections were prepared as a rapid method of detecting trypan blue injected into 
the brain when optimising stereotaxic coordinates. The desired section of 
paraformaldehyde-fixed mouse brain was immersed in Tissue-Tek O.C.T. embedding 
medium (Bright Instruments Ltd) in a small foil wrapper and placed on dry ice to 
freeze. 8 - 20|Lim sections were cut from frozen tissue using a cryostat (Leica) and 
electrostatically attached to Super Frost glass slides (BDH), then left to dry overnight 
at room temperature. Sections were fixed in acetone for 10 minutes and stored wrapped 
in foil at -20°C.
Staining of frozen brain sections
Frozen sections of mouse brains stereotaxically injected with trypan blue were 
counterstained with Nuclear Fast Red (Vector Labs) to visualize brain structure. 
Sections were coverslipped by hand using a permanent aqueous mountant (DAKO).
2.4.3 Immunofluorescent staining of cells on coverslips
Cells grown on glass coverslips (VWR) were washed thoroughly in PBS prior to fixation 
in 4% Paraformaldehyde in PBS, pH 7.4, for 10 minutes at room temperature. The cells 
were then permeabilised in PBS with 0.1% Triton X (Sigma) for 10 minutes at room 
temperature and washed three times in PBS. Non-specific binding was blocked with 
10% FCS in PBS for 30 minutes at 37°C. The cells were washed three times in PBS and 
incubated with primary antibody diluted in PBS containing 1% FCS for 1 hour at 37°C.
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Excess antibody was removed by washing three times in PBS. The cells were then 
incubated with secondary antibody diluted in PBS containing 1% FCS for 1 hour at 
37°C in the dark. Excess antibody was removed by washing three times in PBS followed 
by a final three washes in sterile PBS. The coverslips were then mounted upside down 
on uncoated glass slides (BDH) in fluorescent mounting medium (DAKO) containing 
lpg/ml DAPI (Sigma) to stain nuclei and allowed to dry in the dark. Once dry, the edges 
of the coverslips were sealed with clear nail varnish.
2.4.4 FACS analysis of cell surface PrP
Cells were harvested as usual and washed twice in PBS. The pellets were resuspended in 
lml 4% Paraformaldehdye in PBS and mixed by pipetting so no clumps were visible. 
They were then transferred to 5ml FACS tubes (Becton-Dickinson) and incubated on ice 
for 1 hour to allow fixation. 4ml of FACS buffer (PBS containing 2% FCS, 0.1%
Sodium Azide) was added to each tube and the cells were spun in a centrifuge at 
2000rpm for 5 minutes. The supernatant was removed and the cells were incubated in 
300pl of FACS buffer containing ICSM18 at 12pg/ml fori hour on ice. Excess antibody 
was removed by washing in lml FACS buffer three times. Detection of PrPc labelling 
used secondary antibody PE-Alexa Fluor® 647 goat anti-mouse IgG at 1:500 dilution 
(Molecular Probes) fori hour on ice in the dark. The cells were washed three times in 
FACS buffer to remove any unbound antibody. FACS was performed on a FACSCalibur 
machine (BD) with fluorescein detection of the siRNA duplexes in the FL1 channel and 
PrPc detection in FL3. Analysis was performed using Flowjo software (Tree Star Inc).
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2.4.5 Scrapie cell assay
The scrapie cell assay (SCA) is an in vitro replacement for bioassays for prion infectivity, 
in which a cell line that expresses PrPc is capable of propagating PrPSc and infectivity 
after infection by certain prion strains. A murine neuroblastoma cell line, N2a, is 
susceptible to the mouse strain RML, and subclones have been produced that are 
capable of reporting infectivity at a greater sensitivity than is currently possible using 
reporter mice (Klohn et al., 2003). The SCA was performed by Dr F. Properzi.
PK1 cells (a highly susceptible subclone of N2a cells) were plated at 20,000 cells per well 
on a 96 well plate 16 h prior to addition of samples. Samples to be assayed for 
infectivity were diluted in OptiMEM growth media (Gibco BRL) supplemented with 
10% FCS before application of at least 6 replicates in the assay at 300 |ll per well. After 
addition of samples, cells were passaged at 1:10 dilutions three times over a period of 12 
days to dilute out initial inoculum and allow propagation of prion infectivity. The cells 
were then analysed for PrPSc content by the ELISPOT.
2.4.6 ELISPOT
ELISPOT plates (Multi screen Immobilon-P 96-well filtration plates, Millipore, sterile) 
were activated with 70% Ethanol and washed twice with PBS by suction prior to 
addition of cells. 200pl of OptiMEM containing 20,000 uninfected PK1 cells was added 
to each well to normalise protein content. The OptiMEM was removed by vacuum
suction and the cells were adhered to the membrane. A dilution series was prepared for
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each sample so that 1,250, 2,500 or 5,000 treated IPK1 cells was added to each well with 
a minimum of six wells per sample. The media was removed by suction and the plates 
were dried at 50°C for at least 1 hour and stored at -20°C until ready for use. The 
remaining procedures in the ELISPOT were performed by A. Badhan and Dr F. 
Properzi.
60pl of Proteinase K solution (Roche, specific activity 2.2U/mg) at lpg/ml was added to 
each well to digest non-resistant proteins and the plate was incubated at 37°C for 30 
minutes. The PK was removed by vacuum suction and the wells were washed twice 
with 160pl PBS. 160pl of ImM PMSF (Sigma) was added to each well to inhibit the 
proteinase and the plate was incubated for 10 minutes at room temperature. 120pl of 3 
M guanidinium thiocyanate (GSCN) in 10 mM Tris.HCl (pH 8) was added to each well 
to denature the remaining proteins and the plate was incubated for a further 10 minutes 
at room temperature before washing 7 times with 160j l i1 PBS. 120j l i1 of Superblock 
(Pierce) was added to each well and the plate was incubated for 1 hour at room 
temperature. 60pl of ICSM18 antibody at 1:5,000 dilution in TBST containing 1% milk 
powder was added to each well and the plate was incubated for 1 hour at room 
temperature. The plate was washed 5 times with TBST without suction to reduce non­
specific binding of the antibody to the membrane. 60pl of Alkaline-Phosphatase 
conjugated anti-IgGl antibody (Southern Biotechnology) diluted 1:7,500 in TBST with 
1 % milk powder was added to each well. The plate was incubated at room temperature 
for 1 hour before washing 5 times with TBST without suction. The plastic underdrain 
was removed from the plate and the membrane was dried by pressing onto a clean 
tissue. 54pl Alkaline Phosphatase dye (Biorad) was added to each well and the plate was
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incubated for 16 minutes at room temperature to allow colour development. The 
supernatant was discarded and the plate was washed twice with water. The plates were 
dried at room temperature in a hood and stored at -20°C in the dark. PrPSc-positive cells 
were counted on a Zeiss KS ELISPOT system (Stemi 2000-C stereo microscope 
equipped with a Hitachi HV-C20A colour camera and a KL 1500 LCD scanner and 
WELLSCAN software from Imaging Associates).
2 .5  Lent!viral procedures
2.5.1 Recombinant lentivirus production
Low passage number HEK293FT cells in T75cm2 flasks were transiently transfected at 
80% confluency with the lentivector constructs plus the pCMV_dR8_74 and pMD2G 
helper plasmids. 940pl of warm serum-free DMEM (Gibco BRL) was added to a 1.5ml 
tube for each transfection. 34pl of FuGENE6 transfection reagent (Roche) was added to 
this media without touching the sides of the tube and incubated at room temperature 
for 5 minutes. During this time, 5pg of the lentivector construct was combined in a 
1.5ml tube with 3.75pg of pCMV_dR8_74 and 2.5pg pMD2G for each flask to be 
transfected. The media/FuGENE6 mix was then added to the DNA in slow drops and 
incubated at room temperature for 15 minutes. During the incubation, the old media 
was aspirated from the cells and replaced with fresh growth media. The transfection 
mixture was then added dropwise to the flasks and swirled over the cells. The flasks 
were incubated overnight to allow uptake of the DNA and the media was replaced with
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10ml serum-free OptiMEM (Gibco BRL) for viral collection. Four days post- 
transfection, the media was harvested and the lentiviruses were concentrated. Two 
transfections were typically done for each virus and the media pooled prior to 
concentration.
2.5.2 Concentration of lentiviruses by centrifugal filtration
Lentiviruses were concentrated by centrifugation through sterile disposable filter 
devices. A filter membrane with a molecular weight cut-off of lOOkDa was used to 
retain the virus whilst allowing contaminating proteins and impurities to pass through. 
Culture media from lentiviral-producing cells was harvested and centrifuged at 3000rpm 
at 4°C for 15 minutes to pellet cell debris. The supernatant was collected and filtered 
through a sterile low protein-binding 0.45pm PVDF filter (Millipore) to remove any 
remaining debris. In order to prevent loss of virus through non-specific binding to the 
membrane, the filter unit was primed before use. 10ml of OptiMEM containing 1% 
Foetal Calf Serum (Invitrogen) was added to each Centricon Plus-20 filter device and 
they were spun at 2,500rpm for 20 minutes or until the media spun through.
Up to 20ml of pre-cleared culture media was then transferred into a primed filter unit 
and spun at 2,500rpm at 4°C until it passed through. Any remaining culture 
supernatant was added and spun through the same filter unit to produce the highest 
titre possible for each virus.
A sterile retentate cup was then fitted to the top of the filter unit and the entire device
was inverted. The concentrated virus was collected by centrifugation at lOOOrpm at 4°C
—
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for 3 minutes. A typical yield was approximately 150pl. The concentrated virus was 
then aliquotted and frozen immediately at -70°C prior to titration.
2.5.3 Determination of lentiviral titre
Transduction of HEK293FT cells
A serial dilution method was used to determine the titre of each lentivirus. 2 x 105 
HEK293FT cells were plated in each well of a 6 well plate and incubated overnight. The 
following day, the lentiviral stock was thawed and ten-fold serial dilutions ranging from 
10‘2to 10"6 were prepared in lml complete culture medium. Polybrene was added to the 
dilutions at a final concentration of 8pg/pl to neutralise the charge of the plasma 
membrane and promote interaction with the virus. The culture media was removed 
from the cells and the viral dilutions added. One well received polybrene only as a 
control for any effects of this agent on the cells. The plates were incubated at 37°C 
overnight and the culture medium was replaced the following day. Four days post­
transduction, the cells were examined for GFP expression by fluorescence microscopy 
and harvested for FACS analysis.
FACS analysis of GFP expression
Cells were harvested as usual and washed twice in PBS. The pellets were resuspended in 
lml 4% paraformaldehdye in PBS and mixed by pipetting so no clumps were visible. 
They were then transferred to 5ml FACS tubes (Becton-Dickinson) and incubated on ice 
for 1 hour to allow fixation. 4ml of FACS buffer (PBS containing 2% FCS, 0.1%
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Sodium Azide) was added to each tube and the cells were spun in a centrifuge at 
2000rpm for 5 minutes. The supernatant was removed and the cells were resuspended in 
300pl of FACS buffer.
Analysis of GFP expression was performed on a FACSCalibur machine (Becton- 
Dickinson) running CellQuest software (Becton-Dickinson). The cells that received 
polybrene only were used as a negative control to gate for living GFP-negative cells. 
GFP-positive cells in the transduced samples were detected in FL1 and gated to show 
percentage of total population. At least 20,000 cells were counted.
Calculation of titre
The following equation was used to correct for the viral dilution factor and the number 
of cells plated:
Titre — (% GFP-positive) x (virus dilution factor) x (number of cells plated)
The dilution which gave between 1 — 10% GFP-positive cells was used to minimise the 
chance of underestimating titre by counting cells transduced more than once. Titre was 
expressed as number of Transducing Units per ml (TU/ml).
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2 .6  A nim al procedures
2.6.1 Scrapie transmissions 
Inoculation of RML
Prion inoculation of mice was performed by designated staff, according to established 
local protocols. One week old mice were anaesthetised with isofluorane in an inhalation 
chamber until pinch reflexes were absent. They were then inoculated with 20pl of 1% 
brain homogenate of RML (Rocky Mountain Laboratory) mouse-adapted scrapie strain 
(12425) in PBS using a lml insulin syringe and a 26-gauge hypodermic needle inserted 3- 
4 mm into the right parietal lobe. Mice were allowed to recover in a cage placed on a 
heated pad prior to being replaced in their home cage.
Diagnosis of scrapie symptoms
Mice were examined daily for appearance of scrapie symptoms or other illness. Disease 
in wild-type animals is diagnosed when at least three of the following symptoms are 
present: foot clasping of hind legs when mice were lifted by the tail; tail rigidity; 
decreased motor activity; mincing gait, disorientation; mild hind leg paresis, ataxia; 
kyphosis. All symptoms were recorded on videotape prior to culling of the animal.
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Removal of brains from scrapie sick animals
Terminally scrapie-sick animals or animals sick for other reasons were culled and the 
brains were removed according to local safety regulations in class I cabinet within the 
secure pathogen-free facility.
2.6.2 Stereotaxic surgery
All animal experiments conformed to United Kingdom regulations and institutional 
guidelines and were performed under Home Office project license. Mice were bred in- 
house and were housed in a temperature and light-controlled mouse colony room (12 hr 
light/dark cycle) in groups of 4 - 6. All mice had free access to food and water. All cages 
contained Perspex boxes (‘igloos’), cylindrical cardboard tubes and shredded paper in 
view of the positive effects of such enrichment on cognition in rodents. For surgery, 
animals were anesthetized with lOOmg/kg ketamine (Pharmacia & Upjohn) + lOmg/kg 
xylazine (Bayer PLC) intraperitoneally and positioned in a small animal stereotaxic 
head frame (ASI). The skull was exposed by a small midline incision and a hole was 
drilled at the appropriate coordinates, using bregma as the reference point. Using a 26 
gauge 700 series Hamilton syringe (Hamilton) trypan blue or highly concentrated 
lentivirus was delivered at a rate of approximately 0.5pl/minute. After injection, the 
needle was left in place for a further 5 minutes. The midline incision was closed with 
Vetbond (3M) and animals were monitored on heat pads until they woke up and were 
mobile.
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2.7 M ateria ls
2.7.1 Commercial kits
Bicinchoninic (BCA) assay (Pierce Biotechnology)
Plasmid Mini kit (Qiagen)
Plasmid Maxi kit (Qiagen)
Quantitect® Mulitplex RT-PCR (Qiagen)
RNeasy® Mini prep (Qiagen)
SuperSignal® West Pico Chemiluminescent Substrate kit (Pierce)
2.7.2 Equipment
ABI-377 sequencer (Applied Biosystems)
ABI Prism model 7000 sequence detection system (Applied Biosystems) 
Allegra 25R Centrifuge (Beckman Coulter)
AxioCam MRm camera (Zeiss)
Axioplan 2 MOT microscope (Zeiss)
Beckman Coulter CEQ 8000 
BioMax-MR-I-Film (Anachem)
Centrifuge Universal 32R (Sartorius)
CM1850 Cryostat (Leica)
DH Autoflow CO2 Air-Jacketed Incubator (Nuaire)
Eppendorf Centrifuge 5415C (Cambridge Scientific)
FACSCalibur (Becton-Dickinson)
Gel Doc EQ UY-transilluminator (Bio-Rad Laboratories) 
Haemocytometer (Hausser Scientific Company)
Kodak Image Station 440 CF (Kodak).
LSM 510 META confocal microscope (Zeiss)
Microplate reader Model 550 (Bio-Rad Laboratories)
Nano Drop ND-1000 Spectrophotometer (NanoDrop Technologies) 
Novex X-Cell II ™ Blot modules (Invitrogen)
Raven Incubator (LTE Scientific LTD)
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Robot coverslipping machine RCM3660 (Hacker-Meisei)
UV transilluminator (UVP)
Ventana automated immunostaining system (Yentana Medical Systems)
Video printer (Bio-Rad Laboratories)
XCell SureLock™ Mini-Cell (Invitrogen)
Zeiss KS ELISPOT system (Zeiss)
Xograph imaging machine (Xograph Imaging Systems)
2.7.3 Reagents
16% pre-prepared polyacrylamide Tris-glycine mini-gel (Invitrogen) 
lkb Plus DNA ladder (Invitrogen)
2-log Tri-Dye DNA ladder (New England BioLabs)
6% TBE polyacrylamide gel (Invitrogen)
Alkaline Phosphatase dye (Biorad)
Ampicillin (Sigma)
Annealing buffer (Xeragon)
Antartic Phosphatase (New England BioLabs)
Antartic Phosphatase Buffer (New England BioLabs)
Developer and fixer (Sigma)
Dimethyl sulphoxide (Sigma)
DPX (CellPath)
ELISPOT plates (Multi screen Immobilon-P 96-well filtration plates, Millipore, 
sterile)
Ethanol (Sigma)
Ethidium bromide (Sigma)
Fluorescent mounting media (DAKO)
FuGENE6 (Roche)
Geneticin® (Gibco BRL)
Glycerol (Sigma)
Hyperladder IV (Bioline)
Immobilon polyvinylidene fluoride (PVDF) membrane (Millipore).
Laemmli sample buffer (Bio-Rad Laboratories)
Lipofectamine (Invitrogen)
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Mini EDTA free protease inhibitors (Roche)
NEBuffer 3 (New England BioLabs)
Non-fat milk powder (Marvel)
Not I (New England BioLabs)
Nuclear Fast Red (Vector Labs)
Oligofectamine (Invitrogen)
Optimem (Invitrogen)
Paraformaldehyde (PFA) (Sigma)
PMSF (Sigma)
Proteinase K solution (Roche, specific activity 2.2U/mg) 
RNaseZAP (Ambion)
SeeBlue Plus 2 (Invitrogen)
Sodium dodecyl sulphate (Sigma)
B-mercaptoethanol (Sigma)
Superblock (Pierce)
T4 DNA ligase (New England BioLabs)
T4 DNA ligase buffer (New England BioLabs)
Tissue-Tek O.C.T. embedding medium (Bright Instruments Ltd) 
Transfer buffer (National diagnostics)
Tris-glycine/SDS (National diagnostics)
Triton-X-100 (Sigma)
Trypan blue (Sigma)
Trypsin-EDTA (Invitrogen)
Ultra Pure Agarose (Invitrogen)
Whatman filter paper (Sigma)
Xba I (New England BioLabs)
Xho I  (New England BioLabs)
2.7.4 Vectors
pLL3.7 (ATCC)
pCMV_dR8_74 (kind gift of Trono Lab) 
pMD2G (kind gift of Trono Lab)
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2.7.5 Bacterial strains
JS4 Competent E. coli (kind gift of Professor Jat)
STBL2 Competent E. coli (Invitrogen)
2.7.6 Mammalian cell lines and cell media
Mouse neuroblastoma cell line, N2a (ATCC)
N2aMoPrP
Mouse hypothalamic cell line, GT1
Human Epithelial Kidney cell line, fast-growing clone 293FT (Invitrogen)
DMEM containing 4500mg/L-glucose, 4mM L-glutamine, (Gibco BRL)
OptiMeM (Gibco BRL)
10% FCS (Gibco BRL)
10% Penicillin/Streptomycin (Sigma)
Geneticin® (Gibco BRL)
2.7.7 Antibodies
Alexa Fluor 488 goat anti-rabbit IgGi (Molecular probes)
Alexa Fluor 546 goat anti-mouse IgGi (Molecular probes)
Alexa Fluor 568 goat anti-mouse IgGi (Molecular probes)
Alkaline-Phosphatase conjugated anti-IgGl antibody (Southern Biotechnology) 
Anti-GST rabbit polyclonal (Abeam)
Anti-VSV-G mouse IgGi (Roche)
Goat anti-mouse IgG (Fab specific) peroxidase conjugated (Sigma)
HIV1 p24 mouse IgGi (Abeam)
PE-Alexa Fluor® 647 goat anti-mouse IgG (Molecular Probes)
2.7.8 Prepared solutions 
T E  ( 1  l i t r e )
100ml 1M Tris-HCl (pH 7.0, lOOmM) (Sigma)
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20ml 0.5M EDTA (pH8.0, lOmM) (Sigma)
1 litre with ddtbO
L u r i a  B r o t h  ( L B )
25g Luria broth (Sigma)
1 litre with ddfbO 
Sterilise by autoclaving
T e r r i f i c  B r o t h  ( T B )
47.5 g Terrific broth, modified (Sigma)
8ml glycerol (Sigma)
1 litre with dd H2O 
Sterilise by autoclaving
L u r i a  A g a r
40g Miller’s LB Agar (Sigma)
1 litre ddthO 
Sterilize by autoclaving
After moderate cooling lOOpg/ml ampicillin was added
D N A  l o a d i n g  b u f f e r
0.75g Ficoll 400 (Amersham)
0.005g bromophenol blue (Sigma)
5ml with ddLhO
S a m p l e  b u f f e r
0.5ml lMTris-HCl pH 7.6 
25ml glycerol (Sigma)
0.5ml 10% SDS (Sigma)
0.05g bromophenol blue (Sigma)
Make up to 50ml with ddH20
P B S T
0.1% Tween20 (Sigma) in 1 litre of PBS
*1 m, 95
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TTBS
0.1% Tween20 (Sigma) in 1 litre of TBS
Blocking buffer 
5% Milk powder (Marvel)
50ml PBST
2.7.9 Computer Programs and Web pages
ABI Prism 7000 SDS Software (Applied Biosystems)
Adobe Photoshop 6 Version 6 (Adobe)
Axiovision control software Version 3.2 (Zeiss)
Ensernbl http://www.ensembl.org 
Flowjo software (Tree Star Inc)
Genscan Version 3.1 (Applied Biosystems)
GraphPad InStat Version 3.05 (GraphPad Software)
Microplate Manager® Version 4.0 (Bio-Rad Laboratories)
NCBI httpL//www.ncbitnlm.nihtgQv
Primer Express software v2.0 (Applied Biosystems)
Sequence Analyser Version 3 (Molecular Dynamics)
UniSTS http://www.ncbi.nlm.nih.gov/entrez/query.fcgi7db-unis_ts
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3 .1  In tro d u ctio n
Depletion of neuronal PrPc in mice with established prion infection reverses early 
spongiform degeneration of neurons and prevents clinical disease progression (Mallucci 
et al., 2003). Consequently, reducing PrPc expression in the brain through extrinsic 
means is likely to be an effective therapy for prion diseases. One technique for achieving 
this exogenous knockdown in mammalian systems, both in vitro and in vivo is through 
RNA interference (RNAi). This chapter describes the identification and validation of 
target sequences within Prnp for RNAi-mediated knockdown of expression.
3.1.1 Use o f cell lines as models to study PrPc and prion propagation
Although traditionally studies of prion infection have been performed in vivo, their 
prohibitive cost and complexity has led to many attempts to establish cell lines for the 
study of PrPc and prion propagation. Many cell lines, however, are resistant to prion 
infection for unknown reasons (Rubenstein et al., 1984;Butler et al., 1988). Only a few 
lines have been established which support stable propagation and of these, the mouse 
neuroblastoma cell line, N2a, has been most widely used. N2a cells were first shown to 
propagate prions in 1988 (Butler et al., 1988) and became the first clonal line capable of
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chronic infection. Populations of N2a cells exhibit heterogeneous susceptibility to prion 
infection (Bosque and Prusiner, 2000;Enari et al., 2001;Klohn et al., 2003) which is not 
stable over prolonged periods of propagation (Klohn et al., 2003) and may be due to 
epigenetic features. Therefore, they are often cloned and highly susceptible sublines 
selected for further study. As the siRNA duplexes described here were ultimately 
intended for use in prion-infected N2as, this cell line was also used to evaluate their 
efficacy.
The level of expression of PrPc in standard N2as is not high enough to allow easy 
detection of the protein by all techniques, so for some experiments a PrPc 
overexpressing N2a line, N2aMoPrP, was used which expresses full-length mouse PrPc at 
~3-fold wild-type levels (Kristiansen et al., 2005).
3.1.2 siRNA design features
siRNAs are the specificity determinants of the RNAi pathway with a defined structure 
that enables them to direct cleavage of the target mRNA. Prototypical siRNAs are 21nt 
dsRNAs that contain 19 base pairs and 2 nucleotide 3’ overhanging ends (Nykanen et 
al., 2001;Elbashir et al., 2001a;Chiu and Rana, 2002). I t is proposed that during siRNA 
production, the RN aselll domains of Dicer act as a pseudo-dimer, each hydrolysing 1 
strand of the substrate dsRNA (Zhang et al., 2004). The alignment of the pseudo-dimer 
results in the 2 nucleotide overhang and cleavage of the dsRNA produces 5’ phosphates 
and 3’ hydroxyls. These structural features are important for loading of the siRNA 
duplex into RISC and determining the cleavage site of target mRNA (Elbashir et al.,
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2001b;Tomari et al., 2004) so they must also be preserved when utilising synthetic 
siRNAs. The 3’ overhang of synthetic siRNAs usually consists of two thymine bases for 
ease of manufacture combined with effective silencing ability (Elbashir et al., 2001b). 
The siRNA duplexes used here were manufactured to conform to this structure to 
provide the best chance of being effective.
3.1.3 Comparison against sequences previously shown to silence P rn p
The previously published examples of RNAi against the prion protein provide a 
benchmark against which future silencing attempts can be measured (Daude et al., 
2003;Tilly et al., 2003). Although both studies demonstrated successful reduction of 
Prnp expression, advances in the understanding of RNAi since their publication mean 
more effective sequences may now be possible. For this reason, new sequences were 
investigated and compared to the previously published ones which are henceforth 
referred to as the ‘Daude’ and ‘Tilly’ sequences.
3 .2  S e lec tio n  o f ta rget seq u en ces w ith in  JPrnp
siRNA sequences targeting the mouse prion gene were designed according to established 
guidelines (Reynolds et al., 2004). As the current sequence design software packages 
were not available at the time, 19 nucleotide target sequences within the coding 
sequence of Prnp that conformed to generally accepted rules for design of successful 
siRNA sequences were identified manually. Six sequences (Seq 1-6)  were identified
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that met these guidelines and were then scored in line with the more stringent Reynolds 
criteria for effective siRNAs. The previously published Tilly and Daude sequences were 
also scored for comparison, see Table 3.1.
Table 3.1 Scores of the potential siRNA sequences according to the Reynolds criteria
Criterion Tilly 
et al
Daude 
et al
Seq 1 Seq 2 Seq 3 Seq 4 Seq 5 Seq 6
GC = 36 -  52% (+i) 0 1 0 0 0 1 1 1
A AJ positions 15 — 19 (+1 ea) 3 3 2 2 2 3 2 4
A at 19 (+1) 0 0 0 1 0 1 1 1
A at 3 (+1) 0 0 0 1 0 1 0 0
U at 10 (+1) 1 0 0 0 0 0 0 1
Tra less than 20°C (+1) 0 0 0 0 0 0 0 0
G or C at 19 (-1) -1 -1 -1 0 0 0 0 0
G at 13 (-1) 0 0 0 -1 0 0 0 -1
TOTAL 3 3 1 3 2 6 4 6
According to Reynolds et al, a sequence scoring 6 or above is a good candidate for an 
effectual siRNA. Interestingly, both the Tilly and Daude sequences attain a relatively 
low score of 3, suggesting that the other sequences may be more effective for silencing 
Prnp. The 3 highest scoring sequences, Seq 4, 5 and 6 were chosen and referred to as 
MW1, MW2 and MW3 respectively. MW1 and MW3 were commercially synthesised and 
supplied as duplexes with a 3’ dinucleotide thymine overhang. Due to financial
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constraints, the lower scoring MW2 duplex was not acquired. The Daude and Tilly 
sequences were obtained as positive control duplexes. All duplexes were labelled with 6- 
carboxyfluorescein (6-FAM) on the 3’ end of the sense strand facilitating easy detection 
in vitro and monitoring of transfection efficiencies. The sequences and positions within 
the Prnp open reading frame are shown in Figure 3.1:
Figure 3.1 Position of candidate siRNA sequences within the open reading frame of 
the murine Prnp gene
156 ATGgcgaacc t t g g c t a c tg  g c tg c tg g c c  c t c t t t g t g a  c ta tg tg g a c
tg a tg tc g g c  c tc tg c a a a a  agcggccaaa gcctggaggg  tg g aacaccg
g tg g aag ccg  g ta tc c c g g g  cagggaagcc c tg g ag g caa  c c g t ta c c c a
c c tc a g g g tg  g cacc tg g g g  g cagccccac  g g tg g tg g c t ggggacaacc
cca tgggggc  agctggggac  a a c c tc a tg g  tg g ta g t tg g  g g tc ag cccc
a tg g cg g tg g  a tg g g g ccaa  ggagggggta c c c a ta a tc a  g tggaacaa(r
456 cccagcaaac caaaaaccaa c c tc a a g c a t  g tggcagggg c tg cggcagc  D aude
tg g g g c a g ta  g t g g g ^ m ^ H m H ^ ^ I H H g g g g  ag cg ccg tg a  ■  Tilly 
556 g cag g c cca t g a t c c a t t t t  g g caa cg ac t gggaggaccg c ta c ta c c g t  |^ /|\y\/q
g a a a a c a tR t a c c g c ta c c c  ta a c c a a g tg  ta c ta c a g g c  c a g tg g a tc a  *>i\a/o
656 g ta c a g c a a c  c a g a a c a a c t tc |f tg c a c g a  c tg c g tc a a t  J tc a c c a tc a
ag cagcacac  g g tc a c c a c c  accaccaag g  g g g a g a a c tt caccgagacc ®  MW3
g a tg tg a a g a  tg a tg g a g c g  cg tg g tg g a g  c a g a tg tg c g  tc a c c c a g ta
ccagaaggag  tc c c a g g c c t  a t ta c g a c g g  g ag aa g a tcc  agcagcaccg
t g c t t t t c t c  c t c c c c t c c t  g tc a tc c tc c  t c a t c t c c t t  c c t c a t c t t c
906 c tg a tc g tg g  gaTGA
The position of each candidate siRNA sequence within the Prnp ORF is highlighted. Numbers 
of basepairs refer to position within the full-length mRNA sequence, NM_011170.
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3 .3  Q u a n tifica tio n  o f k n ock d ow n  o f P r P c ex p ressio n
3.3.1 Quantification of knockdown of PrPc in N2aMoPrP cells
To determine if any of the siRNA duplexes reduced Prnp expression, 400nM of each was 
transfected into the PrP-overexpressing cell line, N2aMoPrP, allowing direct comparison 
with the results of Daude et al. According to their protocol, the cells were harvested four 
days later and lysates made for analysis by western blotting. PrPc was detected with 
the ICSM18 antibody which recognises all glycoforms of PrP (Khalili-Shirazi et al., 
2005). As shown in Figure 3.2, all duplexes produced some reduction of PrPc expression. 
The most significant reductions resulted from the MW1 and MW3 duplexes which 
reduced all glycoforms of PrPc, with a modest reduction in the lower glycoforms from 
the Daude and Tilly duplexes.
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Figure 3.2 PrPc expression is reduced in a population of N2aMoPrP cells transfected 
with siRNA duplexes
ICSM18
36 — 
22 —
C D T MW1 MW3
N2aMoPrP cells transfected with 400nM of siRNA were harvested after four days and lysates 
made. 15pg of total protein was loaded per lane and immunoblotted. Untransfected cells were 
loaded as a positive control (C) for PrPc expression in lane 1. The membrane was incubated with 
ICSM18 at 0.5pg/ml and HRP-conjugated secondary antibody. The signal was visualised with 
high sensitivity ECL. A duplicate membrane incubated with secondary antibody only was 
blank. D = Daude duplex, T= Tilly duplex.
Allow ing for a 70%  tran sfec tio n  efficiency (e stim ated  b y  v isu a lisa tio n  o f fluorescein- 
tag g ed  dup lexes u n d er U V  lig h t), d en sito m etric  ana lysis  revealed  each  sequence gave 
th e  follow ing knockdow n  o f  to ta l  P r P c, (T ab le  3.2).
Table 3.2 Knockdown of PrPc obtained by transfection of N2aMoPrP cells with each 
siRNA duplex
Duplex Knockdown of PrPc
MW1 51.4%
MW 3 56.6%
D aude 8.3%
T illy 19.3%
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These results however, are in contrast to the published findings in which cells 
transfected with 400nM of the Daude duplex produced no detectable PrPc (Daude et 
al., 2003). The results obtained with the Tilly duplex are not directly comparable to the 
original research as this utilised a plasmid-based expression system (Tilly et al., 2003).
A major limitation of this approach is the difficulty of accurately measuring knockdown 
in a mixed population of transfected and untransfected cells. The knockdown measured 
represents an average across the population. To visualise knockdown in individual 
positively transfected cells within the population, immunofluorescent histochemistry 
for PrPc was performed following transfection of the duplexes.
In addition, 400nM is a very high concentration of siRNA, so the potential for off- 
target cellular effects is increased (Jackson et al., 2003). To determine the effectiveness 
of the siRNA at a lower concentration, 200nM of each duplex was transfected into 
N2aMoPrP cells seeded on glass coverslips. Three days post-transfection, the cells were 
fixed and immunostained to detect PrPc expression in positively transfected cells.
Vh l *  I ^
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Figure 3.3 PrPc expression is reduced in individual N2aMoPrP cells transfected with 
200nM of each siRNA duplex
200nM Daude 200nM Tilly200nM MW1 200nM MW3
Three days post-transfection with 200nM of each siRNA duplex, N2aMoPrP cells on glass 
coverslips were fixed and immunostained with primary antibody ICSM18 at lOgg/ml. Detection 
of antibody binding was performed with secondary antibody, Alexa Fluor®568 goat anti-mouse 
IgG (H+L) (Molecular Probes) at 1:800 dilution. Coverslips were mounted onto slides with 
DAKO fluorescent mounting medium containing 1 pg/ml 4\6-diamidino-2-phenylindole (DAPI; 
Sigma) and cells were viewed on an Axioplan 2 MOT microscope (Zeiss) with an AxioCam MRm 
camera and Axiovision Control software (Zeiss). The cell nuclei are shown in blue, the green 
signal represents the fluorescein tag on the siRNA duplexes and red labelling indicates PrPc 
staining.
As shown in Figure 3.3, PrPc labelling was considerably reduced in the cells transfected 
with the MW1 and MW3 duplexes. The Daude duplex gave markedly less knockdown at 
this lower concentration and the effects of the Tilly duplex were negligible under these 
conditions.
As successful knockdown of PrPc had been achieved, a commercially available negative 
control duplex was obtained to facilitate a more rigorous investigation of the sequences. 
This control duplex consisted of a scrambled sequence with approximately the same GC 
content as the experimental duplexes and no significant matches to any known mouse 
gene (Invitrogen).
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Transfection with a scrambled duplex provides a control for the effects of activating the 
intracellular RNAi pathway and all future studies were performed with this additional 
control.
3.3.2 Quantitation of PrPc knockdown in standard N2a cells
Previous experiments were performed in the overexpressing N2aMoPrP cells for easy 
detection of the prion protein by western blotting. To examine the efficacy of the 
siRNA duplexes at a more physiologically relevant PrPc level, 200nM of each was 
transfected into the N2a cell line which expresses PrPc at wild-type levels. 48 hours 
later, the cells were fixed and immunostained with ICSM18 followed by a fluorescently 
labelled secondary antibody. FACS was performed to allow a more sensitive analysis 
based on detection of the fluorescein tag in positively transfected cells. PrPc expression 
levels were compared to cells transfected with the scrambled duplex control.
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Figure 3.4 FACS analysis demonstrates reduced cell surface PrPc following 
transfection of N2a cells with 200nM siRNA duplexes
PrPC
Scrambled 
MW]_____
PrPC
N2a cells transfected with 200nM of siRNA duplexes were harvested 2 days post-transfection. 
They were fixed and im munostained for FACS analysis. FACS was performed on a 
FACSCalibur machine (Becton Dickinson) with fluorescein detection of the siRNA duplex in the 
FL1 channel and P rP c detection in FL3. Analysis was performed using F low jo software (Tree 
S tar Inc). A left shift of the histogram  indicates a reduction of expression.
Cell surface PrPc was reduced by 69, 96, 11 and 29% for the MW1, MW3, Daude and 
Tilly duplexes respectively (relative to PrPc expression in cells transfected with the 
scrambled control). These data corroborated the previous observations that the MW 
duplexes were substantially more effective at silencing Prnp.
The knockdown attained with the Daude and Tilly sequences was deemed too low to be 
useful and these duplexes were not used in further experiments.
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3 .4  T im eco u rse  o f P r P c k n o ck d o w n  by siR N A  d u p lexes
Due to dilution below functional levels during cell division and degradation by cellular 
nucleases, effects of the siRNA duplexes are only transient (McManus and Sharp, 2002). 
To determine the onset and end of PrPc knockdown, a timecourse experiment was 
performed. N2a cells were transfected with 200nM of each duplex and PrPc and Prnp 
expression levels were investigated 8- 72  hours post-transfection.
To examine the knockdown of PrPc protein over time, transfected cells grown on 
coverslips were fixed and immunostained at each time-point as before. As PrPc is 
degraded with a half-life of 3 - 6 hours (Caughey et al., 1989;Borchelt et al., 1990), 
removal of the mRNA should clear the cell of PrPc protein within 6-12 hours. Figure
3.5 shows that knockdown of PrPc is evident in some cells within 8 hours of 
transfection, again confirming the rapid action of the siRNA duplexes. There are also, 
however, transfected cells which still stain positively for PrPc, presumably because the 
protein present prior to transfection has not all been degraded yet.
M . W h i n  • 3» i i l !  T!i< s i *
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Figure 3.5 Timecourse of PrPc knockdown in individual N2a cells transfected with 
siRNA duplexes
Scrambled
24* r* 24hrs
48*r*
72*rs 72hf*
At indicated time-points after transfection w ith 200nM of each siRNA duplex, N2aMoPrP cells on 
glass coverslips were fixed and im munostained w ith 1CSM18 at lOpg/ml and secondary 
antibody, Alexa Fluor®568 goat anti-mouse IgG (H+L) (Molecular Probes) a t 1:800 dilution. 
Coverslips were m ounted and viewed as before. The cell nuclei are shown in blue, the green 
signal represents the fluorescein tag on the siRNA duplexes and red labelling indicates P rP c 
staining.
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T he scram b led  d u p lex  d id  n o t knockdow n P rP c an d  in  fac t, th e  s ta in in g  app eared  
su b jec tiv e ly  to  be m ore in tense , possibly ind ica ting  u p -reg u la tio n  o f P r P c .
A t each tim e -p o in t, cells w ere also h arv ested  for R N A  ex tra c tio n  an d  R T -P C R  analysis. 
T he re su lts , show n in  F ig u re  3.6 d em o n stra te  th a t  Prnp  expression  is reduced  very  
rap id ly , w ith in  8 h o u rs  o f tran sfec tio n  w ith  th e  M W  duplexes.
Figure 3.6 Timecourse of Prnp mRNA knockdown in N2a cells transfected with 
200nM siRNA duplexes
Prnp mRNA e x p ress io n  relative to  that in cells tran sfec ted  with 
scram bled  control
200
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1
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□
8hrs
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24hrs 48hrs
Time post-transfection
72hrs
I MW1 
I MW3
Triplicate wells of N2a cells transfected w ith 200nM of siRNA duplex were harvested at 
indicated tim e-points and to tal RNA extracted. One-step RT-PCR amplification of Prnp and (3- 
actin  was performed on a PRISM ® 7000 Taqm an machine (ABI). Primers and probes used were 
commercially available ABI assays: Mm00448389_ml (with FAM labeled probe) for Prnp and 
Mouse ACTB Endogenous control, VIC® labeled MGB probe. All reactions were performed in 
triplicate and negative controls included H 2O only and omission of Reverse Transcriptase. Prnp 
expression was normalized to P-actin and knockdown is shown as a percentage of expression in 
N2a cells transfected w ith scrambled control siRNA duplex. Error bars = s.e.m.
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Prnp expression remained low for at least 48 hours, recovering to normal levels by 72 
hours for the MW1 duplex. The MW3 duplex may have a longer lasting effect, but the 
large variation at the 72 hour time-point suggests that at least some of the cells have 
regained expression by this time.
In light of these results, it is perhaps surprising that the knockdown of the PrPc protein 
persists for over 72 hours. As PrPc has been shown to be transported to the cell surface 
within an hour of biosynthesis (Caughey et al., 1989) and Prnp mRNA levels are 
recovering by this time, a proportion of cells would be expected to have recovered some 
cell surface PrPc. The lack of PrPc staining at 72 hours post-transfection could reflect 
an experimental artifact because the cells destined for immunofluorescent analysis were 
fixed prior to the harvesting of cells for RNA analysis. I t is also possible that these 
observations demonstrate a true phenomenon whereby it takes longer for PrPc 
biosynthesis to recover and the protein to arrive at the cell surface after a period of 
minimal production.
3 .5  O p tim isa tio n  o f s iR N A  co n cen tra tio n
3.5.1 Effect o f siRNA concentration on PrPc protein expression
To evaluate the impact of siRNA concentration on PrPc knockdown, the MW duplexes 
were transfected into N2a cells at 50nM, lOOnM or 200nM. 66 hours post-transfection, 
the cells were immunostained for PrPc and analysed by FACS.
M . W h i O  - !*»iO T hu ' s i *
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Figure 3.7 Increasing concentrations of MW3 but not MW1 siRNA duplex result in 
higher knockdown of cell surface PrPc expression in N2a cells
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N2a cells transfected w ith 50 - 200nM of siRNA duplexes were harvested 66 hours following 
transfection and fixed in 4% PFA. Staining and detection of cells was performed as in Figure 
3.4. Histograms for each concentration of the duplex were overlaid for comparison and a 
leftwards shift indicates reduced expression of P rP c.
O verlay ing  th e  h is to g ram s o b ta in e d  for P r P c expression  revea led  th a t  chang ing  
co n c en tra tio n  h a d  litt le  effect on  P r P c knockdow n for th e  MW 1 d u p lex  (F igure  3.7). 
T h is  in d ica tes  th a t  th e  M W 1 d u p lex  reaches its  m ax im al effect a t  co n cen tra tio n s o f 
50nM . T h ere  w as, how ever, a d o se-d ep en d an t increase in  knockdow n for h igher 
co n cen tra tio n s  o f th e  M W 3 d u p lex  w ith  200nM  produc ing  th e  g rea te s t red u ctio n  in 
P r P c expression .
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3.5.2 Effect of siRNA concentration on P rnp  mRNA
FA CS an a ly sis  m easu res p ro te in  expression b u t desirab le  s iR N A  sequences m ediate  
th e ir effect a t  th e  m R N A  level v ia  th e  ‘classical R N A i p a th w a y ’. P o s t- tra n s la tio n a l 
red u c tio n  o f p ro te in  levels suggests th e  knockdow n is m ed ia ted  th ro u g h  a m iR N A - 
re la ted  tra n s la tio n a l rep ression  m echan ism  (D oench e t a l., 2003; Zeng e t al., 2003). To 
d iffe ren tia te  b e tw een  th ese  tw o possible m echanism s o f knockdow n, R T -P C R  analysis 
w as perfo rm ed  a t  th e  v a ry in g  co n c en tra tio n s  o f each d u p lex  48 hours p o st-tran sfec tio n  
(F igure  3.8).
Figure 3.8 Prnp mRNA knockdown does not vary with siRNA concentration
Prnp expression relative to that in N2a cells transfected with 
scrambled control
n  i i i
MW1 20OnM WV1 100nM fcM/150nM M/V3 200nM MW3100nM
Duplex concentration
Triplicate wells of N2a cells transfected w ith 50 - 200nM of siRNA duplex were harvested and 
to tal RNA extracted. One-step RT-PCR am plification of Prnp and p-actin was performed as 
before. All reactions were performed in triplicate and negative controls included H 2O only and 
omission of Reverse Transcriptase. Prnp expression was normalized to P-actin and knockdown is 
shown as a percentage of expression in N2a cells transfected w ith scrambled control duplex. 
Error bars = s.e.m.
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The reduction in P rPc mRNA obtained for the MW1 duplex was very similar to the 
knockdown in protein previously shown by FACS and western blotting, indicating this 
duplex acts primarily through the classical RNAi pathway. Conversely, the reduction in 
PrPc mRNA obtained for the MW3 duplex was significantly less than that seen by 
FACS analysis, suggesting this duplex may achieve some of its effect through a post- 
translational mechanism.
3 .6  U nexpected  effect o f tra n sfec tio n  o n  P r P  ex p ressio n
3.6.1 P r n p  mRNA expression following transfection
Surprisingly, if the previous RT-PCR results (Figure 3.8) were expressed relative to 
Prnp expression in untreated N2a cells instead of the scrambled duplex, the knockdown 
obtained was noticeably reduced. This implied a confounding effect of the scrambled 
duplex on Prnp expression which is illustrated in Figure 3.9.
114
CHAPTER 3
Figure 3.9 The scrambled siRNA duplex increases Prnp mRNA expression in 
transfected N2a cells at all concentrations
Prnp  e x p r e s s i o n  r e l a t i v e  t o  N 2 a  c e l l s
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Triplicate wells of N2a cells transfected with 50 - 200nM of siRNA duplex were harvested and 
total RNA extracted. One-step RT-PCR amplification of Prnp and P-actin was performed as 
before. All reactions were performed in triplicate and negative controls included H2O only and 
omission of Reverse Transcriptase. Prnp expression was normalized to p-actin and knockdown is 
shown as a percentage of expression in untreated N2a cells. Error bars = s.e.m.
At all concentrations, the scrambled duplex resulted in a mean increase in Prnp 
expression compared to untransfected N2a cells suggesting this effect could not be 
avoided by lowering siRNA concentration.
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3.6.2 PrPc protein expression following transfection
FACS analysis was performed to determine if the increase in PrPc mRNA produced by 
transfection with the scrambled duplex also resulted in an increase in PrPc protein.
Figure 3.10 Transfection of N2a cells with 200nM of scrambled duplex increases cell 
surface PrPc expression compared to untreated cells
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N2a cells transfected with 200nM of scrambled siRNA duplex were harvested 2 days following 
transfection. They were fixed and iinmunostained w ith prim ary antibody, ICSM18 at 12pg/ml 
and secondary antibody PE-Alexa Fluor® 647 goat anti-mouse IgG a t 1:500 dilution (Molecular 
Probes) and analysed by FACS as before. A right shift of the histogram indicates increased 
expression.
Transfection with the scrambled duplex resulted in a 66% increase of cell surface PrPc 
compared to untransfected N2a cells (Figure 3.10), implying that the additional 
mRNAs produced were not degraded but were translated into protein.
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In order to determine if this unanticipated effect on PrPc expression was specific to the 
scrambled sequence, an effect of transfection or due to activation of the RNAi pathway, 
further experiments were conducted.
3.6.3 Investigating the cause of P rn p  overexpression following transfection 
with the scrambled duplex
The siRNA transfection protocol uses Oligofectamine as a transfection reagent and 
requires a 4 hour incubation of the cells in serum-free medium following administration 
of the transfection complexes. In order to reveal any effects of the Oligofectamine and 
serum deprivation on Prnp expression, N2a cells were treated with 4 hours of serum 
deprivation either alone or in the presence of Oligofectamine as in the transfection 
protocol. Eight hours later, immediate effects on Prnp expression were examined by 
RT-PCR and compared to cells transfected with the MW or scrambled duplexes (Figure 
3.11).
M.WIiin- - r ii l*
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Figure 3.11 Prnp  mRNA overexpression is stimulated by transfection conditions not 
the scrambled duplex itself
E x p re s s io n  o f  Prnp  m R N A 8 h rs  p o s t- tra n s fe c tio n  re la tive  to  
u n tre a te d  N 2a ce lls
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Triplicate wells of N2a cells were exposed to  varying stages of the transfection process: serum- 
deprivation for 4 hours and then  a re turn  to normal serum levels, serum-deprivation with 
addition of Oligofectamine for 4 hours before returning to normal medium or standard 
transfection of 200nM siRNA duplexes. 8 hours after the s ta rt of treatm ent, cells were 
harvested, to tal RNA was extracted and RT-PCR analysis was performed as before. All 
reactions were performed in triplicate and negative controls included H 2O only and omission of 
Reverse Transcriptase. Prnp expression was normalized to |3-actin and knockdown is shown as a 
percentage of expression in untreated  N2a cells. Error bars = s.e.m.
Removal of serum from the media for 4 hours was sufficient to stimulate ~69% increase 
in Prnp mRNA relative to untreated cells. Adding Oligofectamine as well caused a 
further ~72% increase which was highly significant (p = 0.0006, 2-tailed Student’s t- 
test). There was no significant difference between cells treated with Oligofectamine only 
and cells that also received the scrambled duplex (p = 0.21, 2-tailed Student’s t-test).
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These results suggested the transfection procedure itself increased Prnp expression 
rather than the specific scrambled duplex sequence or activation of the RNAi pathway 
per se.
I t therefore seemed unlikely that an alternative scrambled sequence would provide a 
better control and the confounding effects of transfection were considered in all future 
experiments. Serum deprivation would not occur during in vivo delivery of RNAi, but if 
siRNA duplexes were administered as complexes with liposomal reagents, the 
possibility of upregulation of Prnp expression should be considered.
3 .7  C heek ing  fo r  a n  in te r fer o n  resp o n se  fo llo w in g  d up lex  
tra n sfec tio n
It was recently discovered that in addition to gene-silencing effects, siRNA can also 
induce non-specific effects including activation of the interferon response (Bridge et al., 
2003;Sledz et al., 2003;Persengiev et al., 2004;Scacheri et al., 2004;Pebernard and Iggo, 
2004). Oligoadenylate synthetase 1 (OAS1) is an interferon-stimulated gene which 
recognizes dsRNA and polymersies ATP (Merlin et al., 1983). This results in 
downstream activation of a latent endoribonuclease that degrades viral and cellular 
RNAs (Samuel, 2001). RNA interference has been shown to induce OAS1 expression by 
50 — 500 fold (Bridge et al., 2003). Expression levels of Oasl were examined following 
siRNA transfection to look for evidence of an interferon response.
Healthy N2a cells were transfected in triplicate wells with each of the siRNA duplexes 
at 50, 100 or 200nM. 48 hours post-transfection, the cells were harvested and total RNA
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extracted. RT-PCR analysis was performed to detect expression levels of the interferon 
gene Oasl.
Figure 3.12 Oasl expression in N2a cells transfected with 50 — 200nM siRNA duplexes
Oast mRNA expression 48 hours after siRNA transfection relative to untreated N2a
cells
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Triplicate wells of N2a cells were transfected with 50 - 200nM siRNA duplex or left untreated. 
Two days after transfection, the cells were harvested, total RNA extracted and RT- 
PCR analysis performed as before. All reactions were performed in triplicate and negative 
controls included H2O only and omission of Reverse Transcriptase. Prnp expression was 
normalized to p-actin and Oasl expression is shown as a percentage of expression in untreated 
N2a cells. Error bars = s.e.m.
As shown in Figure 3.12, transfection with the duplexes at any of the concentrations 
tested did not lead to a marked increase in Oasl expression. There is a small elevation of 
expression levels for the MW3 and scrambled siRNAs when compared to untransfected 
controls but this does not approach the levels of induction seen following a classical 
interferon response.
Due to the lack of evidence for an interferon response, no further interferon-stimulated 
genes were examined.
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3 .8  D isc u ss io n
siRNA sequences targeting the mouse prion gene were designed and evaluated for their 
ability to silence murine PrP mRNA and protein. Two sequences, MW1 and MW3 were 
designed and compared to the previously published Tilly and Daude sequences. Both 
MW duplexes showed significantly greater silencing of PrP, reducing total PrPc protein 
and mRNA by up to 60% and cell surface PrPc by up to 96%. This knockdown was 
rapid, commencing within 8 hours of transfection, and lasted for up to 72 hours. The 
Daude duplex yielded a modest 8% knockdown of total PrPc protein, in marked 
contrast to the published findings of approximately 95% knockdown. The reason for 
this difference is unclear but the original study was performed in a PrPc-overexpressing 
neuroblastoma cell line chronically infected with the Chandler strain of prions and a 
hypothalamic cell line infected with 22L prions. It is not known how prion infection 
may affect the RNA interference pathway and the kinetics of knockdown, but it is 
possible this contributed to the discrepancy.
Under the present conditions, the Tilly duplex also produced substantially less than the 
81 — 88% knockdown of PrPc reported previously. This is not entirely surprising, as 
methodological differences render a direct comparison inappropriate. In the original 
study, the Tilly sequence was expressed from a plasmid vector and directed against 
exogenously introduced PrPc. Whereas here, a duplexed RNA molecule has been 
utilised to knockdown endogenous PrPc, so the kinetics of knockdown are quite 
different between the 2 studies.
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Transfection of the scrambled siRNA duplex increased Prnp expression and a closer 
examination revealed this to be due to the transfection procedure itself. Removal of 
serum from the culture medium for 4 hours resulted in a 69% increase in PrP mRNA 
and FACS analysis revealed this mRNA was translated into PrPc protein. Although 
this effect was not reported in the original study by Daude and colleagues, their western 
blotting clearly shows up-regulation of PrPc following transfection with all 
concentrations of the scrambled duplex tested. A role for PrPc in serum-deprivation 
induced apoptosis has been demonstrated previously (Kuwahara et al., 1999) and the 
cellular response to this stressor was shown to be fairly rapid (Kim et al., 2004). In this 
context, it is unsurprising that Prnp mRNA expression levels change significantly 
within 4 hours of serum removal, possibly reflecting an up-regulation of PrPc in 
response to apoptotic stimuli.
A further significant increase in Prnp mRNA expression was observed upon addition of 
the transfection reagent Oligofectamine. As this was able to up-regulate Prnp 
expression in the absence of any siRNA, the effect seems to be due to the presence of the 
cationic lipids or other unidentified components of the reagent mix. It is possible that 
the resultant overexpression of Prnp is due to perturbation of the plasma membrane 
through lipid binding and/or stimulation of the endocytic pathway during the 
transfection procedure. Either of these options seem possible since PrPc is known to be 
found on the plasma membrane (Stahl et al., 1987), where it is localized to detergent- 
resistant membrane rafts (Gorodinsky and Harris, 1995;Vey et al., 1996) and is recycled 
through the endocytic pathway (Shyng et al., 1993).
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The addition of the scrambled siRNA duplex had no further effect on Prnp expression 
suggesting activation of the intracellular RNAi pathway does not alter expression of the 
prion gene.
Although the MW duplexes showed no evidence of an early increase in Prnp expression 
and in fact had reduced it within 8 hours, it remains possible that the knockdown 
obtained with these duplexes (and indeed, any sequences transfected in this manner) 
may be limited by the opposing effects of transfection on expression. This may account 
for why the knockdown obtained was not as high as may have been expected based on 
the sequence design and high scores on the Reynold’s criteria. The true silencing 
potential of these sequences may be partially obscured in this system and could perhaps 
be revealed by administration in a different manner.
The knockdown obtained with the MW duplexes is not total but they may still be useful 
in treating prion-infected cells as the incubation time of prion-infected mice is known to 
be correlated to expression levels of PrPc (Bueler et al., 1994;Fischer et al., 
1996;Tremblay et al., 1998). Further experimentation is required to determine if the 
knockdown attained is sufficient to allow prion-infected cells to clear PrPSc and 
infectivity.
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OF PrPS* AND INFECTIVITY IN VITRO
4 .1  In tro d u ctio n
The siRNA duplexes described in Chapter 3 were shown to effectively reduce Prnp 
expression in neuronal cell lines. Previous research has shown that reducing Prnp 
expression in neurons in vivo is protective in prion disease and allows long term survival 
of prion-infected mice (Mallucci et al., 2003). This chapter details an experiment 
designed to examine whether RNAi-mediated knockdown of Prnp can reduce PrPSc 
formation and infectivity in a cell model of prion disease.
4.1.1 Clearance of PrPSc
Inhibition of prion propagation by anti-PrP antibodies revealed an apparent half-life of 
~30 hours for PrPScin scrapie-infected N2a cells (Peretz et al., 2001). This indicates that 
it is degraded, albeit slowly, by endogenous mechanisms. From in vitro studies it seems 
likely that PrPSc is hydrolysed in acidic endosomes and lysosomes (Caughey et al., 
1990;Taraboulos et al., 1992). An endogenous clearance mechanism involving lysosomes 
is further supported by the demonstration that the tyrosine kinase inhibitor, STI571, 
clears prion-infected cells in a c-Abl-dependent manner (Ertmer et al., 2004). This 
clearance can be abrogated by raising the lysosomal pH which blocks degradation in
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lysosomes. Interestingly, clearance of PrPc is unaffected by these treatments indicating 
separate degradation pathways exist for the 2 isoforms. The proteases responsible for 
degradation of PrPSc within lysosomes include cysteine pro teases (Luhr et al., 2004b) 
such as cathepsin B and L (Luhr et al., 2004a) which have been shown to degrade PrPSc 
in scrapie-infected cells.
Most recently, bigenic mice in which PrPc expression is regulated by doxycycline 
administration were utilized to demonstrate that clearance of PrPSc also occurs in vivo. 
Supression of PrPc by ~95% in prion-infected mice revealed a half-life for PrPSc in the 
brain of ~1.5 days, in accord with previous in vitro findings (Safar et al., 2005). That the 
brain is able to clear PrPSc implies that inhibiting the conversion reaction should enable 
endogenous clearance mechanisms to slowly degrade existing PrPSc.
4.1.2 Measuring prion infectivity with the Scrapie Cell Assay
Infectivity of prion-infected samples has traditionally been measured by injecting the 
samples intracerebrally into indicator animals and determining the time until 
appearance of clinical symptoms. This is a very time-consuming and costly assay for 
infectivity. Recently, a highly sensitive, quantitative in vitro assay for prion infectivity 
called the Scrapie Cell Assay (SCA) was developed (Klohn et al., 2003). I t is 2 orders of 
magnitude cheaper than the animal bioassay, detects infectivity at dilutions beyond the 
range of the standard mouse bioassay and can be automated. In the SCA, prion- 
susceptible neuroblastoma cells are exposed to prion-infected samples for 3 days, grown 
to confluence and split 1:10 3 times to dilute out the initial inoculum. The proportion of
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PrpSe.containing cells is then determined by automated counting of PK-resistant 
material using a modified ELISA technique called the ELISPOT. The proportion of 
PrpSe.containing cells can be directly correlated with the starting infectivity of the 
samples by comparison to a serial dilution of a prion-infected brain homogenate of 
known bioassay titre. In this way, the equivalent in vivo LD50 units for a sample can be 
calculated.
4.1.3 Treating infected cells with siRNAs against PrPc
Reducing Prnp expression aims to cure a cell by lowering the level of PrPc, the 
substrate for conversion to PrPSc. This is intended to prevent further accumulation and 
allow clearance of existing PrPSc. The approach has been used successfully before, but 
the analysis was limited (Daude et al., 2003;Luhr et al., 2004b). In order to more closely 
examine the consequences of reducing Prnp expression on the formation and clearance 
of PrPSc as well as effects on infectivity, a more detailed study was performed.
The experiment was designed to knockdown Prnp expression in a population of prion- 
infected PK1 cells (IPK1) over 3 days as they grew to full confluence. Once the cells 
became confluent, they ceased to divide due to contact inhibition, producing a static 
population. This makes it possible to measure the production and turnover of PrPSc and 
infectivity without the confounding effects of cell division. I t was anticipated that 
removing PrPc would reduce levels of both PrPSc and infectivity, lending support to the 
use of RNAi as a therapy in prion disease.
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IPK1 cells were plated at approximately 25% confluence in 6 well plates. The following 
3 days, they were transfected in triplicate every 24 hours with 200nM MW1 or 
scrambled siRNA duplex or left untreated. Plating at low confluence allows high 
efficiency transfection of the duplexes and transfecting on successive days targets the 
highest number of cells possible to ensure knockdown of Prnp for the duration of the 
experiment. Before each transfection, the media was replaced to ensure the cells 
remained as healthy as possible.
Following 3 days of Prnp knockdown, the proportion of cells containing PK-resistant 
prion protein (referred to as P rPSc for the purposes of this chapter) was determined on 
days 4 -7  using an ELISPOT, an immunological assay adapted from the traditional 
ELISA. Cells were lifted each day for assessment of PrP mRNA and protein knockdown 
and to make homogenates for subsequent analysis of intracellular infectivity by SCA. A 
schematic detailing this experimental design is shown in Figure 4.1.
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Figure 4.1 Schematic of experimental design for siRNA knockdown of Prnp in prion' 
infected cells
DAY: 1
Transfect Transfect Transfect Elispot Elispot Elispot Elispot
I  I t t t
\  \ I /
H arvest cells
/  \
S crap ie  Cell A ssay M easure PrP ex p re ss io n
To exclude differences due to alterations in total cell number, cells were counted in 
triplicate wells for each condition on the final four days of the experiment. Figure 4.2 
shows that the cells had reached confluency by the 4th day and numbers remained 
relatively constant for the rest of the experiment. Furthermore, there was no significant 
difference between the cells treated with the MW1 or scrambled duplexes and the 
untreated IPK1 cells at any point, indicating no adverse effects of the siRNAs on cell 
growth (Student’s f-test, paired 2 sample for means).
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Figure 4.2 Cells reach confluency and cease dividing by day 4 of the experiment
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Cells were harvested from triplicate wells for each condition and a light microscope was used to 
confirm all cells had been lifted. E ight counts were performed on an improved Neubauer 
haemocytometer for each sample and averaged. The graph shows the mean num ber of cells/well 
from triplicate wells of each condition. Error bars represent s.e.m.
4 .2  Prnp  m llA A  levels in  IP K 1 cells fo llow ing sillA A  
treatm ent
RNA was extracted from triplicate wells of each condition harvested on days 4 -7 and 
RT-PCR analysis was performed to determine the level of Prnp expression in the 
siRNA-treated cells (Figure 4.3).
M. White - PhD Thesis
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Figure 4.3 Prnp  mRNA expression is reduced in IPK1 cells transfected with the MW1 
duplex and increased in cells containing the scrambled duplex
Prnp e x p re s s io n  a s  a  p e rc e n ta g e  of u n trea ted  IPK1 cells
■  S c ra m b le d
■ MW1
Experimental Day
Triplicate wells of IPK1 cells transfected w ith 200nM of siRNA duplex were harvested on 
indicated days and to tal RNA extracted. One-step RT-PCR amplification of Prnp and |3-actin 
was performed using commercially available ABI assays: Mm00448389_ml (with FAM labeled 
probe) for Prnp and Mouse ACTB Endogenous control, VIC® labeled MGB probe. All reactions 
were performed in triplicate and negative controls included H 2O only and omission of Reverse 
Transcriptase. Prnp expression was normalized to  |3-actin and expression is shown as a 
percentage of th a t in untreated IPK lcells. Error bars represent s.e.m.
By the 4th day of the experiment, PrP mRNA expression in the MW1 treated cells was 
36% ± 4 of the expression in untreated IPK1 cells. This expression had fallen to 25% 
±4 of the control by the end of the experiment. In contrast, the expression levels in the 
cells treated with the scrambled duplex were 155% ±20 on the 4th day and remained 
around this level for the duration of the experiment in agreement with previous 
observations (see Chapter 3.6). Both the extent and the longevity of knockdown
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attained was greater in the IPK1 cells than in the PK1 cells used previously. This is not 
due to performing successive transfections as the same trend was observed following a 
single transfection (data not shown), suggesting that prion-infected cells are less 
resistant to RNAi and the stresses of the transfection procedure.
4 .3  P r P c an d  P r P s* p ro te in  lev e ls  in  1P K 1 ce lls  fo llow in g  
siR N A  trea tm en t
To determine the levels of both PrPc and P rPSc, whole cell lysates were made from 
triplicate wells of each condition harvested on days 4-7 .  Total protein was quantified 
and lysates from the same condition were pooled to provide an average read-out at each 
time-point. Aliquots of each lysate pool were incubated with Proteinase K (PK) to 
digest all non-resistant proteins and reveal the PrPSc content. Samples of the lysates 
with and without PK digestion were western blotted and the membranes were 
overexposed to allow visualization of very faint bands. As shown in Figure 4.4, there 
was substantial knockdown of PrPc expression relative to untreated IPK1 cells 
following treatment with the MW1 duplex. PrPc levels diminished from days 4 -7  and 
no PrPSc was detectable by blotting at any stage in these cells.
n.W hlw ■ .i
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Figure 4.4 PrPc and PrPSc protein levels are reduced following Prnp knockdown
IPK1 IPK1 + MW1 IPK1 + Scrambled
Day: 4 5 6 7  4 5 6 7  4 5 6 7
pk: ♦  -  ♦  -  ♦  -  ♦  . + .  +  .  +  . +
I I I I !  114th
50pg of to tal protein from each pooled lysate was loaded per lane and immunoblotted. The 
membrane was incubated w ith ICSM18 at 0.5pg/ml and H RP-conjugated secondary antibody. 
The signal was visualised w ith high sensitivity ECL. Duplicate membranes incubated with 
secondary antibody only were blank. Q uantitation of to tal P rP  protein was performed on a 
Kodak digital science image station 440CF using Kodak ID analysis software (v.3.6.3). 
Identical regions of interest were defined in each lane to encompass all glycoforms and 
degradation products of P rP . Molecular weight is indicated in kDa.
Prpse only became faintly visible in the untreated IPK1 cells on day 7 but it was easily 
detectable from day 5 onwards in the cells treated with the scrambled duplex. The 
earlier appearance of PrPSc in the latter cells probably results from the increased 
expression of PrPc due to the transfection process (see Chapter 3.6). This would lead to 
excess PrPc substrate available for conversion. Densitometry on each PK- lane revealed 
the changes in total PrP expression compared to IPK1 cells at the same time-point (see 
Table 4.1 where a negative value indicates knockdown and a positive value indicates 
over-expression)
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Table 4.1 Changes in total PrP expression following transfection with siRNA 
duplexes
Condition Percent expression change
MW1 Day 4 -42
MWI Day 5 -85
MW1 Day 6 -86
MWI Day 7 -96
scrambled Day 4 + 16
scrambled Day 5 + 14
scrambled Day 6 + 16
scrambled Day 7 -15
Western blot analysis of the whole cell lysates provides information on the total 
quantity of a protein in a population of cells but does not reveal how many cells contain 
detectable levels of that protein. When the protein in question is a marker of infection 
such as PrPSc, it is also important to know the proportion of cells that are infected. 
Additionally, the levels of PrPSc in the IPK1 cells were not high enough for detection by 
western blotting until the 7th day meaning changes that occurred below this threshold 
will not be observed.
To visualise and determine the proportion of cells containing intracellular PrPSc, an 
ELISPOT was performed. Triplicate wells of each condition were harvested on days 1
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and 4 -7  and a dilution series of 5,000 - 1,250 cells per well were seeded into ELISPOT 
plates. Cells were dried onto the membrane, non-resistant proteins were digested with 
PK and the residual PrPSc was detected using an adapted ELISA technique. The 
proportion of cells containing PrPSc in each condition is shown in Figure 4.5.
Figure 4.5 Treatment with MWI siRNA significantly reduces the proportion of cells 
containing PrPSc
P e rc e n ta g e  o f ce lls  co n ta in in g  P rP Sc a s  d e te rm in ed  by ELISPOT
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---------------  r n
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l Scrambled 
IMW1
E xperim en tal day
Triplicate wells of IPK1 cells from each condition were harvested on the indicated days and 
plated into ELISPO T plates (Millipore) with 6 replicates for every sample. The cells were dried 
onto the plates and stored a t 4°C until all plates were ready for analysis. Dr F Properzi 
performed the ELISA detection of PK -resistant material and counted positive cells using a Zeiss 
KS ELISPO T system (Stemi 2000-C stereo microscope equipped with a H itachi HV-C20A 
colour camera and a KL 1500 LCD scanner and WELLSCAN software from Imaging 
Associates). Proportions of positive cells were averaged for each condition and the errors bars 
represent s.e.m.
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The proportion of cells containing PrPSc reduced throughout the experiment in the cells 
transfected with the MWI duplex. This decrease was significant between days 1 — 4 (p = 
0.003, Student’s paired J-test), 5 - 6 (p =0.003) and 6 - 7 (p = 0.03). In addition, 
transfection with the MWI duplex yielded a highly significant drop in PrPSc-positive 
cells compared with untreated IPK I cells on days 4 -7  (Day 7, p = 7.2 x 1011, Student’s 
paired f-test). The proportion of PrPSc-positive cells remained relatively constant over 
days 1 - 4 in the untreated IPK I cells and those transfected with the scrambled duplex. 
This is in agreement with the observation that PrPSc accumulation is associated with 
confluency in this cell model (Dr F Properzi, personal communication). From days 4 -7, 
the proportion of cells containing PrPSc rose significantly in both the untreated IPK I 
cells and those transfected with the scrambled duplex. The cells treated with the 
scrambled duplex contained significantly more PrPSc than the untreated IPK I cells on 
days 5 and 7, although there was no difference on day 6. The western blot in Figure 4.4 
revealed much higher levels of total P rPSc in the cells treated with the scrambled duplex 
on all of the final 3 days. This discrepancy may have arisen because the ELISPOT 
scores cells on the basis of positivity above a defined threshold, but provides no 
information about the degree of positivity of a particular cell. Therefore, whilst a 
similar proportion of cells crossed the threshold set for a positive score in the 2 
conditions, the cells transfected with the scrambled duplex may have been ‘more 
positive’ and contained higher levels of PrPSc which is only revealed by western 
blotting.
vj.Wsmsu 1
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4 .4  Infectivity of IP K I cells follow ing siR N A  treatm ent
As the identity of the infectious agent has not been established in prion disease, it is 
important to examine infectivity levels in addition to PrPSc when evaluating a potential 
therapeutic compound. To determine the intracellular infectivity following siRNA 
treatment, cells were harvested from triplicate wells of each condition on days 4 -7  and 
homogenised. The samples were examined using the SCA and the starting infectivity 
was calculated from the number of PK1 cells positive for PrPSc 3 passages after 
exposure to the homogenates. As shown in Figure 4.6, reducing PrPc expression also 
reduced intracellular infectivity of the MWI treated IPKI cells.
Figure 4.6 Knockdown of PrPc reduces intracellular infectivity of IPKI cells
Infectivity of IPK1 cell hom ogenates determined by SCA
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Triplicate wells of IP K I cells were harvested on the indicated days and homogenates made. 
Total protein was determined by BCA and the concentrations were adjusted to 200pg/ml. A 1:50 
dilution of each homogenate was applied to 6 wells of uninfected PK1 cells for the SCA by Dr F 
Properzi. The cells were passaged at 1:10 dilutions 3 times over 12 days before 25,000 cells from 
each well were transferred to  an ELISPOT plate for detection of PK-resistant m aterial. 
Infectious units (ID50/ml) were calculated from a standard curve of an RML-infected brain 
homogenate of known prion titre. Error bars represent s.e.m.
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The reduction in intracellular infectivity following treatment with the MWI duplex was 
highly significant with a p value of 4.6 xlO'6 by day 7 (Wilcoxon-Mann-Whitney U 
Test, used due to differing numbers of data points between some groups). Interestingly, 
the cells treated with the scrambled duplex had the same level of intracellular 
infectivity as the untreated IPK I cells except for day 6 when they were more infectious 
(p = 0.02). I t is possible that this inconsistency may have arisen due to contamination 
in 5/18 wells of the IPK I condition on day 6, meaning some of the data had to be 
excluded.
4 .5  D iscu ss io n
Removing PrPc, the substrate for prion conversion, by RNAi effectively reduced 
intracellular infectivity and allowed clearance of PrPSc from prion-infected cells.
The proportion of cells containing PrPSc remained constant over the 1st 3 days in the 
untreated IPK I cells and those transfected with the scrambled duplex. This is despite 
the diluting effects of cell division, implying PrPSc doubled at a rate approximately 
equal to the length of the cell cycle. The proportion of PrPSc-positive cells fell 
significantly over the 1st 3 days of treatment with the MWI duplex. I t is not possible to 
distinguish whether clearance of existing PrPSc contributed to this, or if it was simply 
due to prevention of further accumulation and dilution below the detection limit as a 
result of cell division. There was however, a further significant drop in the percentage of 
PrPSc positive cells over the last 4 days of the experiment following treatment with 
MWI. As the cells had ceased dividing by this point, it suggests that removal of the
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endogenous PrPc not only prevented further conversion, but also allowed clearance of 
existing PrPSc in these cells.
The infectivity of the cells treated with the MWI duplex had reached its lowest point by 
day 4 and did not change significantly over the next 3 days of the experiment. This is 
the 1st demonstration that exogenous knockdown of PrPc results in a rapid loss of 
infectivity in prion-infected cells. The loss of infectivity in MWI-treated cells preceded 
clearance of PrPSc by several days and then infectivity levels remained constant as 
residual PrPSc slowly reduced over the last 3 days. This suggests that infectivity is not 
proportional to PrPSc levels and the infectious agent is an early product of the 
conversion reaction. One caveat of these results is that the levels of infectivity in the 
MWl-transfected cells may have been near the lower limit of detection in this system. 
Repeating the experiment with more concentrated homogenates could resolve this. Also 
supporting the interpretation, however, is the observation that both total levels of 
PrPSc an(j proportion of PrPSc-containing cells were significantly higher following 
transfection with the scrambled duplex than in untreated IPK I cells, yet the 
intracellular infectivity levels were remarkably similar in the 2 conditions. Furthermore, 
on day 4 only twice as many of the untreated IPK I cells and those receiving the 
scrambled duplex were positive for PrPSc than the cells treated with MWI, but the 
intracellular infectivity of the MWI-treated cells was lower by one log.
These results are consistent with a model of prion infection in which the infectious agent 
is an intermediate formed during the conversion reaction and PrPSc aggregation within 
the cell would act to limit the number of molecules available to act as a template for 
further conversion of PrPc. Whatever the mechanism of conversion, the results detailed
- F l a i r s  I m '-v
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here show that removal of endogenous PrPc by exogenous means allows clearance of 
PrPSc arl(J more importantly, infectivity from prion-infected cells in vitro and suggests 
that this may be a valuable therapeutic approach in vivo.
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CONSTRUCTION OF LENTIVIRUSES EXPRESSING  
s lill  W  SEQUENCES TARGETING Prnp
5 .1  In tro d n ctio n
Results of experiments detailed in Chapter 4 indicated that RNAi-mediated reduction 
of Prnp expression may be of benefit in prion disease as both PrPSc accumulation and 
intracellular infectivity are reduced in vitro. In order to validate this approach further, a 
strategy for delivering interfering RNA molecules to the brain of prion-infected animals 
is required. This chapter describes the construction and validation of lentiviruses 
expressing shRNAs targeting the prion gene as a potential tool for stable exogenous 
knockdown of Prnp.
5.1.1 Lentiviruses
Lentiviruses belong to the large family of retroviruses which includes the human 
immunodeficiency virus, HIV-1. HIV-1 primarily uses receptor-mediated fusion at the 
plasma membrane to enter a cell in a process mediated by the envelope (Env) protein 
(Gomez and Hope, 2005). Following fusion between the viral and plasma membranes, 
the viral capsid containing the RNA genome and various enzymes required for 
replication is released into the cytoplasm (Chan and Kim, 1998). Once inside the cell, 
the viral reverse transcriptase enzyme copies the HIV-1 sense RNA strand into viral
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cDNA which is converted to dsDNA by host DNA polymerase and can then stably 
integrate into the host cell genome (Zheng et al., 2005) (see Figure 5.1).
Figure 5.1 Lentiviral infection of a target cell
■ pot - reverse transcriptase/integrase 
env  - envelope  
9  gag -capsid
Schematic depicting key events during lentiviral infection of a target cell. Envelope protein 
mediates lentivirus fusion w ith the target cell plasma membrane allowing intracellular release of 
viral capsid contents. The viral RNA (shown in orange) is reverse transcribed into DNA (pale 
blue) and transported to the nucleus where it integrates into the host cell genome (purple).
Integration is mediated by the viral integrase enzyme, requires the presence of long
terminal repeats (LTRs) at the ends of the viral genome and occurs in random places in
the host cell genome. This integration is the basis for persistent infection and allows
long-term expression of genes contained within the viral genome without provocation of
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an immune response, making lentiviruses an attractive tool for gene therapy 
applications.
5.1.2 Production of lentiviruses in vitro
In vitro production of lentiviruses requires transient transfection of helper plasmids 
encoding the genes required for virus production and packaging, in addition to the 
plasmid containing the genetic material to be transferred. This is encoded by a 
lentivector carrying a transgene cassette flanked by cis-acting elements needed for 
encapsidation, reverse transcription and integration into the host cell genome. The 
plasmids are transfected into a cell line such as human 293T cells which can be 
transfected with efficiencies close to 1 0 0 % and the recombinant virus is harvested from 
the media.
The helper plasmids used here include a 2nd generation packaging vector, 
pCMV_dR8.74, and a separate envelope plasmid, pMD2G, which provide viral genes in 
trans. Splitting the requisite viral genes across multiple vectors decreases the likelihood 
of inadvertently generating replication-competent virus through adventitious 
recombination of the lentiviral genome. The 2nd generation packaging vectors are 
additionally deleted in all viral auxiliary genes (vpr, vif, vpu and nef). The 
pCMV_dR8.74 plasmid (Figure 5.2) uses the human cytomegalovirus promoter (CMV) 
to drive high level expression of the HIV-1 gag and pol genes. Gag encodes the viral core 
proteins required for forming the structure of the lentivirus including the viral capsid, 
nucleocapsid and protective matrix. Pol encodes the reverse transcriptase and integrase
M.WliiU'
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enzymes necessary for replication and integration of the lentivirus. Efficient expression 
of gag and pol requires a post-transcriptional regulator called rev which promotes export 
of viral mRNA containing a Rev response element (RRE) from the nucleus.
Figure 5.2 Vector map of the pCMV_c!R8.74 packaging plasmid
AmpR
pCMV_dR8.74
/EEnv (Tat/Rev)
RRE *Vpu
Vector map showing m ajor coding regions of the pCMV_dR8.74 packaging plasmid. The vector 
is deleted in viral accessory genes Env, Vpu, Nef and Vpr and guanine 
phosphoribosyltransferase (GPT) replaces the Env gene for historical reasons.
Although the packaging plasmid contains the minimal genes necessary to produce a 
virion, it has been rendered replication defective by the mutation of viral regulatory 
genes and replacement of the envelope protein. The HIV-1 virus is able to change its cell 
binding specificity by combining with envelope proteins from other viruses in a process
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known as pseudotyping. The envelope protein used here, YSY-G, is provided in trans on 
another helper plasmid, pMD2G (Figure 5.3).
Figure 5.3 Vector map of the envelope plasmid pMD2G
CMV
Beta-globin Intron
pM D 2G
VSV-G
The coding region of the CMV promoter-driven VSV-G coat protein is illustrated in addition to 
the p-globin intron which acts to enhance gag and pol expression in trans.
VSV-G is the coat protein from the Vesicular Stomatitis Virus which confers broad 
tropism to the lentivirus and makes the viral particles more stable. VSV-G pseudo­
typed lentiviruses also appear to preferentially infect neurons over glia making them an 
attractive tool for use in neurodegenerative disease (Duale et al., 2005). In addition to 
the VSV-G protein, the pMD2G vector contains the human P-globin intron which 
enhances expression of the gag and pol genes in mammalian cells.
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The lentiviral expression vector utilized here, pLL3.7, is derived from the pHR’ vectors 
first described by Naldini and colleagues (Naldini et al., 1996a;Naldini et al., 1996b) 
with some modifications. The U3 region of the 3’ LTR was deleted (Sirven et al., 2001), 
rendering the integrated viral DNA replication incompetent and preventing interference 
of the LTR with the transgene promoter (Miyoshi et al., 1998). This modification 
increases transgene expression in addition to improving the safety of the vector. The 
central polypurine tract and the central termination sequence of wild-type HIV-1 which 
together comprise the central DNA ‘Flap’ have been added to the vector. These 
sequences enhance infection of non-dividing cells, probably by facilitating transport of 
the pre-integration complex through the nuclear membrane, and they significantly 
improve transduction of different types of brain cells (Zennou et al., 2001). Finally, the 
woodchuck hepatitis B virus post-transcriptional regulatory element has been added to 
improve RNA stability and transgene expression. shRNA expression is driven by a 
murine U6  promoter and a separate CMV promoter drives expression of the GFP 
reporter protein to facilitate identification of transduced cells. A map of the pLL3.7 
vector is shown in Figure 5.4.
f lu s»
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Figure 5.4 Vector map of pLL3.7 lentivector
A.
pLL3.7
Hpjl
XN*
B.
SENSE ANTISENSE
loop
CMVU6
viral gone*
MCS
A. Vector map illustrating m ajor features of pLL3.7. Viral accessory genes are indicated in blue 
and the restriction sites in the multiple cloning site (MCS) are shown. B. Schematic depicting 
expression cassette for shRNA and cloning of oligonucleotide insert into MCS.
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5.2 Construction of lentivcctors for expression of shRNAs 
directed against M*rnp
5.2.1 Short hairpin oligonucleotide inserts
To construct a lentivector targeting Prnp expression, short hairpin sequences derived 
from the siRNA sequences MWI and MW3 characterised in Chapter 3, plus an 
additional sequence, MW2, identified as a promising candidate according to the 
Reynolds criteria were cloned into the pLL3.7 vector. The short hairpin oligonucleotide 
inserts were designed so that once annealed, they produced a blunt 5’ end and a sticky 
3’ overhang to allow directional cloning into the Hpa I and Xho I restriction sites of the 
lentivector, immediately downstream of the U6  promoter.
The sequences of the short hairpin inserts were as follows:
MWI:
5 ' -  TGTACCGCTACCCTAACCAATTCAAGAGATTGGTTAGGGTAGCGGTACTTTTTTC -  3 ' 
ACATGGCGATGGGATTGGTTAAGTTCTCTAACCAATCCCATCGCCATGAAAAAAGAGCT
MW2:
5 ' -  TGATCAGTACAGCAACCAGATTCAAGAGATCTGGTTGCTGTACTGATCTTTTTTC -  3 ' 
ACTAGTCATGTCGTTGGTCTAAGTTCTCTAGACCAACGACATGACTAGAAAAAAGAGCT
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MW3:
5 ' -  TGTGCACGACTGCGTCAATATTCAAGAGATATTGACGCAGTCGTGCACTTTTTTC -  3 ' 
ACACGTGCTGACGCAGTTATAAGTTCTCTATAACTGCGTCAGCACGTGAAAAAAGAGCT
5.2.2 Ligation of oligonucleotide inserts into lentivector
Ligation reactions were set up using molar ratios of insert DNA : pre-digested pLL3.7 
vector DNA ranging from 0.5:1 — 5:1. Screening of hundreds of resultant colonies by 
diagnostic digest failed to yield the desired constructs so the efficacy of oligonucleotide 
annealing was examined to ensure the inserts were double-stranded.
5.2.3 Confirming annealing of shRNA inserts
Double-stranded DNA molecules can be denatured through heating. Raising the 
temperature of the solution above the melting temperature of the DNA strands causes 
them to dissociate. Rapid cooling on ice prevents efficient re-annealing so that the 
majority of the DNA remains single-stranded. This property of DNA was exploited to 
determine if the shRNA inserts were double or single-stranded following annealing. 
Annealed and heat-denatured aliquots of oligonucleotides were examined for size 
differences by non-denaturing polyacrylamide electrophoresis. Under these conditions, 
dsDNA migrates relative to its size whilst single-stranded DNA often runs anomalously, 
As shown in Figure 5.5, the migration of the annealed oligonucleotides was equivalent 
to a 60bp sequence. The single-stranded oligonucleotides migrated further through the
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gel and appeared as a double band due to the extra 4bp on the anti-sense strand. Heat 
denaturation resulted in the reduction of the dsDNA band and an increase in the 
ssDNA bands. This suggested that the difficulty cloning the inserts into the lentivector 
was not due to a failure of the oligonucleotides to anneal.
Figure 5.5 Heat denaturation of oligonucleotide inserts confirms annealing 
Single-stranded Oligonucleotides Annealed Oligonucleotides
Sense Antisense Heat Denaturation
+ - +
100 bp 100bp
Following heat denaturation of annealed oligonucleotides, lOOng of dsDNA was run on a 10% 
TB E Polyacrylamide gel. Single-stranded oligonucleotides were loaded onto the gel to provide a 
comparison. As ssDNA binds ethiduim  bromide less efficiently than  dsDNA, lpg samples were 
loaded. dsDNA markers were loaded to estim ate the size of the annealed oligonucleotides. Bands 
were viewed under UV light on a Biorad Gel Doc 1000 using Q uantity  One software (version 
4.5.1).
5.2.4 Cloning of short hairpin inserts into the lentivector
Following confirmation of oligonucleotide annealing, further ligation reactions were set 
up for the MW1 shRNA insert at a wider range of molar ratios from 0.5:1 — 100:1. 
Screening for inserts by diagnostic digests revealed a slight increase in band size in 2 
colonies resulting from a 1 0 : 1  ligation.
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The resolution offered by agarose gel electrophoresis was not sufficient to be certain 
these bands contained the desired insert, so the digests were run on a polyacrylamide gel 
to provide better separation of the small DNA fragments. As shown in Figure 5.6, there 
was a clear size difference of approximately 60bp between the fragments obtained from 
digestion of the empty vector and those believed to contain the shRNA insert. 
Throughout the screening, it was observed that bands occasionally appeared to be 
smaller than that obtained from the empty vector. The reason for this was unclear, but 
it was suspected that over-digestion by one of the restriction enzymes may have been 
the cause.
Figure 5.6 Confirmation of lentivector containing shRNA inserts by polyacrylamide 
gel electrophoresis
Xhol Em pty + In sert
o v e rh an g  v ec to r
m iss in g
600bp
500bp
lOOng of diagnostic digest reactions were run on a 6% TBE polyacrylamide gel. E m pty vector 
was run in lanes 4, 5 and 8 to provide a size comparison for unknown samples. Bands were 
visualised as before.
M.White - PhD Thesis
150
C H A PTER  .1
5.2.5 Sequence-verification of constructs
A selection of plasmid preparations that yielded all 3 different sizes of bands in the 
diagnostic digest were sequenced using the following primer within the Flap sequence 
upstream of the U6  promoter in pLL3.7:
5 ' -CAGTGCAGGGGAAAGAATAGTAGAC-3'
Sequencing confirmed the presence of the desired insert in the 2  suspected positive 
constructs indicating that the 10:1 insert: vector ligation had been successful. The 
constructs yielding smaller bands than the empty vector were shown to be missing the 
3’ overhang of the Xho I site verifying there was over-digestion of 5-10% of the 
plasmids by this enzyme.
The remaining short hairpin inserts, MW2 and MW3, were ligated into the pLL3.7 
vector using the 10: 1 ratio shown to be successful for the MW1 insert. All constructs 
were verified by sequencing (Appendix A) but the secondary structure of the hairpin 
insert was problematic. A nucleotide analog, 7-Deaza-GTP which forms weaker bonds 
with its complementary nucleotide was required in the reaction to obtain sequences for 
the MW3 construct.
M I.Hi
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5 .3  P r o d u c tio n  o f len tiv iru s
5.3.1 Confirming integrity o f helper plasmids
Prior to lentiviral construction, each component of the system was transfected 
individually into HEK293T cells to ensure the plasmids expressed the anticipated 
proteins. Integrity of the lentiviral plasmid, pLL3.7, was demonstrated by the 
fluorescence of the GFP reporter in transfected cells (Figure: 5.8A). Western blotting 
confirmed expression of the viral coat protein, YSV-G, from the pMD2G plasmid and 
the Gag polyprotein and its cleaved capsid product from the pCMV_dR8_74 vector 
(Figure: 5.8B and C).
%% . w ?!»<«'
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Figure 5.7 Vectors required for lentivirus production are functional
A. EGFP expression
B. Anti-VSV-G
C 1 2 3
9 8 -
6 4 -
5 0 -
C. Anti-Gag
C 1 2
5 0 -
(A) Expression of the G FP  reporter gene from pLL3.7 was confirmed by visualisation of 
fluorescence in transfected cells under UV light 72 hours post-transfection using a Axiovert 200 
microscope (Zeiss) w ith  a N ikon Coolpix 995 digital camera. Cells transfected with the helper 
plasmids were harvested  72 hours post-transfection, lysates made and 25pl of each was run on a 
16% polyacrylam ide gel. (B) Expression of the VSV-G coat protein from pMD2.G was detected 
by western b lo tting  w ith a prim ary anti-VSV-G antibody (Roche) at 0.5pg/ml. (C) Expression of 
the Gag polyprotein (open arrow) and its cleaved capsid product (closed arrow) was detected 
with a prim ary anti-G ag antibody (Abeam) a t 1:2000 dilution. Binding of both prim ary 
antibodies was visualised w ith  a H R P-conjugated goat anti-mouse secondary antibody and 
ECL reagents. C = control: untransfected HEK293 cells.
—
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5.3.2 Triple transfection to produce lentivirus
To c o n s tru c t fu n c tio n a l v iru ses , th e  helper p lasm ids, pM D 2G  a n d  pC M V _dR 8.74 were 
co -tran sfec ted  in to  H E K 2 9 3 F T  cells w ith  e ith e r th e  e m p ty  pL L 3 .7  v ec to r or pL L 3.7  
co n ta in in g  th e  c loned  s h o r t  h a irp in  co n stru c ts . F ig u re  5.8 show s a re p resen ta tiv e  trip le  
tran sfec tio n  to  m ak e  v iru s  L V -M W 3. G F P -p o sitiv e  cells c o n ta in  th e  pL L3.7-M W 3 
v ec to r a n d  th e  p laq u e -lik e  a p p e a ra n ce  o f green  cells in d ica tes  cell fusion resu ltin g  from  
th e  exp ression  o f th e  Y SV -G  p ro te in .
Figure 5.8 Triple transfection to produce LV-MW3 lentivirus
i - H Q -
m & g . .  £  > :
f i * / :
G FP expression in triple-transfected H EK 293 cells was visualised under UV light 48 hours post­
transfection as before.
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5.3.3 Titering lentivirases
To ensure consistency in subsequent experiments, the titre was calculated for all viruses 
produced. Serial dilutions of virus were added to fresh HEK293FT cells and FACS 
analysis for GFP expression was performed. The percentage of GFP-positive cells was 
double-checked by fluorescence microscopy and always confirmed the FACS result 
(Figure 5.9). The titre was then calculated by correcting for the number of cells plated 
and the viral dilution factor using the following equation:
Titre = (% GFP-positive) x (virus dilution factor) x (number of cells plated)
Titres in the range of 1 - 5 x 108 TU/ml were achieved for each virus.
i v* i t i i
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Figure 5.9 Determination of viral titre by FACS and immunofluorescence
FACS analysis for GFP Fluorescent microscopy
LV-MW3 dilution
1/1,000000
1/1000
1/10,000
56%
8 R1
8
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8
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FL1-H
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Titre = %GFP+ve x Dilution Factor x Number of cells plated 
= 0.088 x 10,000 x 2 x 105 
= 1.8 x 108 TU/ml
Cells infected w ith LV-MW3 a t dilutions ranging from 1:1,000 -  1:1,000,000 were viewed under 
UV light to  estim ate percent positive for G FP  expression 48 hours post-transduction. They were 
then  harvested, fixed and G FP  fluorescence detected by FACS on a FACSCalibur (Becton 
Dickinson). BD Cellquest software was used to measure the percentage of the population 
positive for G FP (R l).
1.16
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5 .4  T e stin g  le n tiv ir u se s  in viira
Once high titre lentiviruses had been prepared, their ability to infect cells and reduce 
PrPc expression was examined. Each virus was added to the media of cells in culture at 
dilutions ranging from 1 / 1 0 0  -  1 / 1 0 0 , 0 0 0  and the cells were monitored daily for the 
appearance of GFP fluorescence.
5.4.1 Testing lentiviruses on N2a neuroblastoma cell line
To provide an indication of whether the viruses might be functional in the brain, they 
were tested on the N2a mouse neuroblastoma cell line, one of very few available 
neuronal cell lines. All three shRNA-expressing viruses, LV-MW1, LV-MW2 and LV- 
MW3 reduced P rPc expression to almost undetectable levels as determined by 
immunofluorescence. As expected, the empty GFP-only virus had no effect on PrPc 
expression (Figure 5.10).
V* . U t:il*
157
CHAPTER 5
Figure 5.10 shRNA-expressing lentiviruses reduce PrPc expression in N2a cells
PrPc GFP M erge
LV - Empty
LV - MW1
LV-MW2
LV - MW3
Four days post infection w ith the lentiviruses, N2a cells on glass coverslips were fixed and 
im m unostained w ith prim ary antibody ICSM18 a t lOpg/ml. Detection of antibody binding was 
performed w ith secondary an tibody, Alexa Fluor®568 goat anti-mouse IgG (H+L) (Molecular 
Probes) a t 1:800 dilution. Coverslips were m ounted onto slides with DAKO fluorescent 
m ounting m edium  containing 1 pg/ml 4\6-diam idino-2-phenylindole (DAPI; Sigma) and cells 
were viewed on an Axioplan 2 MOT microscope (Zeiss) w ith an AxioCam MRm camera and 
Axiovision Control software (Zeiss). T he cell nuclei are shown in blue, the green signal 
represents G FP fluorescence in virally transduced cells and red labelling indicates P rP c staining.
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G F P  fluorescence w as n o t m ax im al in v ira lly  tran sd u c ed  N 2a cells u n ti l  4 d ay s  p o s t­
in fec tion , possib ly  re flecting  th e  p rev iously  rep o rted  low er a c tiv i ty  o f  th e  CMV 
p ro m o te r in  ro d e n t cells th a n  in  h u m an  cells (Ik ed a  e t a l., 2002). T h e  p ro p o r tio n  o f 
tran sd u c ed  cells w as also ap p ro x im a te ly  one log low er th a n  o b serv ed  w ith  th e  sam e 
d ilu tio n  o f v iru s  on H E K 2 9 3 T  cells, revealing  th e  low er perm issiveness o f  th e  N 2a cells. 
E v en  a t  th e  h ig h est co n cen tra tio n s  ad m in is te red , som e cells rem a in ed  u n in fec ted  w hich  
m ay  be in d ica tiv e  o f quiescence a t  th e  tim e o f in fec tion  or d ev e lo p m en t o f o th e r  
u n k n o w n  resistance  facto rs in th ese  u n s tab le  cells.
A lim ited  n u m b er o f tran sd u ced  cells were m an u a lly  p icked  a n d  R N A  e x tra c te d . R T - 
P C R  analysis  was perfo rm ed  to  d e term in e  th e  e x te n t o f Prnp  m R N A  kno ck d o w n  
(F igu re  5.11).
Figure 5.11 shRNA-expressing lentiviruses reduce Prnp mRNA expression
Prnp e x p r e s s i o n  r e l a t i v e  t o  N 2 a  c e l l s  t r a n s d u c e d  w i t h  e m p t y  
l e n t i v i r u s
Lentiviruses
Transduced cells positive for G FP fluorescence under UV light were m anually picked and to ta l 
RNA extracted. One-step RT-PCR am plification of Prnp and |3-actin was performed using 
commercially available ABI assays: Mm00448389_ml (with FAM labeled probe) for P rnp and 
Mouse ACTB Endogenous control, VIC® labeled MGB probe. All reactions were performed in 
triplicate and negative controls included H 2O only and omission of Reverse Transcriptase. Prnp 
expression was normalized to  P-actin and expression is shown as a percentage of th a t  in N2a 
cells transduced w ith the em pty lentivirus. E rror bars represent s.e.m.
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Transduction with the MW1 and MW2 lentiviruses resulted in ~60% knockdown of PrP 
mRNA relative to cells transduced with the empty lentivirus. The MW3 lentivirus was 
more effective, producing ~90% knockdown.
5.4.2 Testing lentiviruses on GT1 hypothalamic cell line
Although the N2a cell line is a useful model in studies of prion disease due to its ability 
to propagate mouse-adapted scrapie prions, the cells are undifferentiated and therefore 
do not represent the in vivo situation. The GT1 cell line is a well-differentiated neuronal 
cell line established from hypothalamic neurons which has many characteristics of 
neurons in vivo (Mellon et al., 1990). Following transduction with the shRNA- 
expressing lentiviruses, PrPc expression was reduced to nearly undetectable levels in the 
GT1 cells (Figure 5.12). As before, the negative control GFP-expressing virus, LV- 
Empty, had no effect on PrPc. In concordance with the previous transduction of N2a 
cells, GFP fluorescence did not reach maximal levels until 4 days post-infection 
suggesting the CMV promoter is either less robust or switches on more slowly in murine 
cells of a neuronal origin than in the HEK293T producer cells.
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Figure 5.12 shRNA-expressing lentiviruses reduce PrPc expression in GT1 cells
LV - Em pty
LV - MW1
LV - MW2
LV - MW3
Four days post infection w ith the lentiviruses, GT1 cells on glass coverslips were fixed and 
im munostained as before (see Figure 5.10). The cell nuclei are shown in blue, the green signal 
represents G FP fluorescence in virally transduced cells and red labelling indicates P rP c staining.
M.White - PhD Thesis
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5.4.3 Testing lentiviruses on primary neuronal cultures
Whilst cell lines are a useful tool for assessing transduction and knockdown by 
lentiviruses, they have often undergone changes which mean they do not provide an 
accurate model of a cells function in vivo. For example, the N2a cell line used here does 
not express the neuronal marker MAP2 (Izant and McIntosh, 1980) and the GT1-1 cell 
line was derived from an artificially induced tumour in a transgenic mouse (Weiner et 
al., 1992). To provide a better indication of whether the lentiviruses would be effective 
in vivo, their effect on primary hippocampal neurons was examined. Freshly dissociated 
hippocampal neurons from newborn rats were kindly provided on glial feeder layers 
plated on glass coverslips by Joost Heeroma (Institute of Neurology). Although the 
lentiviruses would ultimately be administered to mice, the target sequences within the 
rat and mouse prion proteins are homologous enough that primary neurons from the rat 
are also a relevant model. The lentiviruses were added to the culture media at a dilution 
of 1:100 and the cells were incubated for 7 days. As these cultures are a mixture of 
different types of cells from the brain, the cells were immunostained with a neuron- 
specific marker, MAP2, to show th a t the lentiviruses were able to infect primary 
neurons (Figure 5.13).
K4 . ’. 4  - n i l r  i  I m - s K
162
CHAPTER 5
Figiire 5.13 MAP2 immunofluorescence confirms lentiviruses infect primary neurons
MAP2 GFP Merge
LV - Empty
LV - MW1
One week post infection w ith  the lentiviruses, prim ary neurons w ith glial feeder layers on glass 
coverslips were fixed and im m unostained w ith  prim ary antibody MAP2 a t 1:500 (Abeam). 
Detection of an tibody binding was perform ed w ith secondary antibody, Alexa Fluor® 568 goat 
anti-chicken IgG (Molecular Probes) a t 1:1000 dilution. Coverslips were m ounted onto slides 
w ith DAKO fluorescent m ounting m edium  containing 1 pg/ml 4’,6-diamidino-2-phenylindole 
(DAPI; Sigma) and cells were viewed using a confocal microscope (Zeiss microscope LSM510 
META) equipped w ith a “plan-A pochrom at” _63/1.40 oil differential interference contrast 
objective at room  tem peratu re  and controlled by Zeiss LSM software. The cell nuclei are shown 
in blue, the green signal represents G FP  fluorescence in virally transduced cells and purple 
labelling indicates MAP2 staining.
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The co-localisation of M AP2 staining and GFP expression in virally transduced cells 
demonstrates the ability of the lentiviruses to infect primary hippocampal neurons. To 
determine if the lentiviruses were able to reduce Prnp expression in the transduced 
neurons, the cells were stained for P rPc. Figure 5.14 shows the shRNA-expressing 
lentiviruses successfully knocked down PrPc expression in primary neurons, whereas it 
was retained in cells transduced by the empty lentivirus.
VI. h i l r I»M»
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Figure 5.14 shRNA-expressing lentiviruses reduce PrPc protein in primary neurons
PrPc GFP Merge
LV - Empty
LV - MW1
LV - MW2
LV - MW3
One week post infection w ith  th e  lentiviruses a t 1:100 dilution, prim ary neurons with glial 
feeder layers on glass coverslips were fixed and im m unostained w ith prim ary antibody ICSM18 
a t lOpg/ml. D etection of an tibody  binding was performed w ith secondary antibody, Alexa 
Fluor®568 goat anti-m ouse IgG (H +L) (Molecular Probes) a t 1:800 dilution. Coverslips were 
m ounted onto slides and cells were viewed as before. The cell nuclei are shown in blue, the green 
signal represents G F P  fluorescence in  virally  transduced cells and red labelling indicates P rP c 
staining.
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As the primary neurons were maintained on feeder layers of glial cells, it was also 
possible to evaluate the effect of the lentiviruses on this cell type. Figure 5.15 shows the 
strong GFP expression observed in primary glia and the reduction of PrPc to 
undetectable levels in cells transduced with the shRNA-expressing lentiviruses. Cells 
transduced with the empty lentivirus showed no reduction in P rPc. At higher 
concentrations of virus it was possible to transduce all of the cells in the culture - both 
neurons and glia.
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Figure 5.15 shRNA-expressing lentiviruses knockdown PrPc protein in primary glia
LV - Empty
LV - MW1
LV - MW2
LV - MW3
One week post-infection w ith  th e  lentiviruses a t 1:100 dilution, prim ary neurons w ith glial 
feeder layers on glass coverslips were fixed and im m unostained as in Figure 5.13. The green 
signal represents G F P  fluorescence in  virally  transduced cells and red labelling indicates P rP c 
staining.
M. White - PhD Thesis
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5.5 Discussion
The lentiviruses constructed to express the interfering RNA sequences characterized in 
chapter 4 all successfully reduced P rPc expression levels following viral infection. The 
empty virus expressed GFP only and had no effect on P rPc levels. Despite achieving 
high titres of each virus, there appeared to be sub-populations of N2 a cells that were 
resistant to viral infection. As this did not occur with the primary cells, it seemed to be 
a cell line specific phenomenon, perhaps arising due to the unstable karyotype of these 
cells (Prof. C. Weissman, unpublished data).
Whilst all the rodent cells used exhibited weaker GFP expression than the human 
HEK293T cells, the primary neurons showed the lowest fluorescence of all, indicating 
that in vivo GFP expression levels may also be low in neurons. That the GFP expression 
level was consistently lower in neurons than glia suggests that it is probably not 
repression due to the integration site (which would vary from cell to cell), but may be 
due to factors specific to the neurons themselves. Low GFP expression does not 
necessarily reflect low shRNA expression as the interfering hairpins are expressed from 
a separate murine U 6  promoter which has been shown to work well in various mouse 
tissues including brain (Rubinson et al., 2003).
Although viruses coated with the VSY-G envelope protein have previously been shown 
to preferentially infect neurons over glia (Duale et al., 2005), this was not apparent 
here. When virus was added to a culture of primary neurons on glial feeder layers, the 
glia were more readily infected with higher proportions of transduced cells at each 
dilution than the neurons. I t  is, however, also possible that transduced neurons were
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simply more likely to die, resulting in fewer positive cells, or that addition of virus to 
the culture media killed some neurons. I t is unlikely tha t the effect is due to removal of 
PrPc as the same proportions of transduced neurons were also observed with the 
negative control virus, LV-Empty. Accurate neuronal counts could establish whether 
the lentiviruses actually infected more glia than neurons.
The coding sequence of the rat Prnp gene is ~94% identical to the mouse gene so rat 
primary cells are an acceptable model system for assessing knockdown of murine Prnp. 
Interestingly, two of the sequences utilized here, MW1 and MW3, target areas which 
contain a single nucleotide difference in that region of the rat gene. As some mismatches 
between a siRNA sequence and its target mRNA may block cleavage by RISC it was 
possible the single nucleotide difference may have abrogated knockdown. The position 
and type of the mismatch within the siRNA sequence is central to its effect, with 
maximal disruption of silencing occurring with purinerpurine mismatches at the 1 0 th or 
16th position from the 5’ end of the antisense strand (Schwarz et al., 2006). The 
mismatches between the shRNAs and the rat Prnp gene were both 
pyrimidine:pyrimidine changes occurring at position 7 for MW1 and position 11 for 
MW3. These changes have been shown to be well tolerated and did not affect the 
silencing ability of the lentiviruses used here.
All three shRNA-expressing lentiviruses gave excellent knockdown of PrPc in vitro with 
LV-MW1 subjectively appearing to yield the greatest knockdown in primary neurons. 
In  vivo delivery of the lentiviruses to the brains of prion-infected mice would be 
required to determine if reduction of Prnp expression in this way can be of therapeutic 
benefit in prion disease.
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6.1 Introduction
In Chapter 5, lentiviruses expressing shRNAs directed against Prnp were shown to be 
effective at reducing levels of both PrP protein and mRNA in neuronal cell lines and 
primary neuronal cultures. Reduction of neuronal P rPc expression is known to reduce 
pathology and prolong survival in prion-infected mice (Mallucci et al., 2003), but an 
extrinsic mechanism to achieve this is not currently available. To determine if 
extraneous reduction of P rPc expression through lentivirally-mediated RNAi could be 
an effective therapy for prion disease, the efficacy of the viruses must be tested in vivo. 
This chapter describes testing of the lentiviruses in mice and preliminary data from 
therapeutic lentiviral injection of prion-infected mice.
6.1.1 Previous use o f lentiviral-mediated RNAi against the prion protein
The first published use of lentiviral gene therapy in prion disease was the demonstration 
that lentiviruses encoding Prnp containing naturally occurring 4prion-resistant’ 
polymorphisms could inhibit the formation of PrPSc in prion-infected cells (Crozet et al., 
2004). The transgenic P rP c acted in a dominant-negative fashion to inhibit conversion 
of endogenous P rPc into P rP Sc. Although this may have a therapeutic effect in vivo, the 
consequences of expressing this additional P rPc in prion-infected animals still remain 
unknown.
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Another study validated the use of lentiviral-mediated RNAi against the prion protein 
as a method for engineering transgenic livestock which would potentially be resistant to 
prion disease (Golding et al., 2006). Although demonstrating a significant reduction of 
PrPc expression, this strategy is obviously not applicable to the therapeutic situation 
where germline manipulations are not relevant.
A more recent paper by Pfiefer and colleagues also describes the use of lentiviral- 
mediated RNAi against the prion protein (Pfeifer et al., 2006). They tested 6  shRNA 
sequences for reduction of P rP c in N2a cells and showed that 1 of them suppressed 
accumulation of P rPSc in prion-infected N2a cells in agreement with the RNAi- 
mediated reduction of P rP Sc and infectivity demonstrated in the IPK1 cell line here 
(Chapter 4). Stereotaxic injection of their lentivirus into the brains of uninfected mice 
resulted in localised reduction of P rPc expression around the injection site, but the virus 
was not administered to prion-infected mice. Instead, chimeric mice transgenic for the 
shRNA targeting Prnp were made and it was found that 64% of these animals with 
variable chimerism survived longer than controls after prion infection. Whilst this 
study demonstrated the safe use of a stably expressed shRNA against the prion protein 
in vivo, it was not administered in a therapeutic form that can be translated into a 
viable therapy. The chimeric mice created are essentially another transgenic model of 
PrPc depletion. I t still remains to be determined if reduction of PrPc expression by 
stereotaxic delivery of lentiviruses for RNAi can be used to treat prion disease.
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6.2 Optimising stereotaxic coordinates for hippocampal 
targeting of lentiviruses
Intravenous injection of YSV-G coated lentiviruses does not result in efficient 
transduction of the brain (Pan et al., 2002), meaning the viruses must be injected 
directly into the desired region. To achieve precise targeting of structures in the brain, 
stereotaxic surgery is used. To enable comparison of the effects on prion pathology 
following RNAi-mediated Prnp knockdown with the reversal seen after Cre-mediated 
knockout (Mallucci et al., 2003), the same strain of RML prions would be used. In mice, 
RML causes severe neuropathology in the hippocampus so this structure was selected as 
the target for lentiviral transduction. In order to identify the best coordinates for 
hippocampal targeting, a series of pilot injections was conducted using trypan blue dye 
injected into freshly culled mice. Tg37 mice were used, as therapeutic treatment would 
eventually be tested in models of prion disease in this mouse strain.
V i ■•YVSiiil-r
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Figure 6 . 1  Optimisation of stereotaxic coordinates by trypan blue injection
P: 2, L: 3,V:-1.8
P:2, L: 1.7, V: 2
P: 2, L: 2, V: -1.8
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B. ± 3mm ± 2mm ± 1.5mm
-1.8mm
-2.0mm
A. Cryostat sections dem onstrating  representative try p an  blue injections into the hippocampus 
a t a range of coordinates. T he arrow indicates the p a th  of the needle. Measurements are given in 
millimetres relative to  bregm a. P  = posterior, L = lateral, V = ventral. B. Schematic illustrating 
the coordinates targe ting  the  hippocam pus identified by the series of trypan  blue injections. 
Scale bar = 1mm.
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Optimal targeting of the hippocampus was achieved at coordinates 2 mm posterior to 
bregma, 1.5 — 3mm lateral and 1.8 — 2mm ventral.
6 .3  S tereo ta x ic  in je c tio n  o f le n t iv ir u se s  in to  u n in fected  
m ice
To establish if the lentiviruses would transduce cells in vivo, they were stereotaxically 
injected into the hippocampus of uninfected mice using the coordinates determined 
previously by trypan blue injection. The lentivirus expressing the MW1 shRNA 
sequence was chosen as this sequence had consistently shown good reduction of PrPc 
expression and allowed the clearance of P rPSc and infectivity from prion-infected cells 
(Chapter 4). Although the LV-MW3 virus produced a larger reduction of Prnp mRNA 
in the N2a cell line, LV-MW1 appeared to yield the best reduction of PrPc protein in 
primary neuronal cells which are likely to be a better model for the in vivo situation 
(Chapter 5).
Two mice received a single injection of 2pl of LV-MW1 at 5 x 108 TU/ml (equivalent to 
1 x 106 TU) to the right hippocampus only, to control for effects of virus injection and 
examine the brain for possible retrograde transport of the virus to the contralateral 
hemisphere. Two further mice received two injections of LV-MW1 to the right 
hippocampus and two injections of LV-Empty at 2 x 108 TU/ml (equivalent to 4 x 105 
TU/injection) to the left hippocampus to compare transduction efficiencies of the two 
viruses. Seven days later, they were culled and the brains fixed and embedded in
W .  %% i i s l * '
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paraffin. Coronal sections were cut through the hippocampus and every 7 th section was 
stained with an anti-GFP antibody to detect transduced cells. Sections showing positive 
staining are shown in Figure 6 .2 .
Mu***
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Figure 6 . 2  Lentivirally transduced cells in the hippocampus of uninfected mice
A.
Left hippocam pus: LV - Empty Right hippocampus: LV - MW1
Coronal sections of paraffin-em bedded brains were dewaxed and stained w ith an Anti-GFP 
antibody (Abeam) a t 1:200. P rim ary  an tibody binding was detected w ith a H R P  conjugated 
Goat Anti-m ouse an tibody (Sigma) on a V entana autom ated staining machine (Ventana 
Medical Systems) according to  m anufacturers instructions. Sections were counterstained with 
haem atoxylin and m ounted in D PX . A. R epresentative section showing G FP positive cells 
(brown, indicated by red arrows) in the  righ t hippocam pus and lack of staining in the 
uninjected left hippocam pus. Coordinates for injection were: P  = 2mm, L =  -2mm, V = -2mm.
B. Sections from the  b ilatera lly  injected mice showing positive G FP staining for LV-Empty in 
the left hippocam pus and LV-MW1 in the  righ t hippocampus. Coordinates for the injections 
were: P  = 2mm, L =  ±  2m m , V =  -1.8mm and P  = 2mm, L = ± 3mm, V = -2mm. Scale bar = 
1mm. P  = posterior, L = lateral, V =  ventral.
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The initial set of injections demonstrated transduction of cells in the injected 
hippocampi. There was no evidence of transduction of cells in the contralateral 
hippocampus or any other brain structures (remote from the needle track) in the mice 
which received a single injection of virus to the right hippocampus. A single mouse 
showed neuronal loss in the hippocampus but TUNEL staining revealed no evidence for 
neuronal loss in any of the other mice and this was not observed in any other animals. A 
much larger area was virally transduced in mice receiving 2  injections to each 
hemisphere and both the LV-Empty and LV-MW1 virus appeared to transduce cells 
with approximately equal efficiency.
Based on the morphology, many of the positive cells appear to be astrocytic and in 
general, these cells expressed higher levels of GFP than the neurons. This is in 
agreement with the high transduction frequency and GFP expression of astrocytes 
observed in vitro in Chapter 5.4.3. At higher magnification however, it was possible to 
see GFP-positive cells with neuronal morphology and processes that resemble axons, 
suggesting the lentiviruses were also able to transduce neurons in vivo (red arrows, 
Figure 6.3).
5-1 - i :-
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Figure 6.3 Transduction of neurons and astrocytes by lentiviruses
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Higher m agnification images of sections from uninfected mice injected w ith LV-MW1. Green 
arrows indicate G FP-positive cells w ith  astrocytic morphology. Red arrows indicate probable 
neuronal processes from  lentivirally  transduced neurons. All images show regions of the 
hippocam pus except for section B which shows virally transduced cells near the top of the 
needle track  in th e  cortex. Scale bar = 100pm for A, C and D, and 200pm for B.
6 .4  S tereotax ic  in jectio n  of len tiv iru ses in to  the
hippocam pus of RML-infected mice
Following the successful demonstration of lentiviral transduction in uninfected mice, an 
experiment was designed to examine the effects of the lentiviruses on pathology in mice
M. White - PhD Thesis
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with established prion disease. In accordance with the study by Mallucci and colleagues 
(Mallucci et al., 2003), all mice were inoculated intracerebrally with RML-infected brain 
homogenate at 1 week of age and allowed time for the prions to replicate.
6.4.1 The experimental design
To examine the effects on localised prion pathology in the hippocampus, a group of 
mice received 2 2pl injections of LY-MW1 (equivalent to 2 x 106 TU) to the right 
hippocampus and 2  2 pl injections of LV-Empty (equivalent to 8  x I05 TU) to the left 
hippocampus as an internal control. Within this group, I sub-group of mice received the 
lentiviral injections at 8 wpi, a mid-stage of disease equivalent to the time of Cre- 
mediated PrP depletion in the NFH-Cre/Tg37 mouse model, when PrPSc deposition, 
gliosis and hippocampal spongiosis are evident. To determine if a therapeutic benefit is 
possible further into the disease course, a 2 nd sub-group received the lentiviral injections 
at lOwpi, a late-stage of disease when neuronal loss is occurring and the mice display 
early clinical symptoms. All mice were culled 2 weeks after lentivirus administration 
and their brains taken for analysis of hippocampal Prnp mRNA or histological 
examination. Figure 6.4 shows a schematic illustrating this experimental design.
'*hi$
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Figure 6.4 Schematic illustrating the experiment for comparison of LV-MW1 and LV- 
Empty in prion-infected mice.
PRION INOCULATION LENTIVIRUS INJECTIONS
} LV-Empty LV-MW1
MICE CULLEDM id-stage d ise a se
-i- 2 w eeks
LV-Empty LV-MW1
MICE CULLED
♦ 2 w eeks
To confirm the lentiviral expression cassette was able to integrate into the host cell 
genome and produce stable expression and to examine the duration of viral expression 
in prion-infected mice, a timecourse study was performed. RML-infected mice received 
2 2pl injections of LV-MW1 (equivalent to 2 x 106 TU) to each hippocampus at 6 wpi.
Mice were then culled at 2  week intervals and their brains collected for analysis of 
hippocampal Prnp expression and histological examination. A schematic illustrating 
this experimental design is shown in Figure 6.5.
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Figure 6.5 Schematic illustrating study of duration of LV-MW1  expression in vivo
PRION INOCULATION
6 weeks MICE CULLED
m n
♦ 2 + 4 +6 +8 weeks
6.4.2 Effects of lentiviral transduction on PrP expression and neuropathology 
in prion-infected mice
Comparison of the histology of mice injected with LV-Empty in the left hippocampus 
and LV-MW1 in the right hippocampus 8  weeks post-inoculation with prions revealed 
local neuroprotective effects in the area transduced with LV-MW1 (Figure 6 .6 ). There 
was less spongiosis and a more intact stratum pyramidale layer (black arrows, Figure 
6 .6 ) in the hippocampus treated with the shRNA-expressing lentivirus. The 
hippocampus transduced with LV-Empty appeared shrunken with respect to the 
treated one as indicated by the black, red and blue lines showing the combined depth of 
the layers from the top of the stratum pyramidale layer to the top of the dentate gyrus.
LENTIVIRUS INJECTIONS
LV-MW1 LV-MW1
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This is most likely due to loss of cells, projections and interneurons in the LV-Empty 
treated hippocampus.
Figure 6 . 6  Transduction with the LV-MW1 lentivirus protects against pyramidal
neuron loss and spongiosis in the hippocampus of a mouse with mid-stage 
prion disease
+ LV-Empty + LV-MW1
Mice injected w ith  LV-MW1 in the righ t hippocam pus and LV -Em pty in the left hippocampus 
a t 8wpi were culled 2 weeks la ter and stained for G FP expression as before. Image shows left 
and righ t hippocam pi from  th e  same section of 1 mouse. Brown staining indicates virally 
transduced cells in the  hippocam pus. The black arrows highlight the stra tum  pyramidale and 
the combined depth  of cell layers between th e  stra tum  oriens and the dentate gyrus is indicated 
by the vertical bars. Scale bar = 1mm.
HI .White - PhD Thesis
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Protection of the stratum pyramidale layer by LV-MW1 was even attainable in mice 
which received the lentivirus at lOwpi, a late stage of disease when clinical symptoms 
were evident (Figure 6.7).
Figure 6.7 Transduction with the LV-MW1 lentivirus protects against loss of
pyramidal neurons in the hippocampus of a mouse with late-stage prion
disease
+ LV-Empty + LV-MW1
Mice injected w ith  LV-MW1 in th e  righ t hippocam pus and LV -Em pty in the left hippocampus 
a t lOwpi were culled 2 weeks la ter and stained w ith haem atoxylin and eosin. Image shows left 
and right hippocam pi from  th e  same section of 1 mouse. The black arrows highlight the stratum  
pyram idale. Scale bar = 500pm.
The protection of the stratum pyramidale conferred by transduction with LV-MW1 
appears to be even greater than that attained when the virus was administered 8 wpi but 
this may reflect the fact that these mice were allowed to progress 2  weeks further into 
the disease course when the majority of neuronal loss may normally occur. It is still 
   183
M. White - PhD Thesis
CHAPTER 6
significant however, that neuronal protection can be achieved even in late-stage prion 
disease.
Double-immunofluorescence for virally expressed GFP and PrPSc showed little or no 
colocalisation in the brains of mice injected with LV-MW1 (Figure 6 .8 ). This suggests 
that stable expression of the MW1 sequence in vivo in prion-infected mice prevents 
accumulation of PrPSc in a similar manner to that seen in vitro in prion-infected cells in 
Chapter 4.
Figure 6 . 8  LV-MW1 reduces PrPSc deposition in prion-infected mice
LV-MW1 PrPSc Merge
Sections from prion-infected mice injected w ith  LV-MW1 at 8wpi and culled 2 weeks later were 
dewaxed as usual. T hey were incubated in 98% formic acid for 3 minutes to remove P rP c and 
stained w ith A nti-G FP an tibody (Abeam) a t 1:150 dilution overnight to detect virally 
transduced cells. P rP 8* deposition was detected w ith ICSM35 a t 1:1500 dilution. Prim ary 
antibody binding was detected w ith Alexa Fluor®488 goat anti-rabbit IgG (H+L) (Molecular 
Probes) secondary an tibody  a t 1:400 for G FP  and Alexa Fluor®546 goat anti-mouse IgG (H+L) 
(Molecular Probes) for P rP Sc. Scale b ar = 500pm.
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Ongoing analysis is expected to verify that the empty lentivirus does not prevent PrPSc 
deposition as it has been shown to have no effect on Prnp mRNA expression in the 
hippocampus (Figure 6.9), and no effect on PrPc protein expression in primary 
hippocampal neurons (Chapter 5.4.3).
RT-PCR analy sis confirmed LV-MW1 reduced Prnp expression in the hippocampus 
relative to RML-infected Tg37 mice, whereas LV-Empty did not (Figure 6.9). The 
knockdown was detectable 2  weeks after administration of the lentivirus and lasted for 
at least 1 month, signifying the hippocampal cells were stably transduced.
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Figure 6.9 Stereotaxic injection of LV-MW1  results in reduction of hippocampal 
Prnp  mRNA expression for at least 4 weeks
H ip p o cam p a l Prnp e x p re s s io n  o v e rtim e  follow ing lentiviral 
tra n s d u c tio n  in RM L-infected m ice
120 
c 100
1  „
2  60 
*->
S 40 o
a»
20 
0
2 wks 2 wks 4 wks
W eeks post-len tiv ira l in jection
RM L-infected mice were culled a t the indicated tim epoints following lentiviral administration. 
The hippocam pi were dissected out and to ta l RNA extracted. One-step RT-PCR amplification 
of the  MloxP transgene m RN A  and P-actin was performed. Prim ers and probes for the Prnp 
transgene were as follows. Forw ard prim er, 50-GCCCATGATCCATTTTGG-30; reverse primer, 
50-CGGTACATGTTTTCACGGTAGT-30; probe, 50-FAM-AACGACTGGGAGGACC-30. P-actin 
was amplified using a commercially available ABI assay: Mouse ACTB Endogenous control, 
VIC labeled MGB probe. All reactions were performed in triplicate, and negative controls 
included H 2O only and omission of Reverse Transcriptase. Prnp expression was normalized to P- 
actin  and expression levels in lentivirally  injected mice were compared to a pool of 3 Tg37 mice 
a t 8wpi. E rror bars represent s.e.m.
The extent of knockdown attained suggested a high rate of lentiviral transduction of a 
minimum of 20 - 40% of the hippocampus. It was not possible to analyse the mRNA 
levels 6  weeks after lentiviral injection as the group number was reduced due to loss of 
animals during surgery and from fighting. Mice were due to be culled 8  weeks after the
■ Tg37 8wp.
■  ♦ LV-Empty
■ ♦ LV-MW1
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lentiviral injection but had become scrapie sick at this time. As this was in excess of the 
standard incubation time for Tg37 mice however, their brains were taken for 
histological analysis.
Immunohistological staining confirmed continued GFP expression at 8  weeks post- 
lentiviral injection suggesting the shRNA expression cassette had been stably 
integrated into the genome and had not been silenced (see Figure 6.11).
Although the area of transduction in the hippocampus in Figure 6.11 is not as great as 
that seen previously (Figure 6.2), ongoing histological analysis should confirm if this is 
specific to the injections in this mouse, or due to partial loss of transgene expression.
6.4.3 Effects o f lentiviral treatment on survival in prion-infected mice
To examine the effects of treatm ent with lentiviral-mediated RNAi against PrPc on 
incubation time in mice with established prion disease, a group of mice received 2  2 pl 
injections of either LV-MW1 (equivalent to 2 x 106 TU) to each hippocampus or 2 2pl 
injections of LV-Empty (equivalent to 8  x 105 TU) to each hippocampus as a negative 
control, 8  weeks post-inoculation with RML (Figure 6.10). Treatment was not given to 
mice with late-stage prion disease due to the difficulty of performing successful surgery 
on animals with such advanced illness.
VI.
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Figure 6.10 Schematic illustrating experimental design to examine the effect of
treatment with LV-MW1 on incubation time in mice with mid-stage prion 
disease
PRION INOCULATION LENTIVIRUS INJECTIONS
LV-MW1 LV-MW1
8  weeks ^  MICE CULLED
-------------   ^  DEATH
♦ 2 weeks
LV-Empty LV-Empty
8  weeks MICE CULLED
________  DEATH
+ 2 weeks
Two weeks after the administration of the lentivirus, 3 -4  animals from each condition 
were culled and their brains collected for analysis to determine if bilateral injection 
affected prion pathology differently to the unilateral treatment administered in the left- 
right comparison experiment (Figure 6 .6 ). This analysis is currently ongoing.
As the results of the initial timecourse experiment had suggested transduction of the 
hippocampus alone may be sufficient to impact on incubation time in this model, the
M.White - PhD Thesis
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remaining animals were allowed to progress to end-stage disease, were culled according 
to local rules and their brains collected for histological analysis.
Figure 6.11 Bilateral injection of LV-MW1 protects against hippocampal neuronal loss 
in mice with mid-stage prion disease
LV-Empty 
70 days pi
Scrapie sick 85 days pi
LV-MW1 
70 days pi
■ ' f 77 
f t &V ••v  •*
Scrapie sick 104 days pi
•- ■ . ■ f i
Prion-infected mice injected bilaterally w ith LV-MW1 or LV -Em pty a t 8wpi were culled 2 
weeks post-injection or when scrapie sick and their brains were stained for G FP expression as 
before. Brown staining indicates virally transduced cells in the  hippocam pus. The black arrows 
highlight the  s tra tum  pyram idale layer in the  scrapie sick mice. The needle track is evident in 
both mice injected w ith LV-MW1. Scale bar =  500pm.
M. White - PhD Thesis
189
C H A PT ER  6
Immunohistochemical analysis confirmed bilateral transduction of the hippocampi with 
LY-MW1 protected against hippocampal neuronal loss in mice receiving the lentivirus 
at 8 wpi. The stratum  pyramidale layer (black arrows, Figure 6.11) was remarkably 
intact in the longest-surviving mice injected with LV-MW1 which were culled due to 
scrapie sickness at 104 days post-inoculation. These mice survived 16 days longer than 
the average for mice injected bilaterally with LV-Empty and 19 days longer than the 
average for RML-infected mice receiving no lentiviral injections. The survival times of 
all mice is shown in Table 6.1.
-iPi”, 1:1 Tfso-.'S.i*
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Table 6.1 Survival times of RML-infected Tg37 mice with and without bilateral 
lentiviral injections at mid-stage prion disease
Condition Survival time (dpi) Mean survival 
time (dpi) ± sd
RML-only 81
83
84
84
91 85 ±4
+ LV-Empty 85
85
85
91
91
91 8 8  ±3
+ LV-MW1 91
91
97
98
98
104
104 98 ±5
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A single a d m in is tra tio n  o f 2 in jec tio n s  o f LV -M W 1 to  th e  d o rsa l h ip p o cam p u s was 
su ffic ien t to  s ig n ific an tly  p ro lo n g  th e  su rv iv a l tim e  o f p rio n -in fec ted  m ice b y  15% 
co m p ared  to  R M L -in fec ted  co n tro ls  (p =  0.009, M an n -W h itn e y  te s t , 2 ta iled ). T hese 
m ice also su rv iv ed  s ig n ific an tly  longer th a n  th e  m ice in jec ted  w ith  th e  em p ty  len tiv irus 
(p =  0.012, M a n n -W h itn e y  te s t ,  2 ta iled ). T h ere  w as no  sig n ifican t difference in  su rv ival 
tim e  b e tw een  m ice rece iv in g  L V -E m p ty  a n d  u n in fec ted  co n tro ls  (p =  0.066, M ann- 
W h itn ey  te s t ,  2 ta iled ). F ig u re  6.12 show s a su rv iv a l cu rve  for all m ice.
Figure 6.12 Mice injected bilaterally with LV-MW1 in mid-stage prion disease survive 
significantly longer than controls
LV
RML LV
1 0 0
+ LV-MW180
+ LV-E
a) 60 —
4 0 -
2 0 -
10595 1 0 09080 850
Days post infection
Survival of prion-infected Tg37 mice following lentiviral injection compared to  mice receiving 
no injection, n  =  5 for RML only, 6 for L V -E m pty and 7 for LV-MW1.
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6 .5  D isc u ss io n
The data presented here strongly support a therapeutic role for RNAi-mediated 
reduction of P rPc expression in prion disease. A lentivirus expressing a shRNA directed 
against Prnp reduced PrP  mRNA expression in vivo, prevented accumulation of PrPSc 
in transduced cells, protected against neuronal loss in the hippocampus and prolonged 
survival in a mouse model of prion disease relative to treatment with an empty 
lentivirus and RML-infected controls. Furthermore, administration of the lentivirus at 
a late stage of disease, when clinical symptoms are already present and 
neuropathological change is established, was able to protect against neuronal loss in the 
hippocampus demonstrating the rapid action of this intervention.
Most remarkably, a single administration of the lentivirus to a localised area of the 
hippocampus in mice with mid-stage disease was sufficient to significantly prolong 
survival. The mice did eventually succumb to disease, however, as there are clearly 
additional regions of the brain involved in prion pathogenesis.
Ongoing analysis will seek to determine if lentiviral-mediated depletion of PrPc, like 
Cre-mediated excision, results in neuronal recovery, or simply slows the disease process. 
The presence of an intact stratum  pyramidale and lack of spongiosis in the 
hippocampus of the longest surviving mice suggest that recovery may occur if enough 
neurons are virally transduced. Consistent with this is the observation that the mouse 
with the most prominent expression of GFP in the pyramidal neurons survived the
■'MS*
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longest. This would imply that targeting the lentivirus to neuronal cells may be crucial 
to the success of such a therapy.
Further analysis will also be required to ascertain whether there was any silencing of the 
transgene over time. Some of the mice culled 6 - 8  weeks after administration of the 
lentivirus did appear to have reduced GFP expression. Detection of the virally 
expressed GFP, however, was problematic, unreliable and apparently underestimated 
the true extent of viral transduction. RT-PCR analysis of the injected hippocampi 
suggested that even assuming 100% knockdown of Prnp in all transduced cells, a 
minimum of 20-40%  of the hippocampus should have been positive for GFP. As LV- 
MW1 is unlikely to completely remove PrPc expression in vivo, the true figure would be 
even higher, but this degree of GFP expression was seldom detected by 
immunohistochemistry. This may have been due to poor detection sensitivity or low 
expression from the CMV promoter in vivo, in accordance with the in vitro results in 
Chapter 5.
The experiments described in this chapter were designed to replicate the transgene- 
mediated knockout of P rPc achieved in the NFH-Cre/Tg37 mouse model during prion 
disease. This method of PrPc depletion results in complete rescue of pathology and 
normal survival of the mice due to total knockout of PrP expression in all neuronal 
cells. I t  is not surprising therefore, that lentiviral-mediated RNAi against the prion 
protein did not achieve the same extraordinary result, as only a fraction of all neuronal 
cells were virally transduced. It is, however, an important proof-of-principle that 
reduction of PrP expression through extrinsic means can protect those areas which have 
been targeted.
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The work described in this thesis strongly validates the use of lentiviral-mediated RNA 
interference as a therapeutic approach in prion disease: a single administration of this 
treatment in established prion disease prolongs survival and protects against neuronal 
loss in the targeted area. First it was demonstrated tha t reducing PrPc expression with 
siRNA duplexes enabled clearance of P rPSc and infectivity from prion-infected cells in 
vitro. I t was then confirmed tha t stable expression of the interfering RNA molecules 
through lentiviral transduction of the hippocampus reduced local pathology and 
significantly prolonged survival in a mouse model of prion disease. This represents an 
important and novel advance in the treatment of established prion disease.
7 . 1 R e su lts  a n d  p o ss ib le  im p ro v em en ts o n  m eth od o logy
Previously, the only exogenously delivered agents which have been of therapeutic 
benefit in mice with established prion neuropathology are amphotericin B, its 
derivative MS-8209 (Demaimay et al., 1994), and pentosan polysulphate (Doh-ura et 
al., 2004).
Intraperitoneal administration of amphotericin B or MS-8209 to prion-infected mice 
starting ~70% of the way through the incubation period (an approximately equivalent 
stage of disease to those injected with lentivirus here) prolonged survival times by 14% 
and 19% respectively at the highest doses given (Demaimay et al., 1997). This resulted 
from an extension of the incubation time, but, following disease onset, pathology and
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clinical signs were unchanged. The effect has been shown to be dependent on the prion 
strain however, with a loss of efficacy in mice infected with BSE compared to scrapie 
prions (Adjou et al., 1996). Furthermore, the only known treatment of a human CJD 
patient with amphotericin B was unsuccessful (Masullo et al., 1992).
The most promising results published to date have been achieved through intra- 
ventricular infusion of pentosan polysulphate in prion-infected mice (Doh-ura et al.,
2004). A 141% prolongation of survival was observed with continuous, high dose 
infusion into the ventricles starting 1 0  days after infection of transgenic mice (expressing 
hamster PrP), with the 263K hamster prion strain. This fell to 71%, however, when the 
treatment began 70% of the way through the incubation period. The increased 
incubation times were accompanied by a decrease in PrPSc deposition and 
neurodegenerative changes in the treated hemisphere and a reduction in infectivity upon 
subsequent passage to mice. There was no evidence of reduction of pre-existing PrPSc in 
the brain, however, implying that endogenous clearance mechanisms were inhibited. 
Again, the effect was strain-dependent in murine PrP-overexpressing Tg20a mice 
infected with the RML (mouse-adapted scrapie) and Fukuoka-1 (mouse-adapted GSS) 
prion strains. The therapeutic effects of pentosan polysulphate were considerably 
reduced, giving only 46% longer survival in RML-infected Tg20a mice when 
administered 70% of the way through the incubation period.
The anti-coagulant action of pentosan polysulphate caused haemorrhaging in 80% of 
animals around the pump insertion site in mice and continuous high dose infusion 
caused fatal seizures in 4/5 dogs (Doh-ura et al., 2004). Despite these adverse side effects,
pentosan polysulphate has been administered to human prion disease sufferers
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on compassionate grounds in the absence of other available treatments. The 
effectiveness of this treatm ent in humans remains unclear due to small sample sizes, the 
different prion diseases involved, varying treatment schedules, and due to complications 
arising from increasing disability as a result of the disease process itself. A Medical 
Research Council monitoring study of pentosan polysulphate treatment in C JD patients 
found tha t although long-term infusion was well-tolerated, it did not appear to halt loss 
of brain function or disease progression (Bone, 2006). Further experimental work to 
confirm and elaborate on the findings of Doh-Ura and colleagues was recommended.
The effects of lentiviral-mediated reduction in Prnp expression in prion-infected mice 
achieved here are comparable in terms of survival to treatment with amphotericin B or 
MS-8209, and superior in terms of neuropathological protection. Although the 
prolongation of survival was not as great as that attained in RML-infected mice infused 
with the highest dose of pentosan polysulphate, only a single administration of 
lentivirus was given to a very restricted area of the dorsal hippocampus. Increasing the 
area of transduction, either through multiple injections or more efficient delivery 
methods, should offer improved protection. Indeed, recent reports have shown that the 
use of convection-enhanced delivery methods can significantly improve the area of viral 
transduction within the brain (Bankiewicz et al., 2000;Chen et al., 2005;Cunningham et 
al., 2 0 0 0 ;Hadaczek et al., 2006). As incubation times in prion disease are known to be 
correlated with PrPc expression levels, transducing a larger area of the brain would be 
expected to improve the therapeutic outcome.
Furthermore, it may be possible to identify regions of the brain in which reduction of
Prnp expression may have a relatively greater effect on disease course. Previous 
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research in a mouse model of Spinocerebellar Ataxia 1 demonstrated that reduction of 
pathogenic protein by viral-mediated RNAi in only 5 - 10% of cerebellar Purkinje cells 
was sufficient to mediate a significant improval in motor function (Xia et al., 2004). By 
defining and targeting areas of the brain in which prion replication or pathology is the 
highest, a greater prolongation of survival may be attainable. This idea is also supported 
by the observation tha t the degree of chimerism in mice transgenic for an shRNA 
targeting Prnp expression did not always correlate with the survival time following 
prion infection (Pfeifer et al., 2006). Some mice with only 10 - 20% chimerism survived 
as long as mice which were 90 - 95 % chimeric, indicating that the regions of the brain in 
which Prnp expression is reduced are important contributors to the therapeutic 
outcome.
In addition to targeting specific structures within the brain, further increasing the 
efficiency of lentiviral transduction of the most vulnerable cell types may improve the 
therapeutic effect. I t  has been demonstrated tha t PrPc conversion must occur within 
neurons to be neurotoxic (Chesebro et al., 2005;Mallucci et al., 2003), so improving 
transduction efficiency of this cell type should be investigated. Pseudotyping the viral 
particles with a coat protein that preferentially infects neurons, thereby improving the 
ratio of transduced neurons to glia, may facilitate a greater therapeutic benefit from the 
same amount of virus.
I t still remains to be determined if lentiviral-mediated reduction of Prnp expression 
assisted clearance of P rP Sc or simply prevented its deposition, but the in vitro results 
using siRNA duplexes in a prion-infected cell line (Chapter 4) suggest that clearance 
may occur.
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7.1.1 Functional recovery in prion disease
It has only recently been demonstrated that the early stages of prion disease are 
characterised by cognitive and behavioural deficits which precede neuronal and synaptic 
loss (Mallucci et al., 2007). This impairment is independent of PrPSc deposition and 
appears to be related to presynaptic axonal dysfunction. Remarkably, depletion of 
neuronal P rPc rapidly reverses these deficits, demonstrating that the morphological 
recovery previously observed upon Cre-mediated PrP depletion in prion-infected mice is 
also accompanied by a functional recovery. This suggests that there is a window during 
which time it may be possible to not only halt clinical progression, but also reverse 
initial cognitive and behavioural abnormalities associated with prion disease. Early 
reduction of P rPc expression in human prion disease may allow some degree of 
functional recovery in addition to prolonging survival.
7.1.2 RNAi as a therapy for all classes of prion disease
A significant advantage of the RNAi therapeutic approach in prion disease is a lack of 
strain specificity. As all prion diseases involve conversion of endogenous PrPc, removing 
this substrate through RNAi should be an effective general treatment for all strains.
This should also apply to familial prion diseases which arise from a coding mutation in 
PRNP. I t is likely that allele-specific silencing strategies to reduce expression of the 
m utant P R N P  allele, as has been achieved in models of other neurodegenerative
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diseases (Gonzalez-Alegre et al., 2005;Sapru et al., 2006;Xia et al., 2006) would be 
effective here. As the familial prion diseases are the only ones for which there is 
currently an early diagnostic test available, successful treatment of this category may be 
possible through reduction of m utant PrPc expression prior to development of 
pathology.
A further category of prion disease patients that may benefit from RNAi-mediated 
silencing of P R N P  are those individuals known to have been peripherally infected, such 
as recipients of contaminated blood products. Systemic delivery of VSY-G pseudotyped 
lentiviruses has been shown to efficiently transduce the spleen and bone marrow (Croyle 
et al., 2004;Pan et al., 2002), which are crucial for peripheral prion spread and 
neuroinvasion (reviewed in (Aguzzi and Heikenwalder, 2006)). Reduction of PRNP  
expression in these organs may significantly prolong the incubation period. Selective 
targeting of routes of neuroinvasion such as the sympathetic nerves within the vertebral 
column may also significantly extend incubation time and perhaps even prevent 
neuroinvasion.
7.1.3 The therapeutic potential o f siRNA duplexes in prion disease
RNAi-mediated reduction of P R N P  expression is not restricted to the use of viruses. 
siRNA duplexes such as those characterised in Chapter 3 may also be of therapeutic use. 
Systemic delivery results in efficient gene silencing in peripheral organs in mice (Lewis et 
al., 2 0 0 2 ), and may represent a possible treatment to manage peripheral prion levels,
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effectively maintaining a subclinical state. It has also recently been demonstrated that 
systemic delivery of siRNA in non-human primates is well tolerated and results in up to 
90% silencing of the target gene for as long as 11 days following a single administration 
(Zimmermann et al., 2006). Intraventricular infusion can mediate widespread 
knockdown in the brain (Thakker et al., 2004) and may be a valid approach following 
prion neuroinvasion. Preclinical research is already underway to investigate the use of 
this technology in other neurodegenerative diseases such as Parkinson's, Huntington's 
and Alzheimer's Diseases (www.alnylam.com/therapeutic-programs/programs.asp). As 
the effect is transient, treatment for prion disease would need to involve ongoing 
administration to remove PrPc and potentially allow clearance of infectivity to a sub- 
pathological threshold.
7 . 1 . 4  C o m b i n a t i o n a l  t h e r a p y  f o r  p r i o n  d i s e a s e
To further improve the chances of a therapeutic gain, combinational therapy should be 
investigated. It is possible that administration of another agent, such as pentosan 
polysulphate, in conjunction with RNAi-mediated reduction of PrPc expression may 
have a synergistic effect. This has already been observed in combinational therapy for 
Hepatitis B Virus using siRNA with currently available treatments
(www.sirna.com/wt/page/anti viral). Lowering the level of PrPc available for conversion 
may enhance the ability of pentosan polysulphate to inhibit the disease process. 
Lentiviral-mediated RNAi may be more amenable to combinational therapy as
M. White ■ PhD Thesis
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expression of the shRNA is driven by constructs stably integrated into the genome 
whereas the effects of another drug on the uptake and action of siRNA duplexes would 
need to be carefully assessed.
7 . 1 . 5  T h e  u s e  o f  R N A i  i n  h u m a n s
Although the use of lentiviruses for gene therapy is still largely at the experimental 
stage, the recent results of the first clinical trial using a lentivirus in HIV-infected 
humans were very encouraging (Levine et al., 2006). No adverse clinical effects were 
observed for 2  years following administration of the lentivirus, providing initial 
optimistic data on the clinical suitability of lentiviral gene therapy.
Clinical trials utilising RNAi against a variety of diseases are currently underway. 
Several Phase I clinical trials have demonstrated safety of RNAi targeting Respiratory 
Syncytial Virus in healthy volunteers (www.alnylam.com/therapeutic- 
programs/programs.asp). Positive Phase II results have been reported in patients 
suffering from wet age-related macular degeneration
(www.acuitypharma.com/press/releasel5.pdf). and an siRNA that demonstrated 
therapeutic benefit in mouse models of this condition (Shen et al., 2006) has also 
translated to effective treatment in human patients (www.sirna.com/wt/page/ocular).
It is possible that mouse models of disease may be more relevant for RNAi-based 
therapies than traditional drug treatment as the effects of drug metabolism in different 
biological systems are difficult to predict.
M.White - PhD Thesis
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The interfering RNA sequences used here only provide partial knockdown of Prnp 
expression. I t is highly probable that still more effective sequences could be identified, 
however the demonstration of a therapeutic benefit resulting from incomplete 
knockdown suggests this may not be necessary. As the normal function of PrPc remains 
unclear and the effects of depletion in humans unexamined, it may be prudent to only 
reduce its expression enough to tip the balance between conversion and clearance of 
prion infectivity towards a subclinical disease state.
7 .2  F u tu re  w o r k
Future work should aim to translate this proof-of-principle demonstration into a viable 
therapy for prion disease. The in vivo experiments described here were performed in 
PrPc-overexpressing mice to provide a direct comparison with previous results using 
Cre-mediated depletion in this model (Mallucci et al., 2003). Further experiments in 
wild-type mice are planned to assess the effects of the treatment at physiological levels 
of PrPc. Identifying the therapeutic window in which recovery of cognitive and 
behavioural deficits is possible is important and experiments aimed at this are also 
planned.
As mentioned previously, experiments aimed at optimising the transduction of larger 
areas and specific cell types should be performed. Lentiviral reduction of Prnp 
expression in different restricted structures within the brain could provide information 
on which regions are most vulnerable to prion pathology and therefore merit
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therapeutic targeting. Identification of allele-specific sequences capable of silencing 
familial mutations in P R N P  should be attempted because early intervention in this 
category of prion disease is possible due to the availability of diagnostic testing. 
Investigations into RNAi-mediated reduction of peripheral P rPc expression should also 
be conducted as slowing or preventing neuroinvasion offers the best therapeutic hope for 
peripherally-infected patients. The recent demonstrations of prion infection through 
contaminated blood products (Llewelyn et al., 2004;Peden et al., 2004;Wroe et al.,
2006), and the current lack of an effective screening method mean an unknown number 
of people are still at risk of contracting prion disease in this manner.
Finally, the siRNA duplexes and lentiviruses characterised in this thesis can also be used 
as tools for investigation into the function of P rPc and kinetics of prion infection. 
Reducing Prnp expression transiently through the use of siRNA may help further 
elucidate the cellular pathways P rPc normally functions within. The creation of stable 
cell lines expressing PrPc knocked down to varying levels through lentiviral 
transduction may help identify the cellular threshold below which prion replication is 
not supported. This could be used to inform therapeutic development and provide 
information on the kinetics of the conversion reaction.
7 .3  C o n c lu sio n s
This thesis provides a proof-of-principle demonstration that the use of RNA interference 
to reduce PrPc expression may be of therapeutic benefit in prion disease.
fPSi I? 4
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Reduction of focal neuropathology and a significant prolongation of survival were 
attained following a single treatment in mice with established prion disease. Further 
optimisation of delivery and targeting to pathologically important areas may translate 
this approach into a viable therapy for all classes of the currently fatal 
neurodegenerative prion diseases.
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